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Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease 
characterized by the loss of lower α-motor neurons in spinal cord leading to 
progressive muscle weakness, paralysis and in severe cases death. SMA is 
caused by reduced levels of ubiquitously expressed Survival motor neuron 
(SMN) protein. It remains unclear how a SMN deficiency leads to an 
apparently motor neuron specific phenotype and whether other cell types are 
also involved in SMA pathology. One hypothesis is based on SMN‟s critical 
role in assembly of spliceosomal U snRNPs involved in pre-mRNA splicing, 
while another hypothesis proposes motor-neuron specific function of SMN. 
However, the genes downstream of SMN are still largely unknown. Apart from 
this, involvement of other cells in SMA pathology has also been debated. 
Distal spinal muscular atrophy type 1 (DSMA1), like SMA, is a 
neurodegenerative disease affecting motor neurons. It is caused by mutations 
in the Immunoglobulin µ-binding protein 2 (IGHMBP2) gene leading to 
deficiency of this ubiquitously expressed protein. IGHMBP2 is also reported to 
be involved in RNA metabolism similar to SMA. However, molecular 
mechanisms leading to motor neuron degeneration remains elusive. 
Here in this study, I have optimised a protocol for performing RNA 
sequencing on FAC sorted motor neurons and Schwann cells under Smn 
deficient conditions. Using this protocol, the transcriptomes of motor neurons 
and Schwann cells under disease conditions were analysed. Defects in 
axonogenesis related genes were identified to be deregulated in motor 
neurons leading to motoaxonal defects in SMA and DSMA1 diseases. 
Transcriptome analysis identified down-regulation of genes important for 
functioning of motor neurons and Schwann cells. Differentially expressed 
genes, however, were different in both cell types indicating that Smn 
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deficiency leads to cell-type specific mRNA level changes. RNAseq data 
analysis revealed alternative splicing in both cell types. The alternative 
splicing data strongly suggests that Smn deficiency leads to splicing 
abnormalities in motor neurons and Schwann cells, which primarily affect 
genes important for normal physiology including synapse formation and 
axonal transport. I report on the identification of the splicing factor srsf6b in 
zebrafish as a possible novel downstream target of Smn and propose an 
„amplifier mechanism‟ of splicing deficiencies to explain motor neuron 
vulnerability in SMA. Taken together, this study, for the first time, identifies 
splicing abnormalities in zebrafish motor neurons and Schwann cells under 
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1.1 Spinal Muscular Atrophy (SMA) 
1.1.1 Loss of Survival of Motor Neuron 1 (SMN1) causes Spinal Muscular 
Atrophy 
Spinal Muscular Atrophy (SMA), an autosomal recessive neurodegenerative 
disease, is characterized by the loss of lower α-motor neurons in the spinal 
cord leading to progressive muscle weakness, paralysis and in severe cases 
death. It is one of the most common genetic causes of infant mortality (Wirth 
2000). This disease is categorized into five subtypes on the basis of time of 
onset and severity. The most severe form is Type I (Werdnig-Hoffmann 
disease) with an onset before 6 months and an average lifespan of about 8 
months. Type II and Type III (Kugelberg-Welander disease) are less severe 
forms of SMA with onset between 6-18 months and after 18 months, 
respectively. Type IV is the mildest of all forms with first symptoms of disease 
occurring after 30 years (Pearn et al. 1978). Type 0 is the 5th SMA subtype 
which has prenatal onset and the infant dies after birth. 
The SMA-causing gene, Survival Motor Neuron (SMN), is ubiquitously 
expressed and was identified to be located on chromosome 5q13 
(Brzustowicz et al. 1990). Lefebvre et al later reported that the SMN gene is 
present in two copies in humans: SMN1 (telomeric copy) and SMN2 
(centromeric copy), thought to have arisen by intrachromosomal genetic 
duplication (Lefebvre et al. 1995) (Fig. 1). SMN1 and SMN2 genes have a 
very high level of homology including intronic and promoter sequences. The 
SMN2 gene differs functionally from SMN1 gene due to a single nucleotide 
transition, C to T, at position +6 in exon 7. This transition is thought to cause 
disruption of an Exonic Splicing Enhancer (ESE) (Cartegni and Krainer 2002, 
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Cartegni et al. 2006) or creation of an Exonic Splicing Silencer (ESS) 
(Kashmina and Manley 2003) leading to increased skipping of exon 7. This 
results in generation of about 10% of full length protein while the remaining 
90% is truncated protein (SMNΔ7), which is unstable and gets degraded 
(Pellizzoni et al. 1999, Monani 2005, Burnett et al. 2009).   
Most of the childhood-onset patients have recessively-inherited mutations in 
SMN1, with more than 95% of the cases attributed to deletions in exon 7 of 
the SMN1 gene (Lefebvre et al. 1995). Since SMN2 produces low levels of 
functional SMN protein, it cannot fully compensate the homozygous loss of 
SMN1. However, it has been found that SMN2 modulates the severity of the 
disease due to its variable copy number in the human genome (Lefebvre et 
al. 1997). Thus, the copy number of SMN2 and severity of SMA are inversely 
correlated. Yet to date, the exact molecular mechanisms by which the 
reduction of ubiquitously expressed SMN leads to a motor neuron specific 
phenotype in SMA remains unclear. 
SMN is a ubiquitously expressed protein and in motor neurons it is found to 
be localized in both cell bodies as well as in axonal growth cones and 
neurites (Bechade et al. 1999, Dombert et al. 2014). There has been a highly 
controversial debate for more than a decade over how reduction of this 
ubiquitously expressed protein leads to a seemingly cell-type specific defect, 
but the reason is still largely unknown. Currently, there are three hypotheses 
prevailing among the scientific community to explain the role of SMN 
mutations in the pathomechanism of SMA. One hypothesis claims that the 
loss of SMN‟s ubiquitous function, i.e. assembly of U snRNP spliceosomes, 
causes an alteration in the splicing of a motor neuron-specific gene (or genes) 
(Burghes and Beattie 2009). The second hypothesis proposes a motor 
neuron-specific role of SMN, which is regulation of axonal mRNA transport 
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(Burghes and Beattie 2009). Disruption of this function, due to loss SMN, has 
been proposed to cause motor neuron degeneration and ultimately SMA. The 
final hypothesis in this debate is fairly recent and is based on the idea that 
there could be non-cell autonomous contributions from non-motor neurons 
causing the SMA phenotype (Hamilton and Gillingwater 2013, Shababi et al. 
2013, Hua et al. 2015). 
 
Figure 1. Molecular basis of SMA. (A) In healthy individuals, the SMN1 
gene produces approx. 90% full length transcript while SMN2, due to a base 
transition, produces about 10% full length and 90% truncated transcript 
(without Exon 7). Overall sufficient functional protein is produced for survival 
and maintenance of motor neurons. (B) In SMA patients, due to homozygous 
mutations, SMN1 becomes non-functional. SMN2, however, remains 
functional but produces only bare amounts of functional protein which is not 
enough for survival and maintenance of motor neurons. 
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1.1.2 Role of SMN in assembly of U snRNP complexes  
SMN has a well-established role in the assembly of Uridine-rich small nuclear 
ribonucleoproteins (U snRNPs) (Fischer et al. 1997, Meister et al. 2001, 
Pellizzoni et al. 2002), which are important for the formation of the 
spliceosome involved in pre-mRNA splicing (Pellizzoni et al. 1998). There are 
five types of U snRNPs- U1, U2, U4, U5, and U6 snRNP, that play major roles 
in splicing (Sperling 2016). Each of these snRNPs consists of one U snRNA, 
seven Sm proteins and a set of specific proteins (Will and Luhrmann 2001, 
Matera and Wang 2014). During U snRNP biogenesis, U snRNA molecules, 
following their transcription by RNA polymerase II, are exported out of the 
nucleus with the help of nuclear-cap-binding complex proteins (CBC), 
phosphorylated adaptors for RNA export (PHAX), exportin (XPO1) and Ras-
related nuclear protein GTP (RAN) (Fig. 2A) (Izaurralde et al. 1995, Ohno et 
al. 2000). pICln binds to the spliceosomal Sm proteins (D1, D2, E, F G) 
forming a 6S complex in the cytoplasm and delivers them to the Protein 
Arginine Methyltransferase 5 (PRMT5) complex (Fig. 2B) (Chari et al. 2008, 
Grimm et al. 2013, Neuenkirchen et al. 2015). Sequestration of Sm proteins 
by pICln prevents their random association with U snRNAs (Chari et al. 
2008). The PRMT5 complex later methylates the Sm proteins and recruits 
them to the SMN complex (Chari et al. 2008). SMN complex consists of SMN 
oligomer, Gemin2-7 and unr interacting protein (unrip) (Gubitz et al. 2004). 
This complex acts as a scaffold for formation of heptameric ring of Sm 
proteins (B/B‟, D1, D2, D3, E, F & G) onto U snRNAs to form U snRNPs (Fig. 
2C) (Meister et al. 2001, Pellizzoni et al. 2002, Zhang et al. 2011). The SMN 
complex has also been shown to play an important role in preventing non-
specific binding of the Sm core (Kroiss et al. 2008). Pellizzoni et al. showed 
that in the absence of SMN, Sm core proteins bind non-specifically to rRNA 
and tRNA in vitro (Pellizzoni et al. 2002). After the assembly of U snRNPs, 
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the 5‟ 7-methylguanosine (m7G) cap of U snRNP hyper-methylates to 
trimethylguanosine (m3G) with the help of the trimethylguanosine synthetase I 
enzyme (Fig. 2D) (Mouaikel et al. 2002). This acts as a signal for nuclear 
import of the U snRNPs via binding to snurportin1 (SPN) and importin β (IP-β) 
(Palacios et al. 1997, Huber et al. 1998). In vitro studies have shown that 
there is coupled import of SMN and snRNPs into the nucleus (Narayanan et 
al. 2004). Once inside the nucleus, SMN also helps to target U snRNPs to 
Cajal bodies for further maturation to form spliceosomes for pre-mRNA 
splicing (Fig. 2E) (Sleeman and Lamond 1999, Narayanan et al. 2002, 
Narayanan et al. 2004). 
In most of the SMA cases, there is a homozygous loss of SMN1, but there are 
other missense mutations identified in SMN1, which have been linked to SMA 
(Wirth 2000). A common feature of majority of these mutations in SMN1 is 
that they are present in the C-terminus of the protein (Exons 6-8) (Seng et al. 
2015). Seng et al. showed that this region, which is partially absent in SMNΔ7 
transcripts, is very important for snRNP assembly (Seng et al. 2015). Various 
animal models including mouse, zebrafish and Drosophila, have been 
developed to study SMA (Burghes and Beattie 2009, Bebee et al. 2012, 
Edens et al. 2015). All of these animals have one copy of SMN gene 
equivalent to human SMN1, loss of which has been shown to be lethal. The 
time point of lethality, however, is modulated by the levels of maternal SMN 
(Burghes and Beattie 2009). To model a SMA phenotype in mouse, varying 
copies of human SMN2 have been expressed in a Smn null mice background. 
With low copy numbers (two) of SMN2, mice develop a severe SMA 
phenotype while a high copy number (8-16) results in mice with normal 
phenotype (Hsieh-Li et al. 2000, Monani et al. 2000). By adding human SMN2 
lacking exon 7 (SMNΔ7) to a Smn-/-;SMN2+/+ background, this generated Δ7 
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SMA mice or type II SMA mice, which are the most widely used mouse 
models (Le et al. 2005). 
There is a correlation between the levels of snRNP assembly and SMA 
disease severity. The levels of snRNP assembly activity was found to be 
strongly reduced in severe SMA mice (SMN2+/+; Smn-/-), mildly reduced in 
mild SMA carrier mice (SMN2+/+; Smn+/-) but restored to normal levels in 
phenotypically rescued high copy SMN2 mice (SMN2+/-; SMN2(566)+/-; Smn-/-) 
(Gabanella et al. 2007). Other proteins involved in snRNP biogenesis such as 
Gemins 2, 6, and 8, were also found to be significantly decreased in severe 
SMA mice (Gabanella et al. 2007). Introduction of purified U snRNPs has 
been shown to rescue the defective axonal phenotype in Smn knockdown 
conditions in zebrafish as well as the developmental arrest in Xenopus 
embryos (Winkler et al. 2005). Thus, this suggests that there is a connection 
between snRNP assembly and the SMA phenotype. Loss of ubiquitous SMN 
has been reported to result in tissue specific defects in the repertoire of 
snRNAs and pre-mRNA splicing, which suggests that splicing is affected to 
varying extents in many different tissues and is not restricted to motor 
neurons (Zhang et al. 2008). This suggests that at low levels of SMN, certain 
transcripts may be more susceptible to aberrant splicing and down-regulated 
to a greater degree in motor neurons than in other tissues, which leads to the 
defects observed in the motor neurons (Zhang et al. 2008). The eukaryotic 
genes consist of two types of introns which are spliced by two classes of 
spliceosomal snRNPs. Majority of the introns are removed by U2-dependent 
or Major spliceosome comprised of U1, U2, U4, U5 and U6 snRNPs, while a 
small percentage of introns (0.5%), however, are spliced by U12-dependent 
or Minor spliceosome formed by U11, U12, U4atac, U6atac and U5 snRNPs 
(Lotti et al. 2012, Turunen et al. 2013). SMN deficiency alters the snRNP 
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profile of tissues in nonuniform manner by only decreasing levels of the minor 
spliceosome related snRNPs (Gabanella et al. 2007, Zhang et al. 2008). This 
has led to the hypothesis that SMN deficiency affects the splicing of genes 
with U12 introns. Consistent with this, type I SMA patients derived 
lymphoblasts show impaired minor tri-snRNP assembly (Boulisfane et al. 
2011). In another report, Lotti et al. reported that a SMN deficiency perturbs 
the splicing and decreases the expression of U12 intron-containing genes in 
Drosophila. They also identified a U12 intron-containing gene stasimon, 
required for neurotransmitter release in motor neurons of Drosophila, as 
SMN-target gene in this species, which gets aberrantly spliced in SMN 
deficient conditions (Lotti et al. 2012). One of the former Ph.D. students in our 
lab, Kelvin See, also showed alternative splicing of neurexin 2aa (nrxn2aa) 
isoforms upon Smn knockdown in zebrafish embryos (See et al. 2014). 
Neurexins are cell adhesion molecules present at synapses that interact with 
neuroligins for forming functional synapses (Dean et al. 2003). These studies 
provided first evidence that splicing of important neuronal genes is being 
affected by a deficiency in SMN, which in turn affects the functioning of 
neurons and might ultimately lead to a SMA phenotype. 
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Figure 2. Role of SMN in assembly of uridine-rich small nuclear 
ribonucleoproteins (U snRNPs). (A) pre-U snRNAs after transcription are 
exported out of the nucleus following binding with nuclear-cap-binding 
complex (CBC) proteins, export adaptor proteins (PHAX), exportin (XPO1) 
and Ras-related nuclear protein GTP (RAN). (B) In the cytoplasm, Sm 
proteins bind to pICln and then to PRMT5 complex, which methylate these 
Sm proteins. The Sm proteins later dissociate from the pICln-PRMT5 complex 
and bind to SMN complex. (C) SMN complex assembles the Sm core proteins 
(B/D1/D2/D3/E/F/G) via RG domain interaction between SMN and Sm 
proteins. (D) The SMN complex than transfers this assembled Sm core onto 
the U snRNAs to form U snRNPs. The 5‟ cap of U snRNP gets hyper-
methylated and binds to snurportin1 (SNP) and importin β (IP-β) to facilitate 
the intake of the entire complex into the nucleus. (E) Following re-entry into 
the nucleus, the U snRNPs are targeted to Cajal bodies to form spliceosomes 
for pre-mRNA splicing. (Modified from Burghes and Beattie 2009) 
 
1.1.3 The role of SMN in motor axons 
Another hypothesis proposes that SMN is critical for regulation of axonal 
mRNA transport, and disruption of this leads to SMA (Burghes and Beattie 
2009). SMN has been reported to be involved in motor neuron-specific 
functions apart from the canonical snRNP assembly process. Rossoll et al. 
reported expression of SMN at the leading edge of neurite outgrowth and 
growth cones in vitro (Rossoll et al. 2002). A year later the same group 
reported that SMN forms a complex with hnRNP-R, which translocates β-actin 
mRNA along axons to the growth cones in culture. Any deficiency in SMN 
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affects this transport of β-actin mRNA to the growth cones (Rossoll et al. 
2003). Jablonka et al. later reported that the reduced levels of β-actin mRNA 
in growth cones affect the translocation of voltage-gated calcium channels 
(VGCC) to membrane clusters in SMA mouse motor neurons in vitro 
(Jablonka et al. 2007). The VGCC are important for the influx of Ca2+ ions into 
motor neurons during synaptic activity. This defect in VGCC clustering 
correlates to the reduced frequency of local Ca2+ transients (Jablonka et al. 
2007). SMN has also been found to interact with several other RNA binding 
proteins (RBPs), which are involved in the transport, stability and localized 
translation of mRNAs in neurons. Several of these proteins, including hnRNP-
U, hnRNP-Q (Rossoll et al. 2002), and FMRP (Piazzon et al. 2008), but also 
EWS (Young et al. 2003), Nucleolin (Lefebvre et al. 2002) and Unrip 
(Carissimi et al. 2005) have previously been identified as components of 
KIF5-associated RNA transport granules (Kanai et al. 2004). KIFs are kinesin 
superfamily proteins that act as molecular motors for both anterograde and 
retrograde transport of mRNAs selectively to dendrites (Nakagawa et al. 
2000, Setou et al. 2000, Kanai et al. 2004). Recently, Dombert et al. showed 
localization of SMN and hnRNP-R in close proximity in axons and axon 
terminals in vitro and in vivo (Dombert et al. 2014). This report provided 
evidence in support of the hypothesis that SMN is involved in the axonal 
translocation of hnRNP-R and hnRNP-R bound RNA particles. 
However, it remains to be investigated which of the two hypotheses, U 
snRNP assembly defects and axonal mRNA dysregulation, is primarily 
affected by low SMN levels and whether there is a possible link between 
these two hypotheses. It could be possible that reduced level of SMN causes 
aberrant splicing of transcripts found specifically in motor neurons that 
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negatively affect axon outgrowth and guidance, contributing to the 
pathomechanism of SMA. 
1.1.4 Non-cell autonomous effects in SMA 
Traditionally, SMN deficiency was thought to exclusively cause lower motor 
neuron degeneration, leading to denervation and atrophy of skeletal muscles. 
However, there have been several recent reports that challenge this theory of 
SMA being solely a motor neuron disease, and instead claim that SMA is a 
multi-system disorder. This has led to the idea that non-cell autonomous 
mechanisms could play important roles in manifestation of this disease. The 
first significant piece of evidence came from Park et al., where they showed 
that depletion of SMN specifically in motor neurons lead to a dystrophic 
phenotype but not a full blown SMA phenotype (Park et al. 2010). This shows 
that systemic loss rather than motor neuron-specific loss of SMN is 
responsible for generating a SMA disease phenotype.  
Hamilton and Gillingwater have reviewed the function of SMN in a variety of 
cell types other than motor neurons (Hamilton and Gillingwater 2013). Among 
the various tissues that have been studied with regard to SMA, the most 
obvious is muscle. In fetuses with severe SMA, skeletal muscle myotubes 
have been shown to be smaller, thus indicating a delay in muscle growth and 
maturation (Martinez-Hernandez et al. 2009). This report also suggested that 
skeletal muscles and motor neurons undergo different pathogenetic 
processes in SMA during development. Using severe SMA mouse models, 
Murray et al. showed that the extent of pre-synaptic motor nerve terminal loss 
does not correlate with shrinkage of the post-synaptic motor endplate 
suggesting that loss of muscle cells is independent to neuronal degeneration 
(Murray et al. 2008). This further contributes to the idea of SMN is important 
for survival of muscles.  
 11 
 
Apart from muscles, other organs like heart, vasculature, liver, bones and 
others have also been studied in SMA animal models. The cardio-vascular 
system has been suggested to be one of several pathogenic targets in SMA. 
In severe SMA patients as well as severe SMA mouse models, arrhythmia 
and/or cardiomyopathy has been observed with high frequency (Bevan et al. 
2010, Heier et al. 2010). In severe SMA mouse models, these phenotypes 
are observed well before the onset of any neuromuscular abnormalities (Heier 
et al. 2010). SMA mouse models treated with the Histone deacetylase 
inhibitor (HDACi) Trichostatin A showed vascular necrosis raising the 
possibility that vascular dysfunction is a part of SMA pathology (Narver et al. 
2008). Development of an osteoporosis-like phenotype has been reported in 
mild SMA mice (Shanmugarajan et al. 2009, Shanmugarajan et al. 2010). 
This phenotype, unlikely to be caused by muscle atrophy, suggests a possible 
role for SMN in bone development. More recently, Hua et al. reported 
deficiencies in liver-related processes during SMA pathogenesis (Hua et al. 
2011). They identified the reduction of a hepatic protein, IGF-binding protein, 
acid labile subunit (IGFALS), which stabilizes IGF-1 protein, in SMA mice. 
IGF-1 is known to have roles in the peripheral nervous system (PNS), 
postnatal growth, cardiac development and function, which are all affected in 
SMA (Sullivan et al. 2008). Interestingly, reduced gene expression of Igfals 
precedes the neuromuscular phenotype in SMA mice (Hua et al. 2011).  
Neuronal populations other than motor neurons have also been studied in 
SMA animal models. In the spinal cord of the SMNΔ7 mouse model, a 
significant reduction in glutamatergic central synapses, positioned closely to 
the soma and proximal dendrites of motor neurons, was observed (Ling et al. 
2010, Mentis et al. 2011). This was due to the loss of proprioceptive sensory 
neurons that form synapses with motor neurons. A recent study in a 
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Drosophila SMA model also showed that a motor neuron dysfunction is not 
primary to disease pathology but rather a downstream effect of neural circuit 
dysfunction (Imlach et al. 2012). They reported that a SMN deficiency 
primarily affects the function of sensory neurons and interneurons, which can 
be completely rescued by expressing SMN in these neurons (Imlach et al. 
2012). Another recent study describing gastrointestinal symptoms in SMA 
mice provides interesting evidence that the enteric nervous system is involved 
in the pathology of SMA (Gombash et al. 2015). A role of SMN in Schwann 
cells has also been investigated by Hunter et al. These authors reported 
SMN-dependent intrinsic defects in Schwann cells of SMA mice, such as 
myelination defects, delayed maturation of axo-glial interactions and 
abnormalities of the extracelluar matrix in the PNS (Hunter et al. 2014).  
Taken together, all these studies provide support to the idea that SMA is not 
exclusively a motor neuron disease but could also affect other tissues, which 
could directly or indirectly lead to SMA in a non-cell autonomous fashion.  
 
1.2 The role of Schwann cells for maintenance of motor neurons 
The nervous system is basically composed of two cell types, neurons and 
glial cells. Glial cells have many indispensable functions during the 
development and function of the nervous system as well as during disease 
conditions. Schwann cells are a major type of glial cells in the PNS, where 
they form layers of myelin sheaths wrapping around the peripheral nerve 
axons. There are two types of mature Schwann cells, those that are 
myelinating (forming a myelin sheath around large diameter axons) and those 
that are non-myelinating (positioned around smaller diameter axons). 
Myelinated nerves have long myelinated segments interspersed with nodes of 
Ranvier where the myelin sheath terminates and the electrical impulses are 
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conducted along the axons in a saltatory fashion. This increases the impulse 
conduction significantly as compared to non-myelinated axons (Hartline and 
Colman 2007, Nave 2010). Myelination of axons has another advantage in 
reduction of energy consumption during restoration of ion gradients (Nave 
2010). Traditionally, Schwann cells have been believed to be important for 
motor neuron survival and support, but recent studies have highlighted their 
crucial roles in formation, function, plasticity and elimination of synapses 
(Eroglu and Barres 2010). 
Perisynaptic Schwann cells (PSCs) or terminal Schwann cells are an 
important sub-type of non-myelinating Schwann cells found at neuromuscular 
junctions (NMJ) where they form a tripartite synapse between nerve, muscle 
and PSC (Araque et al. 1999, Jessen 2004, Armati and Mathey 2013). 
Although, PSCs are dispensable for the early nerve-muscle contact, they play 
a critical role in the maintenance of NMJs, synaptic growth and maturation 
(Ko and Robitaille 2015). The underlying molecular mechanism, however, is 
not well understood. PSCs induce the formation of NMJs by secreting TGF-β1 
that upregulates neuronal agrin (Feng and Ko 2008). Neuronal agrin is 
important for clustering of postsynaptic acetylcholine receptors (AChR) 
(Sanes and Lichtman 2001). This increased clustering of AChR on muscle 
cells is indicative of the synaptogenesis effect of TGF- β1 (Feng and Ko 
2008). PSCs can detect synaptic activity, decode the transmission and react 
differentially to produce an adapted modulation (Ko and Robitaille 2015). 
They increase intracellular Ca2+ levels in response to nerve evoked 
transmitter release (Jahromi et al. 1992), talk-back to the nerve and muscle 
cells by releasing gliotransmitters and modulate the synaptic communications 
(Araque et al. 2014). PSCs also play an important role in activity-dependent 
synapse elimination during development where they engulf and phagocytose 
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axons that fail to form functional synapses (Eroglu and Barres 2010, Smith et 
al. 2013). 
Schwann cells can also communicate with axons via secreted vesicles 
(Lopez-Verrilli and Court 2012). Schwann cells have been reported to transfer 
polyribosomes to axons after axonal damage and during regeneration (Court 
et al. 2008, Court et al. 2011, Lopez-Verrilli et al. 2013). These transported 
ribosomes, secreted in the form of microvesicles (Lopez-Verrilli and Court 
2012), suggest that Schwann cells support local protein synthesis in axons 
during nerve injury and regeneration. Another study reported that Schwann 
cell-derived exosomes enhance axonal regeneration after nerve injury 
(Lopez-Verrilli et al. 2013). Schwann cell-derived exosomes containing 
pathogenic prions have been proposed as means to spread these proteins 
from CNS to PNS (Fevrier et al. 2004). Taken together, these studies 
highlight a new emerging concept in the field of neuron-glia interaction 
whereby axons receive transcripts and/or protein synthesis machineries from 
Schwann cells. 
Given the importance of neuron-glia interactions in the functioning of motor 
neurons, it is conceivable to postulate an involvement of Schwann cells in the 
SMA pathomechanism. Consistently, SMN-dependent intrinsic Schwann cell 
defects in SMA mouse models have recently been reported (Hunter et al. 
2014). Similarly, a former Ph.D. student in our lab, Kelvin See, had reported 
that Smn deficiency leads to Schwann cell defects which are independent of 
motor neuron activity in a zebrafish model of SMA (Kelvin See Ph.D. thesis; 
manuscript in preparation). Interestingly, the motor axonal defects in zebrafish 
caused by Smn deficiency can be partially rescued by Schwann cell-specific 
expression of Smn in transgenic zebrafish (Shermaine Tay, FYP thesis). 
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Further investigation needs to be done to explain the role of SMN in Schwann 
cells and its association to motor neuron degeneration. 
 
1.3 Distal Spinal Muscular Atrophy Type 1 (DSMA1) 
DSMA1, like SMA, is an autosomal recessive neurodegenerative disease 
likewise affecting the α-motor neurons in the spinal cord. The disease 
normally manifests in the first two years after birth with a characteristic distal 
muscle atrophy and paralysis of the diaphragm (Grohmann et al. 2001, Diers 
et al. 2005, Guenther et al. 2007, Guenther et al. 2009). Although it is known 
that some of these pathological events correspond to motor neuron loss in the 
spinal cord (Grohmann et al. 2001) little is known about the molecular 
mechanisms leading to this motor neuron/axon loss. This disease is caused 
by mutations in the gene encoding Immunoglobulin µ-binding protein 2 
(IGHMBP2) located on chromosome 11 (Grohmann et al. 2001).  
IGHMBP2 is an ATP-dependent helicase, which belongs to the SF1 helicase 
superfamily. The precise cellular function of IGHMBP2 remains elusive, 
although it has been implicated in transcription and pre-mRNA processing 
(Shieh et al. 1995, Molnar et al. 1997, Zhang et al. 1999). More recently, 
IGHMBP2 has been reported to associate with ribosomes and tRNAs 
suggesting that it is functionally linked to translation (de Planell-Saguer et al. 
2009, Guenther et al. 2009). The majority of disease causing mutations 
identified in DSMA1 patients is found in the helicase domain of IGHMBP2 
(Grohmann et al. 2001, Guenther et al. 2007, Guenther et al. 2009). Thus, 
loss of helicase activity could be the primary defect of mutated IGHMBP2. In 
order to study the DSMA1 disease and characterise the function of 
IGHMBP2, the neuromuscular degeneration (nmd) mutant mouse has been 
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used (Cox et al. 1998, Grohmann et al. 2004). The nmd mice carry a point 
mutation in intron 4 of Ighmbp2 that leads to alternative splicing and 
production of a truncated transcript (Cox et al. 1998). Mutant mice initially 
show progressive paralysis in hindlimbs with myopathic changes in the 
diaphragm at later stages (Cox et al. 1998, Grohmann et al. 2004). Grohmann 
et al showed that Ighmbp2 protein is found in the nucleus as well as cell 
bodies, axons and growth cones, but its expression is low in the nucleus 
when compared to cell bodies or axons (Grohmann et al. 2004). Unlike in the 
case of SMA where motor neuron cell death is observed only late when 
paralysis is already clearly detectable, in DSMA1 the motor neuron death is 
prominent already during early stages of the disease followed by endplate 
degeneration (Grohmann et al. 2004, Krieger et al. 2013). This hints at a role 
of IGHMBP2 in motor neuron survival. However, it is still remains to be 
investigated why this disease primarily affects motor neurons. 
 
1.4 RNA sequencing (RNAseq) 
RNAseq is a high-throughput sequencing method which can be used to map 
and quantify the complete transcriptome. Briefly, RNA samples (total RNA or 
mRNA) is used for generating libraries of cDNA fragments with attached 
adaptors. The cDNA libraries are then sequenced in a high-throughput 
manner from one end (single-end sequencing) or both ends (paired-end 
sequencing). The reads obtained after sequencing are between 30-400 bp in 
length depending on the type of sequencing platform used. The sequence 
reads are later mapped to a reference genome or could be assembled 
together without genomic sequence to generate a transcription map which 
provides the information on gene expression levels as well as the structure of 
the gene.  
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RNAseq has gained considerable attention due to its various advantages over 
the existing microarray technology (Wang et al. 2009). First and foremost, 
RNAseq is not dependent on the knowledge of genomic sequence. Thus, it 
can be used for non-model organisms with no genome sequences available. 
Second, RNAseq has a very low background signal and no upper limit for 
quantification. Also, it is highly sensitive for genes with very high and low 
expression levels, which usually are missed with DNA microarrays. Another 
advantage is its high reproducibility even with very low RNA input samples. 
RNAseq has single-base resolution which makes it highly efficient in detecting 
sequence variations like SNPs and importantly splice isoforms.  
RNAseq has become a very attractive tool in zebrafish research. It was 
recently used for improving the zebrafish reference genome annotation by 
adjusting intron/exon boundaries of known genes, confirm their expression 
and improve the coverage of 3‟ UTRs (Collins et al. 2012). With the 
availability of a fully annotated zebrafish reference genome as well as 
pipelines for analysis of zebrafish data, RNAseq has been used for 
identification of splice variants and novel transcripts, SNP discovery and 
quantification of transcript levels in zebrafish (Qian et al. 2014). Rosel et al. 
employed RNAseq to study alternative splicing regulation in zebrafish where 
they identified a new role for U1C (a snRNP protein) as a splicing regulator 
(Rosel et al. 2011). RNAseq has also been used in zebrafish developmental 
biology to understand the changes in transcriptomes during different 
developmental stages as well as retinogenesis (Vesterlund et al. 2011, Uribe 
et al. 2012). Taken together, these studies provide strong arguments for the 





1.5 CRISPR/Cas system 
The clustered regularly interspersed short palindromic repeats (CRISPR)/ 
CRISPR-associated (Cas) system has recently been established as a tool for 
targeted genome editing in zebrafish and other models with high efficiency. 
CRISPR/Cas is a type of bacterial defence mechanism that provides adaptive 
immunity against viruses (Al-Attar et al. 2011, Bhaya et al. 2011, Wiedenheft 
et al. 2012). This system is composed of CRISPR arrays with gene-targeting 
sequences or spacers and Cas genes that encode a family of endonucleases 
(Al-Attar et al. 2011, Bhaya et al. 2011, Wiedenheft et al. 2012). Briefly, the 
CRISPR RNA (crRNA) binds to trans-activating crRNA (tracrRNA) and direct 
sequence-specific degradation of viral genomes using Cas proteins (Brouns 
et al. 2008, Jinek et al. 2012). A recent in vitro study has reported that Cas9 
endonucleases can be programmed to cleave specific sites in the genome 
using a single guide RNA (sgRNA) consisting of fused crRNA and a trans-
activating crRNA (tracrRNA) (Jinek et al. 2012). This paper introduced 
CRISPR/Cas system as a tool for precision targeting similar to Zinc finger 
nucleases (ZFNs) and Transcription activator-like nucleases (TALENs). 
However, unlike ZFN or TALEN, the CRISPR/Cas system has a low cost and 
is easy to design for nearly any genomic sequence, and provides very high 
efficiency of single gene mutations or multiple gene mutations at the same 
time (Jao et al. 2013, Wang et al. 2013). 
In a span of only three years, since Jinek et al published their results (Jinek et 
al. 2012), the CRISPR/Cas system has become an extensively used tool to 
modify target genes with great success in human cells, mice, rat, zebrafish, 
bacteria, fruit flies, nematodes and crops (Pennisi 2013). The CRISPR/Cas 
system has been recently used for generating single mutations and even 
multiple mutations in zebrafish, Drosophila, human and mouse cells (Chang 
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et al. 2013, Cong et al. 2013, Hwang et al. 2013, Mali et al. 2013, Wang et al. 
2013, Bassett and Liu 2014, Ota et al. 2014). The underlying idea, similar to 
ZFNs and TALENs, is to generate site-specific double-strand breaks in the 
genome and allow for erroneous non-homologous end joining (NHEJ) 
mechanism to repair and generate insertions/deletions (indels) at the targeted 
site (Durai et al. 2005, Miller et al. 2011). Apart from knock-outs, knock-ins of 
exogenous sequence is also possible with the CRISPR system (Cong et al. 
2013, Wang et al. 2013). Interestingly, the CRISPR/Cas system is not limited 
to insertions/deletions but can also be used to modulate endogenous gene 
expression (Larson et al. 2013, Qi et al. 2013, Kabadi et al. 2014). Recently, a 
new RNA-guided endonuclease, Cpf1, similar to Cas9 was identified that can 
be used to target specific DNA sequences (Zetsche et al. 2015). Unlike Cas9, 
Cpf1 creates a staggered double-strand cut distal to a 5‟ T-rich PAM 
sequence (Zetsche et al. 2015).  
In 2013, Hwang et al. were the first to show the use of this system in 
zebrafish research (Hwang et al. 2013). After this, the CRISPR/Cas system 
has completely revolutionized the genome editing field in zebrafish. Multiplex 
genome engineering is possible in zebrafish by injecting a single Cas9 mRNA 
along with one or multiple sgRNAs (Ota et al. 2014, Shah et al. 2015). 
Recently, Jao et al. reported biallelic gene disruption in zebrafish by using 
zebrafish codon-optimised Cas9 protein (Jao et al. 2013). The observed 
mutation rates were between 75-99% suggesting complete knock-out of the 
genes in the F0 generation. This is very advantageous for doing phenotypic 
analysis in injected fish without the need to wait for homozygosity in the F2 
generation. Thus, CRISPR/Cas system has proven to be a simple and robust 




1.6 Aim of the project 
The ultimate aim of this project is to study the changes in the transcriptomes 
of motor neurons and Schwann cells under SMN deficient conditions, and 
identify alternative spliced transcripts potentially involved in SMA pathology. 
The working hypothesis in this study is that SMN deficiency leads to splicing 
changes in genes critical for motor neurons and Schwann cells, which lead to 
motor neuron degeneration and finally SMA. These splicing changes could be 
detected as alternatively spliced transcripts by RNAseq data analysis.  
To achieve this goal, the first main aim was to establish a protocol based on 
Fluorescence activated cell sorting (FACS) in order to isolate pure motor 
neuron and Schwann cell populations from transgenic zebrafish embryos. In 
our lab, we already had established motor neuron (HB9:eGFP and 
HB9:mCherry) and Schwann cell (HB9:D3cpv/SC) transgenic reporter lines 
that were used in this study. The optimized protocol was then applied to sort 
these specific cell types under Smn deficient as well as DSMA1 conditions.  
The second aim was to establish a protocol for generating libraries from Smn 
and Ighmbp2 deficient FAC sorted motor neurons and Schwann cells and 
perform RNAseq. The RNAseq data were then used for bioinformatics 
analysis to identify gene expression changes as well as alternative spliced 
transcripts in response to Smn and Ighmbp2 knockdown. These alternative 
spliced transcripts were than screened to identify potential candidate genes, 
expressed exclusively in motor neurons or neurons in general, that can be 
implicated in SMA. Finally, a CRISPR/Cas based functional study of the most 





2. MATERIAL AND METHODS 
2.1 Zebrafish strains and handling 
All wild-type fish used in this study were obtained from the fish facility of the 
Department of Biological Sciences, NUS. All fish were kept under controlled 
conditions (14 hrs light/10 hrs dark, 28°C constant water temperature and salt 
concentration) and were fed three times a day with brine shrimps. To obtain 
freshly fertilized zebrafish eggs, one male was separated from one female by 
a plastic separator in a small mating tank overnight and put together the next 
morning. After spawning, embryos were collected in a small sieve and gently 
washed under running water tap before being manipulated during the course 
of experiments. All injected or chemically treated embryos were kept in 
Danieau‟s solution in a 28°C incubator. To prevent pigment formation 1X PTU 
(0.15 g / 100 ml water) was added to the fish medium at 10 hpf which was 
replaced every 24 hrs until the embryos reached the desired stage.  
Transgenic zebrafish lines 
Motor neuron reporter lines, HB9:eGFP and HB9:mCherry, expressing 
fluorescent reporter proteins under control of the motor neuron-specific 
promoter HB9, were used in this study. The HB9:eGFP line was generated by 
Shermaine Tay (Shermaine Tay, FYP thesis), and the HB9:mCherry line was 
generated by Kelvin See (Kelvin See, Ph.D. thesis). The used Schwann cell 
calcium sensor line, HB9:D3cpv/SC, was also generated by Kelvin See. This 
line drives expression of calcium sensor protein, D3cpv, in Schwann cell 




2.2 Antisense morpholino oligonucleotide (MO) knockdown 
All working solutions for antisense Morpholino Oligonucleotides (MOs; 
Genetools, USA) used for injections were prepared fresh by diluting the stock 
MO solutions in appropriate amounts of sterile MQ H2O. MO solutions were 
incubated at 65°C for 10 mins and cooled on ice before loading into glass 
capillaries (Harvard Apparatus), which had been pulled into sharp tips using a 
needle puller (Narishige, Japan). Using a Femtojet Microinjector (Eppendorf), 
MOs were injected into the yolk region just below the cytoplasm into one to 
two cell stage embryos. Standard Control MO which targets the human β-
globin gene and has no target in the zebrafish genome was used as control.  
Table 1. List of used Morpholinos (MO) 
Name Sequence (5’- 3’) 
Concentration 
(mg/ml) 
SMN MO CGACATCTTCTGCACCATTGGC 3.1 
Control MO CCTCTTACCTCAGTTACAATTTATA 3.1 
IGHMBP2 MO CAACCTCCATAGCTGTTAAGTTGGG 6.25 
 
 
2.3 Whole-mount immunostaining 
At 31 hpf, embryos were manually dechorionated and fixed in 4% PFA/PBST 
at 4°C overnight. Fixed embryos were washed 4 x 5 mins at r.t. with PBST 
before storing them in MeOH at -20°C prior to use. Embryos were rehydrated 
in 50% MeOH/H2O for 5 minutes, in MQ H2O for 5 mins and 1 hour at r.t. The 
embryos were then blocked for 1 hour at r.t. in PBDT solution (1% DMSO, 1% 
BSA, 0.5% Triton X-100, 2.5% sheep serum, 1X PBS, 0.5% Tween-20). 
Embryos were then incubated with primary antibody (Table 2) diluted in PBDT 
at 4°C overnight. Afterwards, embryos were washed in 0.1% Triton X-100 in 
PBST at r.t. 4 x 1 hour each and incubated with the appropriate biotin-coupled 
secondary antibody (Vectastain Elite ABC kit, Vector laboratories, USA) at 
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4oC overnight. Then, embryos were washed again 4 x 1 hour each in 0.1% 
Triton X-100 in PBST. A Vectastain ABC solution was prepared by mixing a 
drop each of Solution A and B (Vectastain kit) in 2.5 ml PBS and incubated 
for 30 min at r.t. After the washes, the embryos were incubated for 1 hour at 
r.t in Vectastain ABC solution followed by 4 x 30 min washes in 0.1 Triton X-
100. The embryos after wash were pre-incubated for 30 min in 
diaminobenzidine solution (DAB, 1 tablet in 5 ml H2O) followed by staining in 
Urea/H2O2/DAB solution (1 tablet DAB and 1 tablet Urea/H2O2 in 5 ml H2O). 
The staining was continued until a strong signal was observed and then 
stopped by removing the staining solution and washing with PBST 3 x 5 min. 
For storage, embryos were kept in PBST at 4°C. 
Table 2. List of antibodies used for immunostaining 
Antibody Species Working solution Company 
Anti-znp1 mouse 1:100 ZIRC 
Anti-HuC/HuD mouse 1:1000 Sigma 







2.4 Whole zebrafish embryo dissociation  
The papain dissociation system kit (Worthington Labs, cat no. LK003150) was 
used for dissociation of zebrafish embryos.  
Preparation of solutions 
Papain enzyme solution was prepared by adding 5 ml of Earle‟s Balanced 
Salt Solution (EBSS) to the Papain vial (Vial 2) to prepare a solution with a 
final concentration of 20 units/ml. The solution was incubated in a 37oC water 
bath for 10 mins for papain to dissolve properly. 500 µl EBSS was added to 
the DNase I vial (Vial 3) to prepare DNase I solution (2000 units/ml). 250 µl of 
reconstituted DNase I solution was added to papain to get a Papain/DNase I 
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solution. 32 ml of EBSS was added to the Albumin-Ovomucoid protease 
inhibitor vial (Vial 4) and mixed properly. The Stop solution was prepared by 
mixing 150 µl DNase I, 2.7 ml of EBSS and 300 µl of the Albumin-Ovomucoid 
inhibitor solution. 
Embryo dissociation 
100 zebrafish embryos at 28 hpf were dechorionated and transferred to an 
Eppendorf tube and excess fish medium was pipetted out. 1 ml of cold 
Ringer‟s solution (116 mM NaCl, 2.9 mM KCl, 5 mM HEPES, 1.8 mM CaCl2, 
pH7.2) was added to the Eppendorf tube and embryos were deyolked by 
pipetting them several times with a 1000 µl pipette tip. The deyolked embryos 
were pelleted down by centrifugation at 300 g for 5 mins at 4oC and the 
supernatant was discarded. 500 µl of Papain-DNase I solution was added to 
the embryos and incubated on a thermomixer at 30oC for 45 mins and 1200 
rpm shaking. The tubes were removed after every 15 min and the embryos 
were triturated by pipetting thoroughly with a 200 µl pipette tip to obtain single 
cell suspensions. The single cells were pelleted down by centrifugation at 300 
g for 5 min at 4oC and the supernatant was discarded. 300 µl of the Stop 
solution was added to the tubes and incubated at r.t. for 5 mins on a rotator 
shaker to terminate papain digestion. The cells were pelleted down by 
centrifugation at 300 g, 5 mins, 4oC and re-suspended in Leibovitz‟s L-15 
medium with 2% Fetal bovine serum (FBS). Cells were filtered through the 
cell strainer cap of a FACS tube and kept on ice until sorting was done. For 
samples with more than 100 embryos, the volume of the used 2% FBS/L-15 





DAPI (1:1000) was added to the cell samples 5 mins before starting of the 
FACS procedure. Cell sorting was performed in a pre-cooled BD FACS Aria II 
SORP cell sorter. First, a light scatter plot (side scatter, SSC-A vs. forward 
scatter, FSC-A) was used to gate homogenous cell populations and to 
exclude debris and cell aggregates according to size and granularity. The 
gated cells were then further analysed to exclude doublets, before cell 
viability was assessed. Only cells with no or low DAPI fluorescence (355 nm 
laser, 450/50 band filter) were considered as viable single cells. Finally, GFP, 
mCherry and YFP positive cells were sorted out at a laser excitation of 488 
nm (530/30 filter), 561 nm (585/25 filter) and 488 nm (540/25 filter), 
respectively. Cells were directly sorted into 400 μl TRIzol® in a 1.5 ml low-
binding reaction tube, whereby multiple sorting rounds of the same sample 
type were combined into one collection tube. However, not more than 80,000 
cells were collected per tube to ensure a 3:1 volume ratio of TRIzol® to 
aqueous component, or 5:1 phenol to chloroform during the RNA isolation 
step. After collection, the tubes were vigorously vortexed for 2 min and stored 
at -80°C until further processing. For collecting more than 80,000 cells in a 
single tube, collection was done into 500 μl of 20% FBS/L-15 medium. The 
cell suspension was kept on ice. The cells were pelleted by centrifugation for 
5 mins at 2000 g at 4oC, the supernatant was carefully removed, leaving 
behind 50 μl of liquid. The cells were finally re-suspended in 400 μl TRIzol® 
for RNA isolation. 
 
2.6 RNAseq library preparation 
Preparation of libraries and RNA sequencing was done in collaboration with 
Dr. Sinnakaruppan Mathavan at the Genome Institute of Singapore. 
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2.6.1 Total RNA extraction 
RNA was isolated using a phenol-chloroform (TRIzol®; Invitrogen) protocol 
with a column-based purification (PureLinkTM RNA Micro Kit; Invitrogen). 
Frozen cell samples were thawed and lysed by vortexing, pipetting and using 
a pestle-homogenizer on ice. Afterwards, the volume was adjusted to 1 ml 
with fresh TRIzol® and the samples were incubated at r.t. for 5 mins. 0.2 ml of 
chloroform was added and the tubes were vigorously shaken for 30 sec, 
before incubating them for another 5 mins at r.t. The tubes were centrifuged 
at ≥ 12,000 g for 15 mins at 4°C. The upper aqueous phase was recovered 
and an equal volume of 100% EtOH was added and mixed by inverting. RNA 
samples were then further purified using the PureLink Kit following the 
manufacturer‟s instructions. RNA was eluted with 14 μl RNase free water. 1.2 
μl of each RNA sample was used for quality assessment and the rest was 
stored at -80oC before proceeding with the RNAseq library preparation. An 
on-column DNA digestion was omitted to avoid RNA loss. An Agilent 2100 
Bioanalyzer and RNA 6000 Pico Kit (Agilent) was used for RNA quality and 
quantity assessment. RNA pico chips were prepared following manufacturer‟s 
instructions. RNA aliquots were heated to 70°C for 2 mins before loading 1 µl 
onto a pico chip. For the following steps, RNA samples with a RNA integrity 
number (RIN) of 8.0 or higher were used. 
2.6.2 Double stranded cDNA synthesis 
First and second strand cDNA synthesis was done with 1-10 ng total RNA 
using the SMARTer® UltraTM Low Input RNA for Illumina® Sequencing Kit, 
following the manufacturer‟s instructions. A positive RNA control with the 
same amount was included. For first strand cDNA synthesis, RNA samples 
and control RNA were diluted with 1 µl Reaction buffer (19 µl of Dilution buffer 
and 1 µl of RNase inhibitor) and Nuclease-free water in a 96-well PCR plate 
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to get a final volume of 10 µl. These samples were than incubated with 1 µl of 
3‟ SMART CDS Primer IIA at 72oC for 3 mins. The following components 
were added to the RNA-Primer mix and mixed thoroughly by pipetting: 4 µl of 
5X First-strand buffer, 0.5 µl of DTT, 1 µl of dNTP mix (20 mM), 1 µl of 
SMARTer IIA oligonucleotide, 0.5 µl of RNase inhibitor and 2 µl of 
SMARTScribe reverse transcriptase. The samples were incubated for 90 
mins at 42oC and the reaction was terminated by incubation at 72oC for 10 
mins. After this, a clean-up was done using SPRI AMPure XP beads 
(Beckman Coulter). For this, 36 μl of the beads were added to the reaction 
mix, and pipetted up and down at least 10 times and incubated for 8 mins at 
r.t. Samples were then placed on a magnetic separation device and left for 
more than 5 mins until the solution was clear. The solution was removed 
using a pipette without disturbing the beads to which the first-strand cDNA 
was bound. The plate was sealed, briefly spun down and placed again onto 
the magnetic stand for 2 more mins and the supernatant was carefully 
discarded. 
For second strand synthesis, a long distance PCR was performed using the 
Advantage 2 PCR kit (Clontech). The following reaction components were 
added to the DNA-bound beads and mixed thoroughly by pipetting: 5 µl of 
Advantage 2 PCR buffer, 2 µl of dNTP mix (10 mM), 2 µl of IS PCR primer, 2 
µl of 50X Advantage 2 polymerase mix and 39 µl of Nuclease-free water. The 
PCR was performed with the following conditions: 1 min 95°C, 15 sec 95°C, 
30 sec 65°C, 6 min 68°C, 10 min 72°C. 13 cycles were used for 10 ng total 
RNA input, 14 cycles for 5 ng and 16 cycles for 1 ng. PCR products were 
purified using 90 µl of fresh SPRI AMPure XP beads. After adding the beads, 
the solution was mixed thoroughly by pipetting 10 times and incubated for 5 
mins to separate the beads. The clear solution was discarded. The beads 
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were washed twice with 200 µl of 80% EtOH and then air dried. 15 µl of 
Purification buffer was used for eluting the cDNA. The plate was incubated for 
2 mins at r.t. and mixed by pipetting 10 times and placed on the magnetic 
stand for 1 min. 13 µl of purified cDNA in the clear supernatant was pipetted 
out carefully without any bead contamination, transferred to DNA lo-bind 
Eppendorf tubes and stored at -20oC.  
cDNA aliquots were analysed using the Agilent 2100 Bioanalyzer and High 
Sensitivity (HS) DNA Chip. HS DNA chips were prepared by following the 
manufacturer‟s instructions and 1 µl of each cDNA sample was loaded onto 
the chip for QC. Successful cDNA synthesis and amplification should yield no 
product in the negative control (see Appendix 1), and a distinct peak spanning 
400 bp to 9,000 bp, peaked at ~2,000 bp for the positive control RNA sample 
(see Appendix 1). Contaminated samples will have a broader peak, and an 
abnormally high yield. Only samples with confirmed quality were used for 
subsequent shearing and library amplification. The libraries were stored at -
20oC until RNAseq submission.  
2.6.3 Covaris shearing 
The Covaris AFA system was used to produce short cDNA fragments of 200-
500 bp. 80 μl purification buffer was added to cDNA samples and the mix was 
transferred to a Covaris tube. Shearing was done with the following 
parameters: duty 10%, intensity 5, burst cycle 200, time 5 mins and sweeping 
mode frequency. The sheared cDNA samples were transferred to new DNA 
lo-bind tubes.  
2.6.4 Qubit assay 
A Qubit® dsDNA HS Assay Kit was used to determine the DNA concentration 
in a Qubit®2.0 Fluorometer. Qubit working solutions were prepared by diluting 
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the Qubit dsDNA HS Reagent 1:200 in Qubit dsDNA HS Buffer in an 
Eppendorf tube. 1 µl of each cDNA sample was diluted in 199 µl of Qubit 
working solution and mixed. For each run, two standards were prepared. 10 
µl of each standard was diluted with 190 µl of Qubit working solution and 
mixed. The solutions were incubated in the dark for 2 mins at r.t. Finally, the 
concentrations were measured on a fluorometer.  
2.6.5 cDNA library generation 
The cDNA libraries were generated using the NEBNext® UltraTM DNA Library 
Prep Kit for Illumina® and NEBNext® Multiplex Oligos for Illumina® (Index 
primer set 1). For this, 55.5 µl of sheared cDNA was mixed with 3 µl of End 
prep enzyme mix and 6.5 µl of End repair reaction buffer, and incubated for 
30 mins at 20oC followed by 30 mins at 65oC. The following components were 
added to the End prep reaction mix and mixed well by pipetting: 15 µl of 
Blunt/TA ligase master mix, 2.5 µl of NEBNext adaptor and 1 µl of Ligation 
enhancer. For cDNA inputs of less than 100 ng, 10 times diluted adaptor was 
used. The samples were incubated at 20oC for 20 mins. 3 µl of USER enzyme 
was added to all samples before incubating for 20 mins at 37oC. A clean-up of 
adaptor-ligated cDNA without size selection was performed with AMPure XP 
beads. 86.5 µl of beads were added to the samples, mixed by pipetting and 
incubated for 5 mins at r.t. The sample plate was placed on the magnetic 
stand for 5 mins to allow the beads to separate and the clear supernatant was 
carefully discarded. The beads were washed thrice with 200 µl of 80% EtOH 
and air dried. The DNA was eluted from the beads by adding 28 µl of 0.1X 
TE, mixed well and the sample plate was placed on a magnetic stand for 
separating the beads from cDNA. 23 µl of clear supernatant containing 
adaptor ligated DNA was carefully removed. 
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The DNA was then PCR amplified by adding 25 µl of NEBNext high fidelity 2X 
PCR master mix, 1 µl of Universal primer and 1 µl of the corresponding Index 
primer (primers 1-12). PCR was done with the following conditions: 98°C for 
30 sec, 98°C for 10 sec, 65°C for 30 sec, 72°C for 30 sec, 72°C for 5 min. 
The used cycle numbers were according to the input amount of sheared 
cDNA based on Qubit readings: 9 cycles for 100-300 ng, 12 cycles for 35-60 
ng, 15 cycles for 20-35 ng, and 18 cycles for 5-20 ng of cDNA. The 
amplification product was cleaned up using AMPure XP beads. Libraries were 
kept at -20°C. A quality assessment was done using an Agilent 2100 
Bioanalyzer as described previously and qPCR was performed for quantifying 
the amount of each library.  
2.6.6 Quantitative PCR 
For qPCR analysis, serial dilutions of the library samples were used with the 
Light Cycler® 480 SYBR Green I Master from Roche together with qPCR 
Primer 1.1 (5‟AATGATACGGCGACCACCGAGAT 3‟) and qPCR Primer 2.1 
(5‟CAAGCAGAAGACGGCATACGA 3‟) from 1st BASE Oligos on a Roche 
Light Cycler®. Two criteria defined a successful qPCR assay: the R2 
(coefficient of determination) values of the linear regression equation were 
bigger than 0.980 and CP (crossing point cycle; or Ct cycle threshold) values 
of the replicates were similar, which also reflected in evenly spaced 
amplification curves. After calculation of the molarities, the libraries were 






2.7 RNAseq data analysis 
RNAseq data processing and alignment 
Raw RNAseq data obtained from sequencing were cleaned by removing 
adaptor sequences (5´-/5Phos/GAT CGG AAG AGC ACA CGT CTG AAC 
TCC AGT C/ideoxyU/A CAC TCT TTC CCT ACA CGA CGC TCT TCC GAT 
C*T-3´) using the CutAdapt 1.9.1 tool (See Appendix 2A for commands). The 
adaptor sequences from the 5‟ and 3‟ ends were removed to yield actual RNA 
sequences. The trimmed sequence reads were then mapped to the zebrafish 
reference genome, Zv9, using TopHat 2.0.12 tool (See Appendix 2B for 
commands). The TopHat output (bam files) contained sequence alignment 
data for all reads, which were used for further downstream analysis.  
Quantification and differential gene expression analysis 
Differential gene expression analysis was done to detect genes, which are 
expressed differentially among control and test samples. The analysis was 
done using Partek Genomics Suite 6.6 at the Bioinformatics Institute 
Singapore. Bam files obtained from the TopHat program were uploaded into 
the Partek software that uses the sequence alignment data to quantify 
expression levels of all genes/transcripts. The expression levels of 
genes/transcripts are denoted in terms of Reads Per Kilobase of exon model 
per Million mapped reads (RPKM). Analysis of variance (ANOVA) test was 
used to obtain the differential expression analysis. Finally, a list of genes with 
significant differential expression (Fold change >2 and p-value <0.05) was 
generated. 
Alternative splicing events analysis 
Multivariate Analysis of Transcript Splicing (MATS; version 3.0.9) was applied 
to the aligned RNAseq data (bam files) to identify alternatively spliced (AS) 
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transcripts. The alternatively spliced events were categorised into: skipped 
exon (SE), mutually exclusive exon (MXE), retained intron (RI), alternative 3‟ 
splice site (A3SS) and alternative 5‟ splice site (A5SS). Events with a false 
discovery rate (FDR) less than 0.1 were filtered out as most significant AS 
events.  
Gene ontology (GO) enrichment analysis 
GO enrichment analysis was performed using the list of genes with 
statistically significant differential expression or significant AS events. Partek 
Genomics Suite 6.6 was used for the analysis. The program applies Fischer‟s 
exact test to quantify the enrichment scores and p-value for each GO term 
identified. Terms with p-value less than 0.05 (Enrichment score >3) were 
filtered out as most significant. 
 
2.8 Whole-mount in situ hybridisation 
2.8.1 Cloning of riboprobes for WISH 
srsf6b riboprobes (sense and antisense) were generated from linearized 
plasmids by in vitro transcription. For plasmid cloning, primers were designed 
to amplify a 593bp region spanning exon 4 to exon 6 in the srsf6b cDNA 
(transcript ENSDART00000002318). Phusion DNA polymerase (Finnzymes) 
was used to amplify the target region from cDNA generated from wild-type 
embryos at 31 hpf. The PCR product generated by phusion polymerase had 
blunt ends, which was suitable for cloning into the pJET 1.2/blunt Cloning 
vector (Thermo scientific). This pJET vector contains multiple cloning sites 
and a T7 promoter site for in vitro transcription. For cloning, 1-4 µl of PCR 
product was mixed with 5 µl of 2X Reaction buffer, 0.5 µl of pJET vector (50 
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ng/µl), 1 µl of T4 DNA ligase (5 U/µl) and topped up to 10 µl with MQ H2O. 
The ligation mix was incubated for 15 min at r.t., before transformation into E. 
Coli DH5α chemically competent cells. Colony PCR and sequencing were 
performed to select positive colonies with proper orientation of the riboprobe 
sequence. Forward integration of the PCR product was used for sense probe 
preparation, while the reverse orientation was used for antisense probes. 
2.8.2 Probe synthesis 
Linearisation of pJET/Insert plasmid DNA 
XbaI (Fermentas) restriction enzyme was used for linearizing the pJET 
vectors containing the inserts. The XbaI cutting site was at the end of the 
insert sequence. The digestion reaction was incubated overnight at 37oC and 
checked on a 1% agarose gel to confirm complete linearization. The 
linearised product was gel extracted and purified to remove digestion reaction 
components before starting the in vitro transcription. 
In vitro transcription 
For in vitro transcription, 1 µg of linearised DNA template was mixed with 4 µl 
of 5X transcription buffer, 2 µl of 10X DIG-labeled NTP mix, 0.5 µl of Ribolock 
RNase inhibitor, 1 µl of T7 RNA polymerase and topped up to 20 µl with MQ 
H2O. The reaction mix was incubated at 37
oC for 2 hrs and 40 mins. 1 µl of 
DNase I was added to the reaction mix and incubated for 20 min at 37oC to 
remove the DNA template. A RNA clean-up was performed using RNeasy 
mini kit and the RNA was eluted in 50 µl. The eluted RNA was mixed with 150 
µl MQ H2O, 20 µl 3M Sodium acetate (pH 5.2) and 500 µl 100% EtOH for 
overnight precipitation at -80oC. Following this, the samples were centrifuged 
at full speed for 45 mins at 4oC and the supernatant was discarded. The pellet 
was washed with 500 µl 80% EtOH and centrifuged at full speed for 30 min at 
 34 
 
4oC. The RNA pellet was air dried to remove excess EtOH and re-suspended 
in 25 µl MQ H2O. To check for the purity and correct size of the generated 
riboprobe, 1 µl was mixed with 1 µl RNA loading dye and 8 µl H2O and 
denatured at 80oC for 10 mins. After denaturation, the solution was visualised 
on a 1% agarose gel. 1 µl of riboprobe was also used for checking the 
concentration on a Nanodrop. The remaining 23 µl riboprobe was mixed with 
77 µl HybMix to generate a stock riboprobe solution, which was stored at -
20oC. 
2.8.3 In situ hybridization 
Preparation of embryos 
Embryos at 31 hpf were fixed in 4% paraformaldehyde/phosphate buffered 
saline containing 0.01% Tween-20 (PFA/PBST) overnight at 4oC. On the next 
day, the embryos were washed in 1X PBST 4 x 5 mins, 1 x 5 mins in 100% 
MeOH and finally stored in 100% MeOH at -20oC until use. The MeOH stored 
embryos were rehydrated in a stepwise gradient of 75%, 50% and 25% 
MeOH/PBST for 5 mins each at r.t., followed by 2 x 5 mins washes with 1X 
PBST at r.t. 
Proteinase K treatment 
The rehydrated embryos were incubated in freshly diluted proteinase K 
(1:8000 dilution in 1X PBST) for 5 mins at r.t. The treatment was stopped by 
two washes with glycine (2 µg/ml in PBST) followed by re-fixation in 4% 
PFA/PBST for 20 min at r.t. The fixed embryos were washed with 1X PBST, 5 






Embryos were pre-hybridised in 500 µl of HybMix in a water bath at 65oC for 
1 hour. The riboprobe stocks were diluted 1:50 or 1:100 in HybMix to prepare 
working solutions. Diluted riboprobes were denatured at 80oC for 10 mins and 
immediately chilled on ice prior to use. After pre-hybridisation, the HybMix 
was removed and embryos were incubated overnight at 65oC in the heat-
denatured riboprobe solution. On the next day, the riboprobes were collected 
and stored at -20oC for future use. The embryos were washed twice in SSCT 
Buffer I (50% formamide/ 2X SSC Tween) for 30 mins, once in SSCT Buffer II 
(2X SSC Tween) for 30 mins and twice in SSCT Buffer III (0.2X SSC Tween) 
for 30 mins. All washes were performed at 65oC. Afterwards, embryos were 
washed twice in 1X PBST for 1 min. 
Antibody incubation 
Embryos were then incubated in 500 µl block solution (5% sheep 
serum/PBST) for 1 hour at r.t., followed by incubation in 500 µl alkaline 
phosphatase coupled Anti-DIG antibody (1:2000) for 2 hrs at r.t. Embryos 
were then washed 6 times in 1X PBST for 20 min at r.t to remove any 
unbound antibody. One wash was performed overnight at 4oC. 
NBT/BCIP staining 
Embryos were incubated twice in pre-staining buffer (0.1 M NaCl, 0.05 M 
MgCl2, 0.1 M Tris-HCl pH 9.5 and 0.1% Tween) for 5 mins at r.t. NBT staining 
buffer (0.1 M NaCl, 0.1 M Tris-HCl pH 9.5, 0.1% Tween and 2% NBT) was 
added to the embryos and the samples were incubated in the dark at r.t until 
the colour had developed. The staining time for srsf6b riboprobe was 4-5 hrs. 
The staining was stopped by three washes of 1X PBST for 5 mins and the 
embryos were finally stored at 4oC in 4% PFA/PBST. 
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2.9 DNA Sequencing 
All sequencing reactions were performed using the BigDye® Terminator v3.1 
cycle sequencing kit on a PCR thermal cycler. A typical setup of the PCR 
sequencing reaction includes 2 μl of BigDye ready reaction premix, 1 μl of 5x 
BigDye sequencing buffer, 1 μl of primer, 100 ng of DNA template and  MQ 
H2O to give a final volume of 10 μl. The thermal cycler conditions used were 
as follows: 96°C for 2 mins, followed by 35 cycles of 96°C at 15 sec, 50°C to 
60°C (depending on the Tm of primers) for 15 sec and 62°C for 4 mins. The 
products were then kept at 4°C before precipitation. To precipitate the PCR 
products, samples were transferred to fresh 1.5 ml tubes. 10 μl MQ H2O, 2 μl 
of 3M Sodium acetate pH 5.2, and 50 μl of 100% EtOH were added to the 
solution and mixed well by pipetting. The samples were then centrifuged at 
full speed for 45 mins at 4°C in a cooling centrifuge (Sorvall Legend, 
Thermoelectron). The supernatant was carefully removed and 500 μl of pre-
chilled 70% EtOH was used for washing the DNA pellet by centrifuging at full 
speed for 30 mins at 4°C. The supernatant was carefully removed and the 
DNA pellet was air dried at 50°C in a heat block for 5-10 mins. The 
precipitated PCR products were kept at -20°C prior to sending for 
sequencing. Sequencing electrophoresis reactions were performed by the 
DNA Sequencing Laboratory (DSL) staff on an Applied Biosystems 3130xl 
Genetic Analyser (ABI) and sequences were analysed using GENtle 1.9.4. 
 
2.10 Agarose gel electrophoresis 
Agarose gels were prepared freshly by dissolving agarose powder (1st Base) 
in 1X TAE buffer to obtain the appropriate concentration, typically 1% to 3%. 
The SYBR® safe DNA gel stain solution was added to the dissolved solution 
at 1:15,000 dilution, and cast into gel casting moulds. Electrophoresis was 
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carried out at 90-110V constant voltage in 1X TAE running buffer using a gel 
electrophoresis chamber (BioRad) and PowerPac™ basic power supply unit 
(BioRad). Gel documentation was performed using the GeneSnap software 
(SynGene) and a G:BOX gel documentation system (SynGene). ImageJ was 
used for quantification of gel band intensities on background corrected 
images. The housekeeping genes gapdh or β-actin were used for 
normalization to ensure equal loading amounts and accurate comparisons of 
ratios or intensities.  
 
2.11 RNA extraction 
20-30 embryos per sample at the appropriate stage were taken for RNA 
extraction. The embryos were homogenised on ice in 350 μl of Buffer RLT 
with β-mercaptoethanol (1:100) using pestles. The lysate was centrifuged for 
3 mins at full speed (14,000 g) using a table top centrifuge (Sorvall legend 
micro 21, Thermoelectron) and the supernatant was transferred to a fresh 1.5 
ml Eppendorf tube. 1 volume of 70% EtOH was added and mixed by 
pipetting. The mixture, up to 700 μl, was then transferred to a fresh RNeasy 
spin column and centrifuged for 15 sec at 10,000 rpm, before discarding the 
flow through. 700 μl of Buffer RW1 was added to the spin column, centrifuged 
at 10,000 rpm for 15 sec before discarding the flow through. 500 μl of Buffer 
RPE was used to wash the spin column by centrifugation at 10,000 rpm for 15 
sec. One more wash with 500 μl Buffer RPE was done by centrifugation at 
10,000 rpm for 2 mins. The RNeasy spin column was transferred to a fresh 2 
ml collection tube and centrifuged at full speed for 1 min to remove any 
residual liquid. The RNeasy spin column was then transferred to a fresh 1.5 
ml Eppendorf collection tube and 30 μl of RNase free H2O was added into the 
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centre of the column for elution by centrifugation at 10,000rpm for 1 mins. The 
elution was repeated with another 30 μl of RNase free H2O.  
2.11.1 DNase I digestion 
All samples used for semiquantitative RT-PCR were subjected to an 
additional step of DNase I digestion to eliminate traces of genomic DNA 
contamination prior to use. 60 μl of RNA samples were incubated with 2 μl of 
DNase I enzyme (Fermentas) for 60 mins at 37°C in a covered heat block 
(Eppendorf Thermostat). Samples were then subjected to a subsequent 
round of RNA clean-up using the RNeasy mini kit. 
2.11.2 RNeasy clean-up 
Clean-up of RNA was performed after DNase I digestion to purify the RNA 
before further experiments. The RNA samples were adjusted to a volume of 
100 μl with RNase free H2O, before addition of 350 μl of Buffer RLT and 
mixed well. 250 μl of 100% EtOH was added to the solution, mixed well and 
transferred to an RNeasy mini spin column. The flow through was discarded 
and the spin column was washed with two successive rounds of 500 μl of 
Buffer RPE by centrifugation at 10,000 rpm for 15 sec and 2 mins, 
respectively. One more round of 1 min centrifugation at 10,000 rpm was done 
on an empty column to remove residual liquid. The RNeasy spin column was 
then transferred to a fresh 1.5 ml tube and 30 μl of RNase free H2O was 
added to the centre of the column and centrifuged at 10,000 rpm for 1 min. 
The elution was repeated with 30 μl of RNase free H2O. The eluted RNA 




2.12 First strand cDNA synthesis for RT-PCR 
Reverse transcription (RT) of the extracted RNA was used to generate cDNA 
using the Revertaid first strand cDNA synthesis kit (Fermentas). Total RNA in 
the range of 1 ng to 1 µg was used as input. RNA samples were mixed with 1 
μl of oligo dT primer and MQ H2O to a volume of 12 μl in PCR tubes. The 
tubes were incubated at 65°C for 5 mins in a PCR machine (Veriti Thermal 
Cycler, Applied Biosystems), spun down and kept on ice. The following 
reagents were added to the tubes: 4 μl of 5X reaction buffer, 1 μl of RiboLock 
RNase Inhibitor (20 U/μl), 2 μl of 10 mM dNTP mix and 1 μl of RevertAid M-
MuLV reverse transcriptase enzyme (200 u/μl) and incubated at 42°C for 60 
mins, followed by 70°C for 5 mins and cooled at 4°C. Minus RT (-RT) controls 
were generated for each batch of RNA samples by using the same setup, 
except for the omission of the reverse transcriptase enzyme. Samples were 
stored at -80°C until further use.  
 
2.13 Alternative splicing assay by semiquantitative RT-PCR 
Semiquantitative RT-PCR was applied for validation of the alternative splicing 
events identified by bioinformatics analysis. Primers were designed to bind to 
exons flanking the alternatively spliced exon (See Table 3). Since the PCR 







2.14 General PCR 
Table 3. List of primers used 
zfSrsf6b_Ex4_Fwd GTTTCGCTCCCACTCTGATATG 
riboprobe for 










zfSrsf6b_Ex1_F GGTGTACATCGGCAAGCTG alternative 
splicing at exon 2 





splicing at exon 6 
of snx9b zfSnx9b_Ex7/8_R CTTCCCCGCTATAAACAGACAAC 
zfZgc:91909_Ex1_F GGAGGAAACACATACTGCTCTTC alternative 
splicing at exon 3 
of zgc:91909 zfZgc:91909_Ex4_R 
CTTGTACTGGCCTGAATGAGAAA
C 
zfSnx27a_Ex10_F CTTTGAATACGTGCGGGGAG alternative 
splicing at exon 
12 of snx27a zfSnx27a_Ex13_R TCTGCGTGTTATGGTGGTCT 
CRISPR RNAamp F CATTATGGTGAAAGTTGGAAC 
gBlock 
amplification 






2.15 Western Blot 
Sample preparation 
70-80 dechorionated embryos at 31 hpf were transferred to an Eppendorf 
tube and excess fish medium was added. 1 ml of deyolking buffer (55 mM 
NaCl, 1.8 mM KCl, 1.25 mM NaHCO3, 4 mM PMSF) was added and embryos 
were deyolked by pipetting them up and down with 200 µl pipette tips. The 
embryos were shaken at 1000 rpm for 5 min at r.t. on a thermomixer followed 
by centrifugation at 300 g, 30 sec at r.t., and the supernatant was discarded. 
The deyolked embryos were washed twice with 1 ml wash buffer (110 mM 
NaCl, 3.5 mM KCl, 2.7 mM CaCl2, 10 mM Tris/Cl pH 8.5) by incubating on a 
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thermomixer at r.t. 1000 rpm for 2 mins and centrifugation at 300 g, 30 sec. 
The embryos were lysed by adding RIPA buffer (50 mM Tris-HCl pH 8.0, 150 
mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 4 mM PMSF; 1 
µl per embryo) and pipetting with 200 µl tips on ice. An equal volume of 2X 
SDS loading buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 0.2% 
bromophenol blue and 10% 2-mercaptoethanol) was added to the tube and 
mixed by pipetting before heating at 95oC for 5 mins. The samples were 
frozen at -20oC until further use.  
SDS-PAGE 
SDS denaturing gels were used for analysing the protein samples. A 10% 
resolving gel and a 5% stacking gel were prepared (Table 4). The frozen 
protein samples were thawed, heated at 95oC for 5 mins and centrifuged at 
full speed for 3 mins. 25 µl of each sample and 5 µl of a PageRuler pre-
stained protein ladder (Fermentas) was loaded onto the gel and run for 60 
mins at a constant voltage of 200V in electrode buffer (25 mM Tris, 190 mM 
Glycine, 0.1% SDS with pH 8.3). 
Table 4. Preparation of SDS-PAGE gels 
 Resolving gel (10%) Stacking gel (5%) 
H2O 4.1 ml 5.7 ml 
30% Acrylamide/Bis 
solution 
3.3 ml 1.7 ml 
Buffer 
2.5 ml of 1.5 M Tris-HCl 
pH 8.8 
2.5 ml of 0.5 M Tris-HCl 
pH 6.8 
10% SDS 100 µl 100 µl 
10% APS 100 µl 100 µl 
TEMED 10 µl 10 µl 






Electrophoretic transfer and immuno blot 
After gel separation, the stacking gel was removed and the remaining gel 
piece was set up for electrophoretic transfer. A PVDF membrane was used 
for transfer after activating it with 100% MeOH. The transfer was done using a 
Mini trans-blot electrophoretic transfer cell (BioRad) at a constant current of 
200 mA for 1 hour. A transfer buffer (25 mM Tris, 190 mM Glycine, 0.1% 
SDS, 10% MeOH with pH 8.3) was used during the transfer and cooled down 
with an ice pad placed into the chamber. After transfer, the PVDF membrane 
was washed thrice with 1X TBST (50 mM Tris, 150 mM NaCl, 0.1% Tween 
with pH 7.4) for 10 mins on a rotator shaker followed by blocking in 5% milk in 
1X TBST for 1 hour at r.t. The membrane was then incubated with primary 
antibody diluted in 5% milk/1X TBST and incubated overnight at 4oC. After 
this, the primary antibodies were recovered and the membrane was washed 3 
times in 1X TBST for 10 mins. This was followed by incubation with 
secondary antibody (diluted in 5% milk/1X TBST) for 1.5 hrs at r.t. The 
membrane was washed 3 times in 1X TBST for 10 mins before visualisation 
of protein samples. For visualisation, the SuperSignal™ west femto 
maximum sensitivity substrate was used.  
Table 5. List of antibodies used for Western blot 
Antibody Species Working solution Company 
Anti-human IGHMBP2 Goat 1:50 Santa cruz 
Anti-PCNA Mouse 1:500 Abcam 
Anti-goat HRP Donkey 1:20,000 Abcam 






2.16.1 CRISPR target site design and gRNA preparation  
CRISPR target sites in srfs6 were identified using the CRISPRscan program 
(http://http://www.crisprscan.org/) (Moreno-Mateos et al. 2015). For this, the 
gene sequence of srsf6b (ENSDART00000002318) was submitted and the 
software predicted all possible target sites with 19 or 20 nt, for generation of 
guide RNAs (gRNAs). Exon 1 was targeted to introduce an early mutation as 
this increased the likelihood to completely disrupt the protein coding 
sequence. Target sites with a score of >70 and no off-targets were selected. 
Score values of >70 indicate highly efficient gRNA sites (Moreno-Mateos et 
al. 2015). Possible off-targets were also identified by performing BLAST 
searches in zebrafish genome. Two target sites were selected, one each in 
exon 1 and intron 1 (Table 6). The selected target sites were used to design 
standard gBlocks® (see Appendix 9) with upstream T7 promoter sequence 
and ordered at IDT (Singapore). 
Table 6. srsf6b CRISPR target sites 




The gBlocks were first amplified using Takara PrimeStar MAX DNA 
polymerase and CRISPR RNAamp primer pairs (Table 3). 4-10 ng of gBlock 
was mixed with 25 µl of 2X PrimeStar enzyme mix and 1 µl each of forward 
and reverse primers. The final volume was adjusted to 50 µl with H2O, mixed 
and run with the following PCR conditions for 25 cycles: 98oC for 10 sec, 
55oC for 5 sec and 72oC for 5 sec. The amplified gBlock DNAs were gel 
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extracted and sequenced with CRISPR RNAamp primers to check for any 
point mutation. 
The gRNAs were transcribed from the respective gBlock using a 
MEGAshortscriptTM T7 kit (Invitrogen). For setting up a reaction mix, 400 ng of 
gBlock was mixed 2 µl of T7 10X Reaction buffer, 2 µl each of T7 ATP, GTP, 
CTP and ATP solution, and 2 µl of T7 Enzyme mix. The total volume of the 
reaction mix was adjusted to 20 µl with H2O and mixed well. The reaction mix 
was incubated at 37oC for 5 hrs, after which 1 µl of TURBO DNase was 
added, for digestion of gBlock DNA, and incubated for at least 45 min at 
37oC. A Sodium acetate precipitation was used for clean-up and purification 
of the gRNAs. 115 µl of fresh MQ H2O, 15 µl of 3M Sodium acetate (pH 5.2) 
and 300 µl of 100% EtOH was added to the reaction mix, mixed thoroughly 
and incubated overnight at -80oC. Then, the precipitated gRNAs were 
centrifuged at full speed for 45 mins at 4oC. The supernatant was discarded, 
and the pellet washed with 80% EtOH and centrifuged again at full speed for 
30 mins at 4oC. The supernatant was carefully discarded and the RNA pellet 
air-dried before re-suspending it in 20 µl of fresh MQ H2O. The quality and 
purity of the gRNAs was assessed by running an aliquot on a 1% agarose 
gel. Samples with single bands were selected for injection. The Nanodrop 
readings were recorded for concentration measurement. gRNAs were stored 
at -80oC. 
2.16.2 Cas9 mRNA preparation  
The Cas9 mRNA was transcribed from the pCS2-nCas9n plasmid (Addgene 
plasmid # 47929) (Jao et al. 2013). This plasmid expressed a zebrafish 
codon-optimised Cas9 protein, having nuclear localisation signal sequence, 
under SP6 promoter (Jao et al. 2013). The plasmid was first digested with 
NotI (Fermentas). 5 µg of pCS2-nCas9n plasmid was linearised with 3 µl of 
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NotI enzyme (30 units) in a reaction volume of 100 µl. The digestion mix was 
incubated 37oC overnight. Then, the entire digestion reaction was run on a 
gel. The linearised plasmid band was gel extracted and stored at -20oC.  
For Cas9 mRNA preparation, a SP6 mMessage mMachine kit (Life 
Technologies) was used. A 20 µl transcription reaction was set up with at 
least 1 µg of linearised pCS2-nCas9n plasmid DNA, 10 µl of 2X NTP/CAP, 2 
µl of 10X Reaction buffer and 2 µl of SP6 Enzyme mix. The reaction mix was 
incubated at 37oC for 2 hrs followed by addition of 1 µl of TURBO DNase and 
incubation at 37oC for another 30 mins. The Cas9 mRNA was purified using 
Sodium acetate precipitation. 115 µl of fresh MQ H2O, 15 µl of 3M Sodium 
acetate (pH 5.2) and 300 µl of 100% EtOH was added to the reaction mix and 
mixed properly before incubating at -80oC overnight. Then, the solution was 
centrifuged at full speed for 45 mins at 4oC, and the supernatant was carefully 
discarded. The RNA pellet was washed with 80% EtOH and centrifuged again 
at full speed for 30 mins at 4oC. Finally, the supernatant was removed 
completely and the RNA pellet was air dried before re-suspending it in 20 µl 
of fresh MQ H2O. The quality and purity of Cas9 mRNA was checked on a 
gel. The concentration was measured on a Nanodrop and the Cas9 mRNA 
was stored at -80oC. 
2.16.3 Microinjection 
100 ng/µl of each gRNA and 300 ng/µl of Cas9 mRNA were mixed and 
injected into one-cell stage zebrafish embryos. The CRISPR mix was injected 
directly into the cytoplasm of the embryos. The injected embryos were raised 
at 28oC until the experimental stage was reached. 
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2.16.4 Genomic DNA (gDNA) extraction 
For gDNA extraction, each injected embryo was lysed in 30 µl of 50 mM 
NaOH at 95oC for 5 mins. The solution was vortexed and spun down, 
repeating these steps three times. After the third round of 95oC incubation, 2 
µl of Tris/HCl pH 8.2 was added for neutralization. The sample was mixed 
properly, vortexed briefly, spun down and incubated on ice for 3 mins. After 
this, the gDNA samples were stored at -20oC until further use.  
For gDNA preparation from immune-stained embryo heads, a DNA lysis 
buffer (10 mM Tris/HCl pH 8.2, 50 mM KCl, 0.3% Tween20, 0.3% Nonidet 40; 
freshly added Proteinase K (18.6 mg/ml) at 1:50 dilution) was used. The 
stained embryos were decapitated in 100% Glycerol and heads were used for 
gDNA extraction. Before starting, the embryo heads were washed thoroughly 
with H2O for 2-3 times to completely remove the glycerol. 20 µl of DNA lysis 
buffer was used for each head sample. The samples were incubated at 55oC 
for 20 mins, vortexed thoroughly, spun down and incubated at 55oC 
overnight. On the following day, the gDNA samples were vortexed thoroughly 
again, spun down and incubated at 95oC for 15 mins for proteinase K 
inactivation. The samples were then stored at -20oC until further use. 
2.16.5 srsf6b mutant screening 
To screen CRISPR injected embryos for introduced mutations in srsf6b, 
gDNA samples were PCR amplified using primers flanking the two CRISPR 
target sites in the srsf6b gene (Table 3). 24 CRISPR injected embryos per 







3.1 A knockdown of Smn leads to motoaxonal defects in zebrafish 
embryos 
Zebrafish is a well-established model organism for SMA and has been 
extensively used in study of the pathomechanism of this disease (McWhorter 
et al. 2003, Winkler et al. 2005, See et al. 2014). Earlier reports have shown 
that MO based Smn knockdown in zebrafish embryos leads to motoaxonal 
defects  in caudal primary motor neurons (CaP) in the form of branching and 
truncation of axons (McWhorter et al. 2003, Winkler et al. 2005, See et al. 
2014). Zebrafish CaP motor neurons have a very stereotypic growth pattern 
with the axons extending ventrally from the ventral root at around 18 hpf to 
the ventral edge of the axial muscles forming NMJs (Myers et al. 1986). By 
about 31 hpf all CaP motor neurons in the anterior spinal cord are fully 
developed with NMJs formed at the ventral muscles. These CaP motoaxons 
can be visualised by immunostaining with α-znp1 antibody that labels 
synaptotagmin 2 on motoaxons. 
To begin with, I repeated the Smn knockdown using MO and performed the 
immunostaining on smn morphants in order to replicate the motoaxonal 
defects shown in earlier reports. The SMN MO used was designed against 
the translational start site of the smn gene (Table 1) and was used at a 
concentration of 3.1 mg/ml as described previously (McWhorter et al. 2003, 
Winkler et al. 2005, See et al. 2014). To assess the specificity of knockdown 
of the smn gene, a standard control MO (Control MO; Table 1) was used. The 
Control MO targets an intron in the human β-globin gene and has no target in 
the zebrafish genome, thus it acts as negative control. I analysed a total of 
120 motoaxons in 10 uninjected HB9-mCherry embryos (12 axons per 
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embryo) and the same axon number in 10 control embryos (Fig. 3B). In both 
control situations, I observed 3.3% (4 defective motoaxons out of 120) of 
motoaxons exhibiting axon outgrowth deficiencies such as ectopic branching 
or axon truncations. Consistent with previous reports (McWhorter et al. 2003, 
Winkler et al. 2005), it was found that upon Smn knockdown the number of 
defective axons was significantly increased to 12.5% (15 defective motoaxons 
out of 120) (Fig. 3C). This suggests that the motoaxonal defects seen in the 
smn morphants was due to the deficiency of Smn protein rather than a non-
specific effect. These defects have been shown to be partially rescued by 
overexpressing full length SMN mRNA (See et al. 2014, Hao le et al. 2015), 
which further confirms that the defects were specific to Smn knockdown.  
 
 
Figure 3. Motoaxonal defects in zebrafish smn morphants. Brightfield 
images of znp1 immunostained HB9-mCherry embryos at 31 hpf. (A) Lateral 
view of HB9-mCherry embryo. Box indicates region above yolk extension 
where motoaxon morphology was assessed. (B) Higher magnification view of 
uninjected HB9-mCherry embryo. (C) Representative embryo after knock-
down of Smn showing severe axon bifurcations (arrows). (D) Motoaxons in 
embryo injected with standard control Morpholino (MO). Scale bar = 50 µm. 
 
3.2 Generation of a zebrafish model for DSMA1 
3.2.1 An IGHMBP2 knockdown leads to motoaxonal defects similar to 
SMA 
Mouse studies have shown that mutations in IGHMBP2 lead to motoaxonal 
degeneration (Grohmann et al. 2004). Given the advantage of zebrafish for 
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live imaging of motor neurons, I wanted to know what happens to motoaxons 
under IGHMBP2 deficient conditions in zebrafish embryos. Antisense 
morpholino oligos were designed against the translation start site of 
Ighmbp2a (Table 1) and injected into zebrafish embryos at the 1-2 cell stage 
at 6.25 mg/ml concentration. Motor neuron morphology was assessed at 31 
hpf using immunostaining with α-znp1. In control embryos at 31 hpf, the 
axons of CaP motor neurons were fully extended and have reached their 
targets in the ventral myotome (Fig. 4A-C). Axon outgrowth was usually 
uninterrupted without obvious branching or truncation of axons, with a few 
rare exceptions (Fig. 4B,F; arrow). A total of 720 motoaxons were analysed in 
60 uninjected wild-type embryos (12 axons per embryo) and the same axon 
number in 60 embryos injected with a Standard control morpholino (Fig. 4C). 
In both control situations, it was observed that 9.3% and 10.1%, respectively, 
of motoaxons exhibited axon outgrowth deficiencies such as ectopic 
branching or axon truncations. In contrast, the number of defective axons was 
significantly increased to 30.0% in ighmbp2 morphants (Fig. 4D,F; 720 axons 
analysed in 60 embryos in six independent injection experiments). In situ 
hybridisation experiment with myoD riboprobe, that stains early muscle 
progenitors, revealed no muscle development defects in ighmbp2 morphants 
(data not shown). The knock-down of endogenous Ighmbp2 protein was 
confirmed by Western blot analysis (Fig. 4E). In mouse model for DSMA1, 
motor axon degeneration occurs very early and precedes fiber atrophy 
(Krieger et al. 2013). Reduced axon elongation and pathfinding has been 
observed in Ighmbp2 deficient cultured motor neurons (Krieger et al, 
unpublished data). Taken together, the results, obtained in zebrafish after 
ighmbp2 knockdown, were similar to what was observed in mouse. This 
opens the possibility to use the motor neuron FAC sorting protocols in the 
zebrafish model also for IGHMBP2 deficient embryos, to address the 
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pathomechanism underlying DSMA1. Also the motoaxonal defects (axon 
branching and truncation) observed in zebrafish ighmbp2 morphants were 
similar to that seen in smn morphants (Fig. 3C) as well as in nrxn2a 
morphants (See et al. 2014). This opens up a new question: Why does a 
deficiency in three different proteins, all having independent yet mutually 
exclusive functions, manifest in a similar cell-type specific phenotypic defect. 
Comparison of differentially expressed genes in motor neurons of smn 
morphants as well as ighmbp2 morphants using RNAseq would help to shed 


























Figure 4. Motoaxon outgrowth defects in Ighmbp2 deficient zebrafish 
embryos. (A) Lateral view of zebrafish embryo at 31 hpf after immunostaining 
with znp1. Box indicates region above yolk extension where motoaxon 
morphology was assessed. 12 motoaxons (6 on either side of the body axis) 
were analysed per embryo. (B) Higher magnification view of uninjected wild-
type (WT) embryo. Note bifurcation in one axon (arrow). (C) Motoaxons in 
embryo injected with Standard control Morpholino (MO). (D) Representative 
embryo after knock-down of Ighmbp2 showing severe axon bifurcations 
(arrows). (E) Western blot analysis of endogenous Ighmbp2 protein levels in 
uninjected (WT), control Morpholino injected (con; 6.25 mg/ml) and Ighmbp2 
Morpholino (MO; 6.25 mg/ml) injected embryos. The equivalent of 
approximately 10 embryos was loaded per lane. PCNA (proliferating cell 
nuclear antigen) was analysed on the same filter as loading control. (E) 
Quantitative analysis of motoaxon defects. Percentage of defective axons in 
ten randomly picked embryos derived from six independent injection 
experiments (total number of axons analysed per sample: 720). Significant 
increase in frequency of motoaxon outgrowth defects (bifurcations, 
truncations) in Ighmbp2 deficient embryos (p = 0.0096 for uninjected versus 





3.3 HB9:eGFP/mCherry embryo dissociation and FAC sorting of 
motor neurons 
3.3.1 Optimization of embryo dissociation conditions and FAC sorting of 
motor neurons  
With the SMN MO knockdown working well in my hands, I next used whole 
embryo dissociation to obtain single cell suspensions. For establishing an 
optimised protocol, HB9-mCherry embryos were used for generating single 
cell suspensions that were subjected to FAC sorting. A „Papain Dissociation 
System protocol‟ (Worthington Labs), similar to one reported by Cerda et al., 
was adopted for dissociating whole zebrafish embryos (Cerda et al. 2009).  
Initially, I started dissociating the embryos according to the manufacturer‟s 
instructions with some modifications. 100-300 dechorionated HB9:mCherry 
embryos at 28 hpf were deyolked in Ringer‟s solution and incubated with 500 
µl of Papain/DNase I solution at 30oC followed by mechanical dissociation. 
Cells were recovered in L-15 media containing 1% FBS and observed under 
the Fluorescence microscope. The critical step in this protocol was to 
optimize the papain incubation condition to obtain a maximum yield of live 
mCherry positive cells (motor neurons). Initially, 30 min papain incubation on 
a thermomixer at 700 rpm (as described in Cerda et al. 2008) was used, but 
these conditions were too mild to yield single mCherry positive cells. When 
observed under the fluorescence microscope, cell clumps and small tissue 
fragments were seen indicating incomplete dissociation (Fig. 5A). 
Next, the incubation time was increased to 2 hrs with 1400 rpm shaking. 
These conditions yielded 12,500-23,400 single mCherry positive cells per 100 





Figure 5. Hb9-mCherry positive cells after embryo dissociation. (A) 
Fluorescence image after papain dissociation for 30 min. mCherry positive 
tissue fragments (arrow) were visible indicating incomplete dissociation. (B) 
Single mCherry positive cells obtained from 120 embryos after 2 hrs of papain 
incubation. 
 
Table 7. Number of cells obtained after embryo dissociation with 2 
hrs of papain incubation  
 
Next, it was necessary to assess the condition of these single cells, i.e. 
whether they were still alive after being dissociated from whole embryos. For 
this, an initial round of FAC sorting was employed. The FACS instrument can 
quantify the exact percentage of live and dead cells in the sample.  
HB9:eGFP were used for FACS optimisation and all subsequent experiments. 
The sorting was done using a BD FACSAria Cell sorter available at the 
Biopolis Shared Facility. The single cell suspensions after dissociation were 
stained with DAPI for labeling dead cells and introduced into the FACS 




















cells per 100 
embryo 
1 120 1.9 million 15,000 0.76 1.6 million 12,500 
2 105 3.2 million 24,588 0.76 3.0 million 23,416 
3 318 9.4million 58,300 0.62 2.9 million 18,333 
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machine where they were sorted using different parameters. Firstly, the total 
sample was analysed to separate a homogeneous cell population from cell 
aggregates and cell debris on the basis of size (Forward Scattering, FSC) and 
granularity (Side Scattering, SSC) (Fig. 6D). 60% of cells were gated at this 
step while rest was discarded as debris or cell aggregates. This population 
was then further scrutinized to obtain single cells and eliminating doublets 
using SSC and FSC gating (Fig. 6E,F). More than 90% of cells were selected 
for the next step. These defined single cells were subjected to live/dead 
screening by analysing DAPI fluorescence. DAPI does not penetrate cell 
membranes well and therefore live cells do not take it up efficiently. In 
contrast, DAPI enters dead cells readily, thus labeling them (Fig. 6G). More 
than 99% of the gated cells were found to be alive. Finally, after removing 
DAPI positive dead cells, live single cells were screened for specific 
fluorescence. Cells with high fluorescence intensity were then sorted from the 
rest of the weak/non-fluorescent cells (Fig. 6H). The sorted cells were 
collected in L-15 medium containing 20% FBS. Wild-type embryos as well as 
non-transgenic sibling embryos were used to optimize the parameters for 
FAC sorting.  
Using these reference settings with minor adjustments, I was successful in 
identifying and collecting motor neuron cell populations from dissociated cells 
obtained from whole embryos after 2 hrs of Papain incubation. Unfortunately, 
the yield of mCherry positive cells was low in the initial attempts (approx. 
0.3% of total live cells). This indicated that the selected embryo dissociation 
conditions were too harsh, thus destroying the cells. To improve the number 
of sorted cells, the dissociation conditions were made milder by reducing 
papain incubation time to 45 min and shaking to 1200 rpm. The cell survival 
increased and the yield of cells also increased from 0.3% to 1% yielding a 
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significantly higher number of mCherry positive cells. Also with reduction in 
papain incubation time, total duration of the whole procedure was reduced to 
less than 2 hrs. This is important as a shorter procedure ensures that the 
transcriptome profile of sorted cells does not change much and RNAseq 
results are therefore more accurate. On average, 35,000 GFP positive motor 
neurons were sorted out from 290 HB9:eGFP embryos. The sorted GFP 
positive motor neurons were collected in 20% FBS/L-15 medium, pelleted 





Figure 6. FAC sorting of eGFP positive motor neuron cells. (A) 
HB9:eGFP embryo at 30 hpf. Brightfield (B) and fluorescent image (C) of 
sorted GFP positive cells. (D) Total cells were presented in a FSC-A vs. SSC-
A plot to screen for homogenous cell populations (enclosed region) without 
cell debris and cell aggregates (everything except enclosed region). (E and F) 
The cell population was then checked again on SSC and FSC plots to remove 
any doublets and for selection of only single-cell populations (SSC and FSC 
gating). (G) These populations were checked for live cells (enclosed region; 
DAPI negative) among the entire single cell population. Cells on right side of 
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plot were dead (DAPI positive). (H) Finally live single cells were sorted on the 
basis of eGFP fluorescence. The GFP POS gated population represents live 
eGFP positive cells that were finally collected in L-15 media containing 0.5% 
FBS. 
 
3.3.2 Total RNA extraction from sorted motor neurons 
The cell samples frozen in TRIZOL were used for extracting total RNA. For 
obtaining RNA samples with optimal quantity and high quality from the FAC 
sorted motor neuron cells, a phenol-chloroform based extraction method 
followed by column purification was used. RNA extraction from very low cell 
numbers (less than 5,000) usually gave low quality RNA. To improve quality 
and quantity of RNA, the TRIZOL frozen cells were pooled together to 
achieve more than 15,000 cells. With the optimised RNA extraction protocol, 
28 ng of total RNA was purified from 35,000 GFP positive motor neurons. The 
quality of the purified RNA samples was assessed using RNA 6000 Pico kit 
and Agilent 2100 bioanalyser. The Agilent bioanalyser gives an RNA Integrity 
Number (RIN) as a read out for RNA quality. A RIN value of 1 represents 
degraded RNA while value of 10 indicates an intact RNA. All of the RNA 
samples generated had RIN values >9 which was suitable for the 
downstream RNA library preparation. Fig. 7A shows an Agilent bioanalyser 
profile for one of the GFP positive motor neuron RNA samples with a RIN of 
9.7. RNA samples were stored at -80oC until the start of the library 
preparation. 
To confirm the identity of the sorted cells, a RT-PCR was performed on RNA 
obtained from sorted HB9:eGFP positive motor neurons. Primers were 
designed for the following specific lineage markers: hb9, gfp, isl1, sox2 (for 
motor neurons); prl1 (pituitary gland); and gcga (pancreas). The RT-PCR 
results showed strong expression of hb9 and isl1. A strong gfp band indicated 
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presence of motor neurons in the sorted cells (Fig. 7B). Sox2 is expressed in 
motor neuron progenitors until they exit the cell cycle, switch off sox2, turn on 
hb9 expression and differentiate into mature motor neurons (Briscoe and 
Novitch 2008). A considerable sox2 band can be explained by the presence 
of HB9:eGFP positive motor neurons with residual sox2 transcripts (Fig. 7B). 
Absence of bands for prl1 and gcga indicates absence of pituitary and 
pancreatic cell types in the sorted cell population, respectively (Fig. 7B). 
Taken together, the RT-PCR results suggest an enrichment of motor neurons 
in the sorted cells after FACS. 
 
Figure 7. Total RNA extracted from FAC sorted motor neurons. (A) 
Agilent bioanalyser profile for a GFP positive motor neuron RNA sample with 
a RIN of 9.7. (B) RT-PCR gel image showing strong expression of motor 
neuron markers (hb9, isl1, sox2 and gfp) but no expression of non-motor 
neuron lineage markers (prl1 and gcga) suggesting enrichment of motor 
neuron populations after FAC sorting. β-actin was used as loading control. 
 
3.4 Preparation of cDNA libraries from Smn-deficient motor 
neurons  
After having optimised the protocol for embryo dissociation, FAC sorting and 
RNA extraction for control embryos, the next step was to use these conditions 
for sorting out GFP positive motor neurons from Smn deficient zebrafish 
embryos (hereafter named „SMA MN‟ for simplicity). SMN has a well-
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established role in the assembly of U snRNPs and is thus important for 
formation of spliceosome (Pellizzoni et al. 2002, Gubitz et al. 2004). It has 
been proposed that alternative or aberrant splicing of transcripts occurs in 
motor neurons under SMN deficient conditions (Zhang et al. 2008). To identify 
alternatively or aberrantly spliced transcripts, RNAseq was performed on RNA 
from motor neurons under Smn deficient conditions. HB9:eGFP transgenic 
embryos were injected with SMN MO and Control MO. Embryos were 
dissociated at 28 hpf and subjected to FAC sorting to obtain motor neurons. 
Total RNA was extracted from the sorted motor neurons and high quality RNA 
samples (RIN >9.5) were then used for preparation of cDNA libraries using 
the SMARTer Ultra Low Input RNA for Illumina sequencing-HV (Clontech 
Laboratories) and NEBNext Ultra Library Prep kit for Illumina (New England 
BioLabs).  
3.4.1 Synthesis of double stranded cDNA from total RNA derived from 
Smn-deficient motor neurons  
The first step in library preparation was synthesis of cDNA from total RNA. 
For cDNA synthesis, the SMARTer Ultra Low Input RNA for Illumina 
sequencing-HV system from Clontech Laboratories was used. This kit has 
been previously used for preparation of high quality cDNA samples for 
RNAseq from very low input RNA (Head et al. 2014, Shanker et al. 2015) as 
well as single neurons (Qiu et al. 2012). For RNAseq library preparation, 1-10 
ng of RNA samples with high quality (RIN >9.5), as assessed from Agilent 
bioanalyzer, were used (Fig. 8A,B). A total of three sets of the motor neuron 
sample from smn morphants (SMA MN) and control (Control MN) embryos 
were used for RNAseq library generation. Table 8 lists the details of all 
samples that were used for preparing SMA motor neuron RNAseq libraries. 
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RNA samples were subjected to cDNA synthesis followed by amplification 
using long-distance PCR. The PCR cycles were increased from the 
recommended 12 to 13 cycles for Sample 1 (both SMA MN and Control MN), 
and to 16 PCR cycles for Sample set 2 and 3. Positive and negative control 
reactions were also set up to check whether the kit was working properly as 
well as to exclude any contamination in the reaction mixture. Next, the 
amplified double stranded cDNA samples were assessed for quality using HS 
DNA kit and Agilent bioanalyser (Fig. 8C,D). Finally, the cDNA samples were 
sheared into 200-500 bp fragments using Covaris AFA system which uses a 
focused ultrasonic acoustic energy. The fragmented cDNA samples were 
then used for library preparation. 






















254 36000 27.4 9.5 6.81 4.8 
Sample 
2 
405 37370 29.7 9.7 2.7 145.41 
Sample 
3 





259 18000 10.2 9.5 7.65 5.15 
Sample 
2 
378 15600 11.4 9.6 2.7 137.64 
Sample 
3 
191 15200 19.9 9.5 2.7 157.06 
 
3.4.2 Preparation of cDNA libraries 
NEBNext Ultra Library Prep kit for Illumina (New England BioLabs) was used 
for preparing libraries from fragmented cDNA samples. cDNA samples were 
subjected to blunt-end repair and dA-tailing followed by ligation of adaptors 
which contain annealing sites for index primers and the universal primer. 
Index primers 6 and 12 were used for multiplexing two libraries while primers 
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2, 6, 7 and 12 were used for multiplexing four libraries in one lane. The 
number of PCR cycles for amplification step was optimised according to 
different input cDNA amounts. Finally, the libraries were cleaned up using the 
AMPure beads followed by assessment of quality of each library using HS 
DNA kit and Agilent bioanalyser (Fig. 8E,F). Successful cDNA library samples 
were multiplexed and submitted for RNAs sequencing 
 
Figure 8. Assessment of quality for extracted RNA, amplified cDNA and 
final library during SMA MN library preparation using Agilent 2100 
bioanalyser. Each step in the protocol was checked by running 1 µl sample 
on a bioanalyser. The Y-axis represents the fluorescence intensity detected 
(FU). The X-axis represents fragment size of RNA or DNA in nucleotides (nt) 
or base pair (bp), respectively. Representative profiles for one SMA MN 
sample and one Control MN sample are shown. (A,B) Electropherograms of 
input RNA for SMA and control MN sample used for RNAseq library 
preparation. RIN value for both samples was 9.5. (C,D) Electropherograms of 
amplified cDNA obtained after first strand cDNA synthesis and amplification 
during SMARTer protocol. (E,F) Electropherograms of cDNA libraries after 
completion of NEBNext library prep protocol, with lengths of all the 




3.4.3 RNA sequencing of Smn-deficient motor neurons 
All individual libraries generated were multiplexed into one lane to achieve 
100-200 million sequencing reads and were sequenced using the paired-end 
sequencing method on an Illumina HiSeq platform. Libraries were quantified 
using qPCR and multiplexed before submitting for sequencing at the Genome 
Institute of Singapore (GIS). Performing qPCR was necessary for achieving 
accurate normalisation and clustering, which was not possible using the Qubit 
assay or bioanalyser (Vuyisich et al. 2014). A total of three sets of motor 
neuron libraries were generated from Smn deficient and control embryos. 
Ideally, a single lane in Illumina HiSeq platform can generate more than 400 
million paired-end reads. The number of samples/libraries to be multiplexed 
was dependent on how much depth/number of reads was required for each 
library. For identifying the changes in gene expression profile, low depth 
(approx. 30-50 million reads) is sufficient. In my case where the aim was to 
identify alternative splice transcripts or for identification of novel genes, very 
deep sequencing was required (more than 100 million reads). The Sample 1 
library for both SMA MN and Control MN was run on a single lane on the 
Illumina HiSeq platform, while library sets for Samples 2 and 3 were 
multiplexed and run on one lane. The sequencing was performed using the 
paired-end method, where each cDNA fragment was sequenced from both 
directions (forward and reverse), with read lengths of 75-100 bp. The data 
generated using this method was suitable for identification of alternatively 
spliced transcripts expressed at very low levels. Typically, 40 million mapped 
reads provides reliable measurement of a single transcript per cell (Mortazavi 
et al. 2008). The RNAseq was performed with a Next Generation Sequencing 




3.4.4 RNA sequencing of FAC sorted DSMA1 motor neurons 
An ighmbp2 knockdown leads to motoaxonal defects in zebrafish embryos 
(Fig. 4D), which were similar to those observed after smn knockdown (Fig. 
3C) (McWhorter et al. 2003, Winkler et al. 2005, See et al. 2014) and nrxn2a 
knockdown (See et al. 2014). In order to understand what leads to such 
defects, I generated RNAseq data for FAC sorted motor neurons from 
IGHMBP2 deficient and control embryos. Using the optimised protocols for 
embryo dissociation, FAC sorting and RNA extraction protocols, high quality 
total RNA (RIN >9) was extracted from FAC sorted motor neurons under 
IGHMBP2 deficient and control conditions.  




















179 15,720 33.5 9.4 2.7 207.01 
Control MN       
Sample 1 
142 21,760 33.3 9.3 2.7 311.91 
 
Only one set of motor neuron library was generated from IGHMBP2 MO 
injected (DSMA1 MN) and control (Control MN) embryos. Details for the 
samples used for RNAseq is listed are Table 3. In this case, 2.7 ng of input 
RNA (Fig. 9A,B) was used as input with the SMARTer kit for preparing cDNA 
and later it was amplified using LD-PCR with 16 cycles. The resulting 
amplified cDNA was checked for quality using Agilent bioanalyser (Fig. 9C,D) 
and subjected to Covaris shearing. The sheared cDNA samples were then 
quantified using Qubit HS DNA assay and used for preparing libraries using 
NEBNext kit with the PCR cycles adjusted according to the sheared cDNA 
input (Table 9). Index Primers 7 and 12 were used for barcoding the libraries.  
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The libraries were assessed for quality using an Agilent bioanalyser (Fig. 
9E,F) and multiplexed together on the basis of qPCR results. The libraries 
were finally run on Illumina HiSeq platform using paired-end sequencing 
method with 100 bp read length. 
 
Figure 9. Assessment of quality for extracted RNA, amplified cDNA and 
final library during DSMA1 motor neuron library preparation using 
Agilent bioanalyser. Each step in the protocol was checked by running 1µl 
sample on bioanalyser. The Y-axis represents the fluorescence intensity 
detected (FU). The X-axis represents the fragment size of RNA or DNA in 
nucleotides (nt) or base pair (bp), respectively. (A,B) Electropherograms of 
input RNA for DSMA1 and control MN samples used for RNAseq library 
preparation with RIN values of 9.4 and 9.3, respectively. (C,D) 
Electropherograms of amplified cDNA obtained after first strand cDNA 
synthesis and amplification during SMARTer protocol. (E,F) 
Electropherograms of cDNA libraries after completion of NEBNext library prep 




3.5 Transcriptome analysis identifies differentially expressed 
genes in Smn deficient motor neurons 
After the completion of sequencing run, the multiplexed libraries were de-
multiplexed to sort the reads according to their barcodes (index primers) and 
finally the data for individual libraries were downloaded from the GIS server in 
fastq formats. Sample 1 motor neuron library set which was sequenced alone 
produced more than 200 million reads each (Table 10). Sample 2 and 3 
library set were multiplexed together thus yielding approx. 100 million reads 
(Table 10) except for Sample 3 Control MN library (78 million reads). This 
difference in the no. of reads obtained could be due to improper pooling of the 
four libraries (Sample 2 and 3 library set) before submitting for the 
sequencing run. However, the overall quality of sequencing, as assessed by 
FastQC, was very high in that the average base Phred quality score (Q) was 
around 35 (Table 10). As a point of reference, a value of 30 for Q represents 
base call accuracy of 99.9%. The % of >=Q30 bases (percentage of base 
calls with greater than 99.9 % accuracy) was higher than 90% for all the 
libraries (Table 10).  











SMA MN Sample 1 14,676 216,714,968 90.10 35.20 
Control MN Sample 1 14,784 218,480,980 90.27 35.29 
SMA MN Sample 2 10,164 108,355,474 90.12 35.02 
Control MN Sample 2 10,014 106,870,888 90.33 35.1 
SMA MN Sample 3 9,984 106,732,056 90.65 35.21 
Control MN Sample 3 7,411 78,892,948 90.64 35.2 
 65 
 
The raw RNAseq data (fastq files) was then used for bioinformatics analysis, 
which was done in collaboration with Dr. Candida Vaz, Dr. Vivek Tanavde 
and Dr. Brian Parker at the Bioinformatics Institute Singapore (BII).  
3.5.1 Mapping of RNAseq data to zebrafish genome 
The raw fastq files contain sequences of all the reads obtained for a particular 
library. These read sequences were comprised of actual cDNA sequence plus 
the adaptor sequence which was added during the library preparation step 
and thus needs to be removed before mapping them to the zebrafish 
reference genome. For trimming off the adaptor sequence, CutAdapt tool was 
used (See Appendix 2a). This tool identifies any particular sequence in the 
reads and removes it. It can be used to remove poly-A tails, primer, or in case 
of RNAseq data, adaptor sequences. The trimmed read sequences were then 
mapped to zebrafish reference genome, Zv9, using the TopHat version 2.0.12 
(see Appendix 2b).  
Table 11. SMA MN RNAseq reads mapped to zebrafish reference 
genome Zv9 using TopHat 
 
The total no. of reads per sample were between 78,892,948 and 218,480,980 
(Table 11); between 71.4% and 83.2% of the reads were uniquely mapped to 
the zebrafish reference genome. The no. of aligned pairs per sample were 
between 22,498,973 and 75,375,208 (Table 11), out of which concordant pair 
 
Control MN SMA MN 
 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
Total Reads 218,480,980 106,870,888 78,892,948 216,714,968 108,355,474 106,732,056 
Reads Mapped 83.2% 72.6% 73.7% 81.9% 71.4% 73.5% 
Total Paired 
Reads 
75,375,208 29,919,473 22,498,973 74,202,859 29,763,979 30,416,870 
Concordant 
Pairs Mapped 
74.6% 58.5% 59.1% 74.1% 57.3% 59.6% 
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reads were between 57.3% and 74.6% uniquely mapped to the zebrafish 
reference genome (Table 11).  
3.5.2 Differential gene expression analysis of Smn deficient motor 
neurons identifies deregulated transcripts 
After running the TopHat tool for mapping of raw RNAseq data, bam files 
were generated as an output which contains sequence alignment data for all 
the mapped reads. This was the main file for all the downstream RNAseq 
data analysis. The bam files for all six libraries were used for differential gene 
expression analysis using Partek Genomics Suite 6.6 (Partek Inc.). This is 
one of the most commonly used software for NGS and Microarray data 
analysis. All the bam files were imported into the software and the mRNA 
quantification was done to identify all the transcripts that were differentially 
expressed across the samples. The normalisation method used by Partek 
Genomics Suite was Reads Per Kilobase of exon model per Million mapped 
reads or RPKM, which represents the expression of particular gene 
normalised to gene length and the total no. of mapped reads obtained in the 
RNAseq experiment. These RPKM values can then be compared across 
different experimental conditions to determine the changes in regulation for 
each gene. 
A total of 13,923 expressed genes were identified in motor neurons at 28 hpf 
out of which 312 genes were found to be differentially expressed in SMA MN 
(Fold change >2 and p-value <0.05). Out of 312 differentially expressed 
genes, 133 were down-regulated in SMA MN as compared to Control MN 
while 179 were up-regulated. A list of all differentially expressed genes is 
provided in Appendix 3. I categorised the differentially expressed genes 
based on their available expression data in the ZFIN database. The genes 
were categorised into five groups (Fig. 10): (1) Neuron-specific genes, 
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expressed exclusively in zebrafish neurons; (2) Neuron-related genes, which 
not specific to neurons but also expressed in other tissues of zebrafish; (3) 
Non-neuronal genes, which are not reported to be expressed in neurons but 
found in other non-neuronal tissues of zebrafish; (4) Uncharacterised genes 
with known human homologs but with no known zebrafish function; (5) 
Uncharacterised genes without human homolog thus representing novel 
zebrafish-specific genes. Interestingly, 33% of the down-regulated and 50% 
of the up-regulated genes were found to be uncharacterised in zebrafish, 
among which a majority of transcripts have known human homologs (Fig 10). 
In case of down-regulated genes, 34% have a neuronal expression while the 
rest (33%) has no reported neuronal expression. On the other hand, only 20% 
of the up-regulated genes have neuronal expression and 30% were without 
reported neuronal expression. 
 
Figure 10. Summary of transcriptomic changes identified in SMA motor 
neurons by RNAseq analysis. Pie-charts showing the genes identified in 
down-regulated and up-regulated gene lists, classified by the expression data 




3.5.3 Gene Ontology (GO) enrichment using Partek 
To determine the biological relevance of the differentially expressed genes 
under Smn knockdown conditions, Gene set analysis feature in Partek 
genomics suite was used. Gene Ontology (GO) analysis revealed a list of GO 
terms that were over represented in the list of differentially expressed genes. 
This would consequently suggest a particular biological process or function 
that was being affected because of Smn knockdown in motor neurons. A total 
of 166 GO terms were found to be over represented with a p-value cut-off of 
0.05. The top ten most enriched terms are shown in Fig. 11. Many of these 
terms were related to developmental processes suggesting that a Smn 
deficiency in motor neurons affects genes related to neuronal differentiation. 
 
Figure 11. Gene Ontology (GO) analysis of differentially expressed 
genes between Smn deficient and control motor neurons. GO analysis 
was performed on differentially expressed genes with at least a 2-fold change 
and p-values less than or equal to 0.05. Top 10 GO terms enriched are 
represented in a bar graph with the Y-axis showing the enriched GO terms 
and the X-axis showing the respective enrichment score values. 
 
3.5.4 Identification of differentially expressed genes in DSMA1 MN  
The RNAseq data for DSMA1 MN and Control MN libraries were analysed in 
a similar fashion as mentioned above for SMA MN. In this case, only one set 
each of DSMA1 MN and Control MN libraries was generated and sequenced. 
95,716,496 and 103,384,698 reads were obtained from sequencing of Control 
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MN and DSMA1 MN libraries, respectively, with high sequencing quality 
(Table 12). The Mean Phred quality score (Q) was 35 for both the samples 
with more than 90% of base calling at 99.9% accuracy. After the adaptor 
trimming of the raw RNAseq data using the CutAdapt tool, the trimmed reads 
were mapped to Zv9 zebrafish reference genome using TopHat. 73.1% and 
68.4% of total reads in Control MN and DSMA1 MN data respectively, were 
mapped uniquely to the zebrafish reference genome (Table 12).  
Table 12. DSMA1 MN RNAseq results 
 
Control MN SAMRD1 MN 
Sample 1 Sample 1 
Total Reads 9,57,16,496 10,33,84,698 
Reads Mapped 73.1% 68.4% 
Total Paired Reads 2,62,94,281 2,73,35,743 
Concordant Pairs Mapped 39.1% 56% 
 
Using Partek Genomics Suite, 13,487 expressed genes were identified out of 
which 1,666 were differentially expressed in DSMA1 MN (Fold change >2). In 
this case, p-values were not obtained as the dataset was n=1, so only a fold 
change cut-off was used. Out of 1,666 differentially expressed genes, 740 
were down-regulated while 926 were up-regulated.  
In order to analyse genes that were differentially regulated in both the SMA 
MN and DSMA1 MN, I compared the two differential gene expression lists. 93 
genes were found to be overlapping among the two lists out of which 21 
genes had opposite regulation pattern in both lists (Table 13A), 19 genes 
were down-regulated in both lists (Table 13B), and 53 were up-regulated in 
both lists (Table 13C). GO enrichment analysis was performed to determine 
the biological relevance of these overlapping genes. A total of 197 functional 
terms were identified to be significantly over represented (p-value <0.05) 
among the overlapping genes. Some of the top terms were related to 
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regulation of cellular component movement, dedifferentiation, regulation of 
axon guidance and axonogenesis etc. This suggests that genes involved in 
axonogenesis or axon guidance were commonly affected both in SMA or 
















































Table 13. List of differentially expressed genes that overlap between 




A. Genes with opposite regulation 







urp2 -10.15 2.75 
zgc:162324 -4.31 4.66 
si:dkey-169i5.4 -3.55 2.56 
tdrd6 -3.33 2.46 
si:dkey-188i13.10 -3.04 2.91 
lmcd1 -2.93 2.09 
zgc:193681 -2.88 2.02 
slc27a6 -2.68 2.08 
plxnb2b -2.54 3.95 
hcst -2.37 2.66 
rad21l1 -2.37 12.33 
serpinb1 -2.25 2.10 
zgc:195173 -2.16 2.94 
acvrl1 -2.03 2.06 
si:ch211-14a17.7 -2.03 4.10 
zgc:172079 2.08 -2.26 
apobec2a 2.08 -2.55 
adh8a 2.96 -3.73 
nitr3c 3.94 -6.22 
olfm2b 4.93 -2.67 
ugt2a1 13.83 -4.48 








gnb3a -31.97 -4.55 
zp2l2 -8.12 -14.27 
si:dkey-11p23.7 -5.07 -11.99 
zgc:195356 -4.06 -9.99 
tnni2a.1 -3.04 -21.09 
ahr1b -2.88 -2.41 
si:ch211-251b21.1 -2.75 -2.34 
arl3l2 -2.71 -3.22 
glis3 -2.71 -16.43 
npas4a -2.56 -2.59 
sst1.1 -2.35 -2.37 
cdnf -2.25 -4.57 
rtn4rl2a -2.24 -5.24 
rx2 -2.20 -3.59 
vax1 -2.14 -2.21 
smyd1a -2.08 -3.49 
camk2a -2.03 -4.88 
ctssa -2.03 -2.85 
zgc:66455 -2.00 -3.60 














tspan15 2.01 2.80 LOC100536659 3.16 3.35 
hsd3b7 2.02 2.03 fbxo32 3.16 3.11 
ttpa 2.03 2.22 cdh15 3.22 4.42 
tnfaip2a 2.03 2.04 myl4 3.25 2.34 
si:dkey-261j4.5 2.08 3.10 zgc:113363 3.36 3.21 
eva1bb 2.09 4.78 si:ch211-222k6.3 3.38 2.76 
eif2ak2 2.13 6.70 zgc:101663 3.40 2.56 
abhd6b 2.14 2.36 zp3a.2 3.52 2.42 
fam129aa 2.15 3.79 dkk1b 3.55 4.67 
rbm24a 2.15 2.42 ggh 3.63 2.61 
mmp9 2.21 2.42 lingo3a 3.78 2.82 
hmox1a 2.21 3.01 apoeb 3.84 4.38 
zgc:113337 2.34 3.05 ccdc106b 3.94 4.27 
si:ch211-237l4.6 2.37 2.14 si:dkey-222p3.1 3.94 3.02 
slc9a2 2.46 6.25 sepw2b 4.02 2.74 
gata1a 2.56 2.09 jam2a 4.59 2.74 
kcnc4 2.56 2.45 dmrt2a 4.70 2.60 
cyp2k16 2.58 6.57 gnmt 4.86 2.36 
efemp2b 2.66 2.84 slc5a2 4.93 3.76 
tagln2 2.69 2.45 tmed1a 5.27 2.44 
si:ch211-81a5.5 2.71 3.55 chrng 5.62 2.75 
csf2rb 2.74 2.21 apoc1l 5.83 6.29 
fn1b 2.80 3.74 fbxl22 5.96 2.26 
cyp3c1 2.81 2.36 mespba 8.87 19.49 
phlda2 2.90 2.24 pcdh8 10.36 3.38 
calhm2 2.96 6.74 mgspbb 10.84 39.23 
baiap2l1b 3.12 3.03  
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3.6 Smn knockdown causes alternative splicing changes in motor 
neurons 
For identification of alternatively spliced transcripts, the Multivariate Analysis 
of Transcript Splicing (MATS) software was used. The bam files, obtained 
after TopHat mapping, were used as input for the MATS program. MATS 
uses, for each exon, the counts of RNAseq reads mapped to exon-exon 
junctions for estimating the exon inclusion levels in two samples. The 
statistical model of MATS then calculates a p-value and the values for the 
false discovery rate (FDR) for each exon. MATS automatically detects and 
analyses the alternative splicing (AS) events related to all major alternative 
splicing patterns. It analyses skipped exon (SE), mutually exclusive exons 
(MXE), retained intron (RI), alternative 3‟ (A3SS) and 5‟ (A5SS) splice site 
events (Fig. 12B). Overall 13,721 AS events were detected by MATS on 
comparing the SMA MN and control MN RNAseq data. Out of these 13,721 
AS events, 284 events were found to be significant based on a FDR cut off of 
0.1 (10%). Appendix 6 provides the list of all the significant AS events 
identified in SMA MN. The majority of these 284 events were SE events (222 
events, 78%) (Fig. 12A). Apart from SE, other types of alternative splicing 
patterns were also detected (Fig. 12A): MXE (58 events, 20%), A3SS (1 
event), A5SS (1 event) and RI (2 events). The number of AS events was not 
directly proportional to the number of genes as some genes had more than 
one AS event happening at different exons. There were only 248 genes found 
to be alternatively spliced with 27 of them having more than one AS event. 
All of the 248 AS genes were screened for potential candidate genes with the 
search criteria that they were expressed in motor neurons or any other type of 





Figure 12. Alternative splice events in Smn-deficient motor neurons 
identified by MATS software. (A) Total number of significant AS events, 
identified in Smn-deficient motor neurons, represented as pie chart. A FDR 
cut-off of 0.1 (10%) was used for defining significant events. (B) MATS 
detects five types of alternative splice events and analyses them. SE event 
represents inclusion or exclusion of an exon between two constitutive exons. 
A5SS and A3SS events represent use of alternative 5‟or 3‟ splice site, 
respectively, during the splicing. MXE event represents inclusion of mutually 
exclusive exons in between two constitutive exons. RI event represents 
inclusion of an intron during splicing. 
 
potential candidate genes based on either known biological function in 
zebrafish neurons or reported function of their human, mouse or other 
homologs in neurons. All of these shortlisted genes had exon skipping in their 
respective transcripts. Table 14 lists the shortlisted candidate genes with their 
respective inclusion values. These values represent level of 
inclusion/exclusion of a particular exon in the transcripts. Negative values 
indicate exclusion of the exon from transcripts under Smn deficiency, while 
positive values mean that the exon is normally excluded in controls, but is 
retained in smn morphants. Most of these 16 genes were found to be involved 
in intracellular transport (9 out 16) like endocytosis, intracellular trafficking etc. 
All significant AS events were then analysed for their biological relevance 
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using the elim method for GO enrichment. A total 100 GO terms were found 
to be significant with elim value less than or equal to 0.01 (1%). A list of all the 
significantly enriched GO terms is provided in Appendix 8. Among the top 
enriched GO terms were Integral to membrane, cytoplasm, catalytic activity, 


















Table 14. List of potential candidate genes with alternative splicing in motor neurons under Smn deficiency 
S. 
No. 





Consequence Affected protein domain Related neuronal diseases 
1. foxp2 Forkhead box P2 4 -0.362 
Loss of first 92 aa corresponding 
to exon 4 
Transcription factor, fork head 
domain 
Developmental verbal dyspraxia 





Truncated protein of 37 aa instead 
of 355 aa RNA recognition motif domain 
Huntington‟s disease (Fernandez-
Nogales et al. 2016) 
3. snx9b Sorting nexin 9b 6 -0.294 
Truncated protein of 188 aa 
instead of 581 aa WASP binding domain  
4. zgc:91909 Ras-related protein rab-7-like 3 -0.294 
Truncated protein of 147 aa 
instead of 204 aa with only first 18 
aa conserved 
Small-GTP binding domain 
Charcot-Marie-Tooth disease 
(Cogli et al. 2010, Ponomareva et 
al. 2016) 
5. cadm1a Cell adhesion molecule 1a 10 -0.27 
Loss of 11 aa corresponding to 
exon 10  
Autism spectrum disorder (Zhiling 
et al. 2008) 
6. rab15 
RAB15, member RAS 
oncogene family 
5 -0.24 
Loss of 30 aa corresponding to 
exon 5 Small-GTP binding domain  
7. zgc:77650 ADP-ribosylation factor 4 2 0.069 Inclusion of exon 2 




DEAH (Asp-Glu-Ala-His) box 
polypeptide 36 ATP-
dependent RNA helicase 
(DHX36) 
17 0.075 Inclusion of exon 17 
Helicase-associated domain  
9. nrxn1a Neurexin 1a 11 0.099 
Inclusion of exon 11 at Splice site 
3 (SS3) Laminin G domain 
Pitt-Hopkins like mental 
retardation (Zweier et al. 2009, 




Uncharacterised 7 0.114 Inclusion of exon 7 Sodium:Neurotransmitter 
symporter 
 
11. snx14 Sorting nexin 14 22 0.133 Inclusion of exon 22 
Sorting nexin C-terminal domain 
Spinocerebellar ataxia (Thomas 










Consequence Affected protein domain Related neuronal diseases 
12. nav3 Neuron navigator 3 6 0.191 Inclusion of exon 6 
  
13. snx27a Sorting nexin 27a 12 0.251 Inclusion of exon 12 
  
14. vcla Vinculin a 19 0.313 Inclusion of exon 19 
Vinculin/alpha-catenin domain  
15. copz2 
Coatomer protein complex, 
subunit zeta 2 
9 0.333 Inclusion of exon 9 
  
16. ptenb 
Phosphatase and tensin 
homolog B 
4 0.412 Inclusion of exon 4 Dual specificity phosphatase, 
catalytic domain 
Spinal muscular atrophy (Little et 
al. 2015) 
*Inclusion values represent level of inclusion/exclusion of a particular exon in the transcripts in SMA MN as compared to Control MN. Negative 
values indicate exclusion of the exon while positive values mean inclusion of exon under Smn knockdown condition.
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3.7 RT-PCR validation of alternative splice events identified in 
SMA motor neurons 
Semiquantitative RT-PCR was performed to validate the results obtained from 
alternative splicing analysis on RNAseq data. For this assay, I used cDNA 
from FAC sorted motor neuron samples. I shortlisted a total of 16 candidate 
genes with alternative splicing that can possibly be implicated in SMA 
pathology. Out of these, I successfully validated three genes with alternative 
splicing in sorted motor neurons.  
Sorting nexin (SNX) is a family of proteins characterised by the presence of a 
phox homology (PX) domain and is involved in diverse intracellular functions 
like endocytosis, protein sorting and endosomal signalling (Cullen 2008). 
Three genes from this family were found to be alternatively spliced in SMA 
motor neurons, snx9b, snx14, snx27a. I successfully confirmed the alternative 
splicing for snx9b and snx27a. From the alternative splicing analysis, snx9b 
was observed to have increased skipping of exon 6 in SMA MN as compared 
to controls (Table 14). This skipping leads to creation of a pre-mature stop 
codon resulting in a truncated protein of 188 aa instead of 581 aa and would 
possibly reduce overall Snx9b levels. Alternative splicing was confirmed by 
RT-PCR analysis, where a lower band, corresponding to exon 6 skipped 
transcripts, was present in SMA MN (Fig. 13A). Also the upper band, 
representing exon 6 including transcripts, was reduced in intensity as 
compared to the upper band in case of controls.  
In case of snx27a, alternative splicing analysis revealed an increased 
retention of exon 12 in SMA MN as compared to controls (Table 14). This was 
validated by RT-PCR where a stronger upper band (ex10-11-12-13) in SMA 
MN was observed as compared to controls, while the lower band (ex10-11-
13) was reduced in case on SMA motor neurons (Fig. 13B). This shows that 
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Smn deficiency leads to increased retention of exon 12 in snx27a transcripts. 
Exon 12 retention in snx27a only affected the last two exons in the gene and 
did not lead to a truncated protein. 
zgc:91909 is an uncharacterised gene in zebrafish that codes for a novel 
protein similar to human RAB7A, which is a member of the RAB family of 
proteins involved in regulation of vesicular transport (Pfeffer 1994, 
Hutagalung and Novick 2011). In case of zgc:91909, there was increased 
skipping of exon 3 in SMA MN leading to frameshift in the coding sequence 
and translating into non-functional protein (Table 14). Alternative splicing was 
also confirmed by RT-PCR that revealed the presence of a lower band 
corresponding to the exon 3 skipped transcripts (Fig. 13C).  
Interestingly, the alternative splicing in all three genes did not manifest into 
mRNA level changes, indicating that Smn deficiency did not affect the overall 
gene expression (Zhang et al. 2013). Taken together, the above results 
suggest that Smn deficiency leads to alternative splicing of genes which could 





Figure 13. RT-PCR validation of alternative splicing events in SMA MN 
identified by RNAseq. RT-PCR reactions confirmed exon skipping in SMA 
MN. snx9b and zgc:91909 showed increased exon skipping (exon 6 and 3, 
respectively) in smn morphants while snx27a showed increased exon 
retention (exon 12) in smn morphants as compared to Control MN. β-actin 
was used as loading control. Spliced isoforms are shown as boxes labeled 
with the corresponding exon number. Black dots on top of the boxes indicate 
primer binding sites. 
 
 
3.8 Transcriptome analysis of FAC sorted Schwann cells after 
Smn knockdown 
Schwann cells wrap around motor axons and play a crucial role in support 
and maintenance of neuromuscular junctions (NMJs), which are found to be 
defective in SMA cases. Gillingwater‟s group has shown that a SMN 
deficiency leads to intrinsic Schwann defects in a mouse model of SMA 
(Hunter et al. 2014). A former graduate student in our lab, Kelvin See, 
showed that Smn knockdown in zebrafish leads to Schwann cells defects, 
which are independent of motor neuron activity (Kelvin See, PhD Thesis). 
Shermaine Tay, a graduate student in our lab, also showed that the 
motoaxonal defects upon Smn knockdown can be partially rescued by 
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transgenic expression of Smn in Schwann cells alone (Shermaine Tay, FYP 
thesis). This opens up the possibility that splicing defects in Schwann cells 
might contribute to motoaxonal defects. To address this, I performed RNAseq 
on FAC sorted Schwann cells in the zebrafish SMA model. I used a 
transgenic Schwann cell calcium sensor line, HB9:D3cpv/SC, generated by 
Kelvin See, for this experiment. This line expresses calcium sensor D3cpv in 
Schwann cell precursors as well as immature in Schwann cells (Fig. 14A). 
3.8.1 Dissociation of Smn deficient HB9:D3cpv/SC embryos and FAC 
sorting 
The optimised protocol for HB9:eGFP embryo dissociation and motor neuron 
FAC sorting was used for sorting Schwann cells from HB9:D3cpv embryos 
under Smn deficient and control conditions at 28 hpf. Since the age of 
embryos used was the same as in the case of HB9:eGFP embryos, the 
dissociation conditions were not changed. The calcium sensor protein, D3cpv, 
which emits fluorescence in CFP as well as in the YFP channel (by FRET in 
its Ca2+ bound form) was used for sorting Schwann cells. Interestingly, almost 
all of the sorted cells were YFP positive while only a few cells were CFP 
positive (Fig. 14H). This could be due to the presence of excessive calcium 
the L-15 medium and serum. Thus, only YFP emission was used for FAC 
sorting Schwann cells from dissociated HB9:D3cpv embryos (Fig. 14D-H).  
On average, 100 HB9:D3cpv embryos generated close to 108,000 YFP 
positive cells after FAC sorting. The yield of sorted YFP positive cells was 
between 4-5%, which was considerably higher than the GFP positive MN 
cells (0.8-1%). The sorted Schwann cells generated on an average 11 ng of 




Figure 14. FAC sorting of YFP positive Schwann cells. (A) HB9:D3cpv 
embryo at 30 hpf. Brightfield (B) and fluorescent (C) image of sorted YFP 
positive cells under fluorescence microscope. (D) Total cells were 
represented in a FSC-A vs. SSC-A plot to screen for homogenous cell 
populations (enclosed region) without cell debris and cell aggregates 
(everything except enclosed region). (E and F) The selected cell population 
was then checked again on SSC and FSC plots for removing any doublets 
and only single cell population was selected (SSC and FSC gating). (G) Cells 
were checked for live cells (enclosed region; DAPI negative) among the entire 
single cell population. Cells on right side of plot were dead (DAPI positive). 
(H) Finally live single cells were sorted on the basis of YFP fluorescence. The 
YFP gated cells were the live YFP positive cells that were finally collected in 
L-15 media containing 0.5% FBS. (I) Agilent Bioanalyser profile of total RNA 
extracted from the sorted YFP positive cells. BF- bright field. 
 
3.8.2 cDNA library generation and RNA sequencing of SMA Schwann 
cells 
Two sets of high quality RNA samples (RIN >9) isolated from FAC sorted 
Schwann cells, both from smn morphants (SMA SC) and control embryos 
(Control SC), were selected to generate cDNA libraries for RNAseq (Table 
15; Fig. 15A,B). The library preparation protocol was identical to the one used 
for SMA MN and DSMA1 MN libraries. First, the RNA samples were used for 
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ds cDNA synthesis with Oligo-dT primer and Moloney Murine Leukemia virus 
reverse transcriptase followed by LD-PCR amplification. The amplified ds 
cDNA was purified using magnetic beads and checked on an Agilent 
bioanalyser using the HS DNA assay kit (Fig. 15C,D). Both sets of samples 
produced high quality cDNA profiles similar to the cDNA profile for control 
RNA (see Appendix 1).  
 






















48 111,000 12.5 9.4 5 24.4 
Sample 
2 





298 144,000 25.8 9.8 5 67.5 
Sample 
2 
229 92,000 9.4 9.5 2.7 121 
 
Next, the amplified cDNA samples were subjected to Covaris shearing to 
generate small fragments of 200-500 bp in size. These fragmented cDNAs 
were than used to generate libraries using adaptors and barcoded with 
different Index primers. Finally, the libraries were purified and checked for 
quality on an Agilent bioanalyser. All libraries produced good profiles with a 
distinct peak spanning 200-500 bp, peaked at approx. 300 bp (Fig. 15E,F). All 
cDNA libraries were quantified using qRT-PCR and pooled to give identical 
amounts of each library. The multiplexed libraries were submitted for 
sequencing with the Next Generation Sequencing platform at the Genome 
Institute of Singapore in collaboration with Dr. S. Mathavan. The sequencing 
was performed on an Illumina HiSeq platform with paired-end sequencing 




Figure 15. Assessment of quality for extracted RNA, amplified cDNA and 
final library during SMA Schwann cell library preparation using Agilent 
bioanalyser. Each step in the protocol was checked by running 1µl sample 
on a bioanalyser. The Y-axis represents the fluorescence intensity detected 
(FU). The X-axis represents the fragment size of RNA or DNA in nucleotides 
(nt) or base pair (bp), respectively. Representative profiles for one SMA SC 
and one Control SC sample are shown here. (A,B) Electropherograms of 
input RNA for SMA and control SC sample used for RNAseq library 
preparation with RIN values of 9.5 and 9.7, respectively.                            
(C,D) Electropherograms of cDNA obtained after first strand cDNA synthesis 
and amplification during SMARTer protocol. (E,F) Electropherograms of 
cDNA libraries after completion of NEBNext library prep protocol, with lengths 
of all the fragmented cDNA between 200-500 bp. 
 
3.8.3 Differential gene expression analysis of Schwann cells 
The RNAseq data obtained from sequencing SMA SC libraries was used for 
bioinformatics analysis in collaboration with Dr. Candida Vaz and Dr. Vivek 
Tanavde at Bioinformatics Institute Singapore. The RNAseq results for SMA 
SC libraries are shown in Table 16. The total number of reads obtained was 
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between 103,973,678 and 204,591,620. The Mean Phred quality score (Q) 
obtained was above 35 with more than 90% of base calls at 99.9% accuracy. 











SMA SC Sample 1 17,151 182,588,058 92.25 35.7 
Control SC Sample 1 19,237 204,591,620 92.1 35.63 
SMA SC Sample 2 9,728 103,973,678 90.14 35.05 
Control SC Sample 2 10,767 116,017,986 90.58 35.27 
 
Similar to the SMA MN and DSMA1 MN RNAseq data, adaptor sequences 
were first removed from all reads obtained and mapped to the zebrafish 
reference genome, Zv9, using TopHat tool (2.0.12). The total number of reads 
per sample was between 103,973,678 and 204,591,620 (Table 17); between 
71.4% and 83.2% of reads were uniquely mapped to the zebrafish reference 
genome. The no. of aligned pairs per sample were between 20,631,802 and 
57,931,738 (Table 17), out of which concordant pair reads were between 
29.3% and 61.3% uniquely mapped to zebrafish reference genome (Table 
17).   
The mapped reads when analysed on Partek for differentially expressed 
genes. A total of 13,910 genes were identified to be expressed in the sorted 
Schwann cells at 28 hpf out of which 226 genes were found to be differentially 
expressed in SMA SC (Fold change >2 and p-value <0.05). Out of 226 
differentially expressed genes, 129 were down-regulated in SMA SC as 
compared to Control SC while 97 were up-regulated. A list of all the 
differentially expressed genes is provided in the Appendix 4. Comparison of 
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differentially expressed genes in SMA SC and SMA MN revealed only 27 
overlapping genes, indicating cell type-specific defects under Smn deficiency 
(Zhang et al. 2013). 
Table 17. SMA SC RNAseq reads mapped to zebrafish reference genome 
Zv9 using TopHat 
 
Control SC SMA SC 
 
Sample 1 Sample 2 Sample 1 Sample 2 
Total Reads 204,591,620 116,017,986 182,588,058 103,973,678 
Reads 
Mapped 
76.2% 47.2% 76.2% 72.4% 
Total Paired 
Reads 




29.3% 36.7% 61.3% 58.3% 
 
To determine the biological relevance of these differentially expressed genes 
in SMA SC, Partek software was used. GO enrichment analysis identified 195 
GO terms to be over represented with a p-value cut-off of 0.05. Interestingly, 
terms related to development and differentiation were the most enriched 
terms with “regulation of neurogenesis” and “regulation of nervous system 
development” as the top most enriched term in the list. Apart from this, 
neuropeptide signalling pathway was also found to be affected in SMA SC. 
Fig. 16 shows a graphical representation of the top 10 GO terms with their 








Figure 16. Gene Ontology (GO) analysis of differentially expressed 
genes in Smn deficient and control Schwann cells. GO analysis was 
performed on differentially expressed genes with at least a 2-fold change and 
p-value less than or equal to 0.05. The top 10 GO terms enriched are 
represented in a bar graph with the Y-axis showing the enriched GO terms 
and X-axis showing the respective enrichment score values. 
 
 
3.9 Smn knockdown leads to alternative splicing in Schwann cells 
3.9.1 Identification of alternative splice events using MATS 
Alternative splicing analysis was also performed on the SMA SC RNAseq 
data using MATS. The analysis identified a total of 7133 AS events, out which 
only 39 AS events were filtered as significant (FDR <0.1). Appendix 7 lists out 
all the AS events in SMA SC. Unlike in motor neurons, only a few significant 
AS events were detected in Schwann cells. This could be due to low 
percentage mapping of the Control Schwann cell RNAseq data. A total 37 
genes were found to be alternatively spliced with two of them having more 
than one AS event. Out of 39 AS events, 38 were skipped exon events while 
only one mutually exclusive event was detected. Interestingly, 29 AS events 
were similar to those found in SMA motor neurons while only 10 AS events 
were unique to Schwann cells. Among these 37 AS genes, five of them were 
found in the potential candidate gene list (Table 14), although, with different 
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inclusion values. These genes were srsf6b, snx9b, zgc:91909, snx27a and 
ptenb which were validated using RT-PCR. 
3.9.2 RT-PCR validation of alternative splice events identified in SMA 
Schwann cells 
Using a semiquantitative RT-PCR assay, I successfully validated the 
alternative splicing of snx9b, snx27a and zgc:91909. cDNA obtained from 
FAC sorted Schwann cells was used for the assay. snx9b, as per alternative 
splicing analysis, had exon skipping at exon 6 which was confirmed by RT-
PCR. A lower snx9b band, corresponding to exon 6 skipped transcripts, was 
observed in SMA Schwann cells, while control Schwann cells did not show 
expression of this transcript (Fig. 17A). The same was the case with 
zgc:91909, where alternative splicing analysis showed increased skipping of 
exon 3 in zgc:91909 transcripts. RT-PCR result also showed that SMA 
Schwann cells expressed transcripts with exon 3 skipped along with full 
length transcripts. Control Schwann cells, on the other hand, showed 
expression of only full length transcript (ex1-2-3-4) (Fig. 17B). 
For snx27a, alternative splicing analysis reported increased retention of exon 
12 in SMA Schwann cells as compared to controls. This was also confirmed 
using the RT-PCR assay. The gel showed presence of a strong snx27a upper 
band (ex10-11-12-13) in SMA Schwann cells while the controls appeared to 
express the exon 12 skipped transcripts (strong lower snx27a band) (Fig. 
17C). This, unlike other previous cases, showed an almost switch from exon 
12 skipped transcripts in controls to exon 12 retained transcripts under Smn 
deficiency. Taken together, these results indicate that Smn deficiency leads to 





Figure 17. RT-PCR experiments validated alternative splicing changes in 
SMA Schwann cells identified by RNAseq. RT-PCR reactions confirmed 
the exon skipping events in SMA Schwann cells. snx9b and zgc:91909 
showed increased exon skipping (exon 6 and 3, respectively) in smn 
morphants while snx27a showed increased exon retention (exon 12) in smn 
morphants as compared to Control SC. β-actin was used as loading control. 
Spliced isoforms are shown as boxes labeled with the corresponding exon 
number. Black dots on top of the boxes indicate primer binding sites. 
 
3.10 srsf6b splicing factor as a novel candidate target of Smn 
Smn deficiency leads to alternative splicing of genes in motor neurons as well 
as Schwann cells. From alternative splicing analysis of both cell types one 
potential candidate gene serine/arginine-rich splicing factor 6 (srsf6b) 
garnered particular interest. Srsf6b belongs to Serine-arginine (SR) family of 
proteins characterised by the presence of carboxy-terminal Arginine-serine 
(RS) domain and at least one RNA binding domain (RRM) preceding it 
(Zahler et al. 1992). SR proteins are involved in both constitutive (Mayeda et 
al. 1999) and alternative splicing (Zahler et al. 1993) of pre-mRNA, as well as 
post-splicing activities like mRNA nuclear export, translation and nonsense 
mediated decay (Shepard and Hertel 2009). Interestingly, SRSF proteins 
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have been shown to regulate splicing of SMN1 and SMN2 transcripts (Wee et 
al. 2014).  
Alternative splicing analysis revealed increased skipping of exon 2 in srsf6b 
transcripts in both motor neurons and Schwann cells under Smn deficient 
conditions. Semiquantitative RT-PCR assay was performed to validate this 
alternative splicing. RT-PCR performed using primers flanking exon 2 of 
srsf6b showed a weak lower band corresponding to exon 2 skipped 
transcripts in both SMA motor neurons and Schwann cells (Fig. 18A). In case 
of controls, the majority of RT-PCR product was corresponding to exon 2 
inclusive transcripts (upper band) while the lower band was very weak (Fig. 
18A). These results confirm that Smn deficiency affects the splicing of srsf6b 
in motor neurons and Schwann cells. Exclusion of exon 2 in srsf6b transcripts 
would lead to creation of pre-mature stop codon generating a 37 aa truncated 
protein with no RS and RRM domains. This suggests that Smn deficiency 
leads to reduction in functional Srsf6b proteins in SMA MN and SC and might 
lead to enhanced splicing defects in these cell types. 
3.10.1 Expression pattern of srsf6b 
Having established the effect of Smn on alternative splicing of srsf6b, it was 
important to verify whether srsf6b was expressed in motor neurons of 
zebrafish. According to ZFIN database and literature, there was no reported 
expression of srsf6b in zebrafish. To determine the expression pattern of 
srsf6b whole mount RNA in situ hybridization was performed.  
It was found that srsf6b was expressed in various parts of the central nervous 
system including telencephalon, midbrain, hindbrain and spinal cord, with 
highest levels in its anterior part (Fig. 18B). Expression of srsf6b in the spinal 
cord was restricted to its ventral domain where it was expressed in the region 
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containing motor neurons and V2 interneurons (Fig. 18C). Expression in 
Schwann cells, however, was not detectable using this method. This suggests 
a possible role of srsf6b in zebrafish nervous system development, and 
importantly in the development of motor neurons.  
 
Figure 18. Smn deficiency leads to alternative splicing of srsf6b in 
motor neurons and Schwann cells. (A) RT-PCR assay validated the 
alternative splicing of srsf6b in FAC sorted motor neurons and Schwann cells 
under Smn deficient conditions. Loss of Smn increases skipping of exon 2 in 
srsf6b transcripts in both cell types. β-actin was used as loading control. 
Spliced isoforms are shown as boxes labeled with the corresponding exon 
number. Black dots on top of the boxes indicate primer binding sites. (B) 
Whole mount in situ hybridization identified expression of srsf6b in 
telencephalon (tel), midbrain (mb), hindbrain (hb) and spinal cord (sc) at 31 
hpf. (C) Transverse sections through trunk of srsf6b stained embryo showing 
expression in the ventral spinal cord labeling regions of primary motor 
neurons (blue arrow) and V2 interneurons (black arrow). nc- notochord. 
 
3.10.2 CRISPR/Cas mediated knock-out of srsf6b 
Having demonstrated that Smn deficiency causes alternative splicing of 
srsf6b and that srsf6b is expressed in the ventral spinal cord, I speculated 
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that it might be important for motor neuron development. Therefore, I next 
analysed the effect of a mutation of this gene on motor neurons. For this, I 
employed a transient CISPR/Cas based functional study. Two CRISPR target 
sites were identified in srsf6b using CRISPRscan program with high score 
and no off-targets. The target sites, 93 bp apart, were located in exon 1 and 
intron 1 of the srsf6b gene (Fig. 19A). These target sites were used for 
preparing gRNAs. 100 ng/µl of each gRNA and 300 ng/µl of Cas9 mRNA 
were injected into wild-type embryos and surviving injected fish were 
analysed for indels in srsf6b gene sequence. The evaluation of CRISPR 
efficiency and identification of srsf6b potential mutants was done by analysing 
gDNA from CRISPR injected fish using primers flanking the two target sites 
(Fig. 19A). The two gRNAs would recognize their respective target sites in the 
srsf6b gene and direct the Cas9 protein for producing double stranded breaks 
at these sites. These breaks, repaired by erroneous Non-Homologous End 
Joining (NHEJ) mechanism would generate insertions and/or deletions 
(Indels), which were identified using the flanking primers. In my case, with 
double CRISPR, ideally a big deletion corresponding to the distance between 
the two target sites was expected. The wild-type band was 475 bp in size. 
Because of the mosaic character of the introduced mutations, a positive 
mutant embryo was expected to have wild-type band along with smaller 
mutant band. A total of 46 CRISPR injected embryos were analysed, out of 
which 26 embryonic gDNAs showed smaller bands of varying sizes. Fig 19B 
shows a representative result. Wild-type gDNAs were used as negative 
controls, which gave a single band of 475 bp. Mutant embryos showed 
mutant bands in the size range of 200-400 bp, with a majority of them having 
an approx. 400 bp mutant band. Five embryos showed a large deletion in the 
srsf6b gene, with mutant bands of 200 bp. The overall efficiency of F0 
potential srsf6b mutants was 56.5%. The injected embryos, at 100 ng/µl dose 
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of each gRNA, did not show a high lethality, however, a few embryos 
developed morphological defects like a curved body curvature and delayed 
development. Some, but not all, of the defective embryos showed mutations 
in srsf6b suggesting that the loss of Srsf6b leads to morphological defects in 
embryos. 
 
Figure 19. CRISPR/Cas mediated srsf6b knock-out. (A) Structure of srsf6b 
gene with RRM and RS domains. Exon 2 marked with red box is skipped in 
Smn deficient motor neurons and Schwann cells. CRISPR target sites are 
marked with black arrows and screening primers are marked with blue 
arrows. (B) Representative gel image showing screening of 24 srsf6b double 
CRISPR injected embryos. Mutant embryos with smaller bands are marked 
with red star. Four wild-type embryos (1, 2, 3 and 4) were used as negative 
controls. 
 
Next, I performed whole mount immunostaining on srsf6b double CRIPSR 
injected embryos to analyse the effect of a mosaic srsf6b knock-out on motor 
axonal development. Injected embryos were raised until 31 hpf and surviving 
embryos were used for the analysis of motor axonal phenotypes. Embryos 
 93 
 
were stained with the α-znp1 antibody that stains motoaxons and embryos 
were analysed in similar manner as was done for smn and ighmbp2 
morphants. A total of 39 srsf6b double CRISPR injected embryos were 
analysed for motoaxonal defects. Interestingly, 27 out of 39 embryos 
(69.23%) were found to have two or more axonal defects (referred to as 
„defective‟) in the form of branching or truncation. Fig. 20C-E shows 
representative images of embryos with motoaxonal defects. gDNA extracted 
from heads of all of these embryos was separately analysed for mutants. A 
total of 19 embryos (48.7%) showed mutant bands. However, when the two 
results were compared, the data was not completely overlapping. Out of the 
27 defective embryos, 12 showed a corresponding mutant band while 15 did 
not show the mutant band. On the other hand, six out of seven embryos that 
showed a mutant band had only one defect, while one embryo had no defect 
but still showed mutant band on gel. The absence of mutant bands for the 
defective embryos could be explained by the fact that only one of the two 
CRISPRs worked leading to small indels that could not be picked up on the 
gel, but disrupted the protein coding sequence. Alternatively, due to the 
mosaic character of the introduced biallelic mutations, this could have 




Figure 20. srsf6b knock-out leads to motoaxonal defects. (A) Lateral view 
of wild-type embryo. Box indicates region above yolk extension where 
motoaxon morphology was assessed. (B) Higher magnification view of wild-
type embryo. (C-E) Representative images of three srsf6b double CRISPR 
injected embryos (M1, M2, M3) showing severe axon defects (branching and 
truncation). Arrows mark the defective axons.  Scale bar= 100 µm. 
 
Taken together, these results indicate that srsf6b is indeed important for 
motor neuron differentiation, as a knock-out of srsf6b caused motoaxonal 
defects similar to those seen in smn or ighmbp2 morphants (Fig. 3C and 4D). 











Currently there are three main hypotheses to explain why a reduction of 
ubiquitous SMN protein leads to degeneration of motor neurons. The first 
hypothesis is based on SMN‟s well-established role in U snRNP assembly. 
According to this, loss of SMN causes reduced U snRNP levels, consequently 
affecting proper splicing of the motor neuron-specific genes, leading to motor 
neuron defects (Pellizzoni et al. 1998, Meister et al. 2001, Pellizzoni et al. 
2002, Winkler et al. 2005). Apart from this, a role of SMN in motoaxonal 
mRNA regulation (Rossoll et al. 2002, Rossoll et al. 2003) and finally in the 
maintenance of a neural circuitry has been proposed (Imlach et al. 2012). A 
common denominator in all the three hypotheses is that SMN loss directly or 
indirectly causes motor neuron defects, which ultimately leads to SMA 
phenotype. Recent reports have identified transcriptomic changes and 
alternative splicing in motor neurons under SMN deficient conditions (Zhang 
et al. 2013, Huo et al. 2014, Maeda et al. 2014, Saal et al. 2014, Ng et al. 
2015). Microarray analysis in whole zebrafish embryos identified nrxn2a as a 
novel downstream target of Smn which gets alternatively spliced when Smn 
levels are reduced (See et al. 2014). Schwann cells defects are also reported 
in the mouse SMA model (Hunter et al. 2014). However, little is known about 
the transcriptomes of motor neurons or surrounding Schwann cells in the 
zebrafish SMA model. Here, I report transcriptomic and splicing changes in 




4.1 Method development for RNAseq of FAC sorted motor 
neurons and Schwann cells from zebrafish embryos 
In this study, I report a method for transcriptome profiling of FAC sorted motor 
neurons and Schwann cells from whole zebrafish embryos. As a first step 
towards this, I optimised protocols for dissociation of whole embryos and 
isolating motor neurons and Schwann cells using FACS. A papain 
dissociation system, adopted from Cerda et al., was used for dissociating 
whole zebrafish embryos (Cerda et al. 2009). Papain, a cysteine protease, 
has previously been reported to be better than trypsin, collagenase or other 
proteases for dissociation of rat neural tissues (Huettner and Baughman 
1986). It has also been used for dissociating neural cells from rat spinal 
cords, particularly for creating neuroblast and neural stem cell cultures 
(Shihabuddin 2008). Cerda et al reported dissociation of zebrafish transgenic 
embryos using papain to FAC sort interneurons for RNA profiling (Cerda et al. 
2009).  
I successfully optimised the protocol for dissociation of 28 hpf zebrafish 
transgenic embryos to obtain live single cell suspensions of motor neurons 
and Schwann cells suitable for FACS. Since papain is a protease, it was 
critical to optimise the incubation time for the dissociation so as to prevent cell 
lysis. 30 mins of papain incubation was used for dissociation of cells from 
trunks of zebrafish embryos at 27 hpf (Cerda et al. 2009). However, in this 
study, 45 mins of papain incubation at 30oC was found to be optimal for 
recovery of live single cells. As per the manufacturer‟s recommendations, 
papain incubation should be performed at 37oC. However, 38-39oC has been 
reported to induce heat shock in zebrafish embryos causing an unfolded 
protein response (UPR), activation of innate and adaptive immunity and 
changes in the transcriptome (Shoji and Sato-Maeda 2008, Todd et al. 2008, 
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Costa et al. 2011, Long et al. 2012). Loss of SMN has recently been reported 
to activate UPR in motor neurons generated from iPSCs derived from SMA 
patients (Ng et al. 2015). Therefore, to avoid any non-specific effects of the 
heat shock on transcriptomes of motor neurons and Schwann cells, 30oC was 
used as incubation temperature, which did not affect the dissociation of 
embryos.  
The single cells obtained after dissociation were subjected to FACS for 
sorting of motor neurons and Schwann cells. Wild type embryos as well as 
non-transgenic siblings were used for setting up the FACS parameters to sort 
true fluorescent positive cells.  On an average 12,000 GFP positive motor 
neurons (0.8-1%) and 108,000 YFP positive Schwann cells (4-5%) were 
sorted out from 100 transgenic embryos (HB9:eGFP or HB9:D3cpv/SC). With 
the optimised FACS settings, the percentage of cells sorted out was 
consistent throughout the study. The entire optimised protocol, from 
dissociation to cell sorting, was done in less than 2 hrs. This ensured that any 
possible transcriptomic changes in the cells were kept to a minimum during 
the procedure and consequently resulted in more reliable RNAseq results. A 
recent study discussed the effect of isolation and separation procedures on 
transcriptomic changes (Richardson et al. 2015). The group used microarray 
analysis and concluded that the isolation procedure rather than FACS 
perturbs the gene expression of cells (Richardson et al. 2015). In order to 
avoid any significant differences among the samples due the dissociation 
protocol, all the samples were prepared with exactly similar conditions. Also, 
the transcriptomic or splicing changes that might still occur due the embryo 
dissociation protocol could be normalised while comparing controls and SMN 
morphants. For RNA extraction from FAC sorted cells, a phenol-chloroform 
based extraction method followed by column purification was used. High 
 98 
 
quality (RIN >9) total RNA, suitable for RNAseq, was achieved from this 
approach. The identity of the sorted cells was confirmed by analysing them 
with a fluorescence microscope and by performing RT-PCR for motor neuron-
specific markers like hb9 and isl1. Although this entire protocol was 
developed for motor neurons and Schwann cells from whole zebrafish 
embryos, it can be easily be adapted for other cells types and adult tissues. 
Using the optimised protocol for dissociation of embryos and FACS, I 
successfully sorted motor neurons and Schwann cells under Smn deficient 
conditions from HB9:eGFP and HB9:D3cpv/SC embryos, respectively. Motor 
neurons were also sorted from HB9:eGFP embryos under Ighmbp2 deficient 
conditions. For cases with low RNA inputs, RNA amplification kits are usually 
applied prior to library construction for transcriptomic profiling (Shanker et al. 
2015). The RNA yields obtained from sorted motor neurons and Schwann 
cells was also very low, thus RNA amplification was performed using the 
SMARTer kit (Clontech) to generate high quality amplified cDNA. Shanker et 
al. evaluated different RNA amplification kits and reported that libraries 
generated using Clontech had the highest percentage of unique reads as well 
as exonic reads compared to other kits (Shanker et al. 2015). High quality 
cDNA libraries were then generated using NEBNext library prep kit (and 
submitted for sequencing. The sequencing was performed on an Illumina 
HiSeq platform with sequencing depth between 100-200 million reads which 
was suitable for alternative splicing analysis as well as to identify differentially 
expressed genes. Additionally, sequencing was done using the paired-end 
method to generate high quality data suited for alternative splicing analysis. 
The RNAseq data was finally used for bioinformatics analysis to identify 




4.2 Smn deficiency affects gene expression in motor neurons and 
Schwann cells 
Low levels of SMN leading to reduced snRNP levels has been hypothesised 
to result in aberrant splicing of pre-mRNAs leading to degradation of wrongly 
spliced transcripts by non-sense mediated decay (Pellizzoni et al. 1998, 
Pellizzoni et al. 2002, Gubitz et al. 2004, Behm-Ansmant et al. 2007, Zhang et 
al. 2008, Wittkopp et al. 2009). Microarrays have been previously used for 
differential gene expression studies using smn morphant zebrafish embryos 
(See et al. 2014), motor neuron cultures (Anderson et al. 2004) and whole 
spinal cords from SMA mouse models (Zhang et al. 2008, Baumer et al. 
2009, Murray et al. 2010). As mentioned previously, RNAseq is advantageous 
for transcriptomic profiling because high signal-to-noise ratio, independence 
from hybridization efficiency, high reproducibility for low RNA inputs and 
identification of novel RNA transcripts. In this study, RNAseq was performed 
on FAC sorted motor neurons and Schwann cells under Smn deficient 
conditions. Mapping of RNAseq data to the zebrafish reference genome, Zv9, 
identified similar numbers of expressed genes in both cell populations, i.e. 
13,923 and 13,907 genes in motor neurons and Schwann cells, respectively. 
Differential gene expression analysis revealed 312 and 226 genes (Fold 
change >2, p-value <0.05) to be deregulated in SMA MN (n=3) and SC (n=2). 
Comparing the differentially expressed genes identified in zebrafish SMA MN 
with earlier microarray and RNAseq studies in other animal models identified 
only a few overlapping genes (Huo et al. 2014, Saal et al. 2014, Ng et al. 
2015, Doktor et al. 2016). This could be due various reasons like use of 
different animal models (mouse, cell culture or zebrafish), different time points 
analysed (asymptomatic, pre-symptomatic, post-symptomatic) or differences 
in techniques (RNAseq or microarrays). Although both cell populations 
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surprisingly expressed similar genes overall (∼95% overlap between motor 
neuron and Schwann cell expressed genes), only 27 genes were affected in 
common (see Appendix 5), indicating that Smn deficiency causes cell type-
specific mRNA level changes (Zhang et al. 2013). Out of these 27 
overlapping genes, three genes had opposite regulation patterns while 24 
genes were regulated similarly in both cell types. Also, the total number of 
differentially expressed genes was about 2.2% and 1.6% of expressed genes 
in motor neurons and Schwann cells, respectively. This suggests that a Smn 
deficiency does not cause widespread transcriptome changes (Zhang et al. 
2013). 
Low levels of mapping were observed for Control SC samples (29% and 36% 
mapping of Sample 1 and 2, respectively) to the zebrafish genome. This 
could be either due to low quality of cDNA libraries or degeneration of 
libraries during sequencing. Neither of them was plausible reason, as the 
quality was assessed for libraries prior to sequencing as well sequenced 
reads, analysed by FastQC reports. Both of the QC results were good. 
Contamination of NGS data with microbial genome sequences has been 
reported earlier (Lusk 2014, Strong et al. 2014), which lowers the percentage 
of mapped reads to reference genome. Since the quality of mapped reads 
was good, the data was used for downstream analysis. 
GO enrichment analysis was performed on the differentially expressed genes 
from both cell types to determine the biological relevance of these genes. 166 
GO terms were found to be significantly over-represented (p-value<0.05) 
among the deregulated genes (both up- and down-regulated) in SMA MN. 
The most enriched GO term identified was “calcium ion binding”, indicating 
that Smn deficiency affects genes that encode for calcium ion-interacting 
proteins. Reduction in SMN has been previously reported to affect regulation 
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of intraterminal Ca2+ levels (Ruiz et al. 2010), indicating a possible 
deregulation of calcium ion binding proteins. In a zebrafish SMA model, 
reduced levels of Smn causes significant reduction of evoked Ca2+ influx into 
the pre-synaptic axon terminal (See et al. 2014). A total of 26 genes in the list 
were found to be related to “calcium ion binding” (Table 18). 15 out of these 
26 genes were down-regulated, suggesting that loss of Smn leads to 
deficiencies in these proteins, and consequently, reduced Ca2+ levels in pre-
synaptic axon terminals. A recent study on RNAseq of SMA mESC-derived 
motor neurons, reported down-regulation of transcripts related to neuron 
development and up-regulation of pluripotency and cell proliferation genes 
(Maeda et al. 2014). bHLH transcription factors like ascl1a, neurog1, olig2; 
fox genes, pax6b, fezf2 among others that have been reported to be involved 
in neuronal cell fate specification and commitment were differentially 
expressed. A total of 75 genes related to developmental processes were 
found to be deregulated in SMA MN (Table 18). Taken together, this indicates 
a possible effect of Smn reduction on neuronal development in zebrafish. 
Table 18. List of deregulated genes in SMA MN related to calcium ion 
binding and developmental process 
Genes GO term 
actn3a, casq1a, casq1b, casq2, dld, jag1a, mmp13a, 
myl1, mylz3, pvalb2, pvalb3, s100z, tnnc2, zgc:162595,  
zgc:66455 
anxa13, capn2a, cdh15, efemp2b, myl4, myl9a, oc90, 
pcdh8, pls3, s100v2, scgn 
Calcium ion binding 
lft1, foxg1d, rtn4rl2a, neurog1, camk2a, tnnt3b, ascl1a, 
zic5, rx2, olig2, smyd1a, fezf2, tnni2a.4, sox21b, tspan12, 
rx1, six3b, murca, dld, npas4a, stac3, apobec2a, pou3f3a, 
pax6b, fzd5, tbx2b, cx43, grem2b, vax1, dmrt3a, jag1a, 
hoxa13a, eng1b, apela, sfrp1a, mibp2 
kdrl, csad, acvrl1, gata1a, parp3, optn, ptpreb, ttpa, 
smad9, sox7, socs1a, fsta, trim2a, kremen1, arrb1, 
rbm24a, mmp9, unc45a, foxi1, tagln2, snrkb, dmrt2a, 
klf17, epor, jam2a, oc90, nfe2, casp8, mink1, hapln4, fn1b, 




Gene names in black represent down-regulated genes while red represents 
up-regulated genes.  
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Genes affected in SMA SC showed enrichment of terms related to 
development and differentiation, indicating Smn deficiency affects similar 
pathways in Schwann cells and motor neurons. Although the differentially 
expressed genes between the two cell types were not similar (only 27 
overlapping genes), the affected processes appeared to be similar. 
Neuropeptide signalling pathway was also found to be affected in SMA SC, 
indicating defects in axon-glia communication. Neurotransmission from nerve 
terminals leads to increase in intracellular Ca2+ levels in Schwann cells as 
well as regulates their gene expression (Jahromi et al. 1992, Georgiou et al. 
1994). Taken together, Smn deficiency leads to Ca2+ deregulation in both, 
motor neurons and Schwann cells, affecting their activity at NMJs. Apart from 
this, the RNAseq data from both cell types identified interesting genes that 
would allow elucidating new pathways involved in neuron-Schwann cell 
communication. 
 
4.3 Deficiency of Smn and Ighmbp2 affects genes related to 
axonogenesis 
Loss of IGHMBP2 due to mutations in the protein coding gene leads to motor 
neuron degeneration and ultimately to DSMA1 (Grohmann et al. 2001). 
Ighmbp2 deficient mouse motor neurons showed defects in axon outgrowth 
and pathfinding in culture (Krieger et al., unpublished data) similar to the 
axonal defects observed in zebrafish ighmbp2 morphants in vivo. The axonal 
defects were significantly increased in ighmbp2 morphants (30% defective 
axons) as compared to control or uninjected embryos (10% and 9.3%, 
respectively). Interestingly, these axonal defects in ighmbp2 morphants were 
similar to those observed in smn and nrxn2a morphant zebrafish embryos 
(See et al. 2014). It has been reported that axons in smn and nrxn2a 
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morphants pause at the choice point for a longer duration than normal and 
eventually grow ventrally towards the second intermediate target (McWhorter 
et al. 2003, See et al. 2014). However, they remain truncated and eventually 
sprout branches at later stages. A similar axonal out-growth pattern can be 
speculated in case of ighmbp2 morphants. 
In order to understand what causes such defects, RNAseq data were 
generated from Ighmbp2 deficient FAC sorted motor neurons and control 
embryos. Differential gene expression analysis identified 1,666 affected 
genes with fold change >2. Since the data were generated for n=1, p-values 
could not be determined, hence the large number of differentially regulated 
genes. Out of the 1,666 differentially expressed genes, 740 were down-
regulated and 926 were up-regulated. To analyse the genes commonly 
regulated in both SMA MN and DSMA1 MN, the differentially expressed gene 
lists in both cases were compared. A total of 93 genes were found commonly 
regulated in both disease conditions. Interestingly, GO analysis of these 
overlapping genes identified terms like “regulation of axonogenesis” and 
“regulation of axon guidance” among the top most terms. This suggests that 
reduced levels of Smn and Ighmbp2, directly or indirectly, affect genes that 
are important for axon out growth and guidance. It could also be speculated 
that Nrxn2a deficiency could also affect similar genes. Taken together, 
Ighmbp2 and Smn deficiency leads to motoaxonal defects in zebrafish 





4.4 Identification of alternatively spliced transcripts in SMA motor 
neurons and Schwann cells 
Reduced snRNP levels, in SMN deficiency, not necessarily lead to aberrant 
splicing of pre-mRNAs, alternative splicing is also possible (Zhang et al. 
2008). This could lead to changes in the ratio of the two spliced isoforms, 
generation of aberrantly spliced isoforms not found in unaffected controls or 
do not correspond to any known isoform (Zhang et al. 2008). RNAseq, as 
mentioned earlier, has inherent advantages over traditional microarrays in 
identification of novel splice isoforms. Microarrays have been used to identify 
splicing changes in SMA mouse models (Zhang et al. 2008, Baumer et al. 
2009) as well as SMN-depleted neuroblastoma cells (Huo et al. 2014). Zhang 
et al. reported that SMN deficiency affects the snRNPs repertoire of each cell 
uniquely, thus producing cell type-specific effects on splicing (Zhang et al. 
2008). There has been an ongoing debate on whether SMN deficiency has 
any preferential effect on the minor spliceosome splicing pathway (Gabanella 
et al. 2007). More recently, RNAseq has been employed to analyse the 
splicing changes as well as to identify spurious or novel splice isoforms 
(Doktor et al. 2016). This is majorly due to the inherent advantages of 
RNAseq over traditional microarray that lack complete coverage of whole 
transcriptome with high efficiency. A very recent RNAseq study in the SMA 
mouse model showed increased splicing defects in U12-dependent introns, 
which leads to dysregulation of genes related to neuronal function (Doktor et 
al. 2016). Alternative splicing analysis, performed using the MATS program, 
identified 284 significant AS events (FDR <0.1) in SMA MN while 39 events 
were identified in SMA SC. Exon skipping is the most prevalent type of 
alternative splicing in vertebrates and invertebrates and is believed to 
contribute most to phenotypic complexity (Sugnet et al. 2004, Kim et al. 
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2008). In case of SMA MN and SMA SC, the majority of AS events were due 
to exon skipping. AS analysis identified only a small number of splicing 
changes in SMA SC which could be attributed to the relatively low alignment 
of Control SC reads (29% and 36% mapping of Sample 1 and 2, respectively) 
to the zebrafish genome. Interestingly, out of these 39 AS events, 29 were 
similar to those identified in SMA MN while only 10 were unique to SMA SC. 
Due to high similarity of the AS events in both cell types, the enriched GO 
terms were also found to be similar (data not shown). This indicates that Smn 
deficiency leads to splicing defects in similar genes in both cell types.  
A total of 284 and 39 splicing events (in 248 and 37 genes, respectively) were 
identified in SMA MN and SC, respectively. Most of these did not overlap with 
differentially expressed genes (only five genes in motor neurons and one 
gene in Schwann cell were common). This finding suggests that most of the 
alternative splicing events affect the relative abundance of various isoforms 
but not the overall transcript level (Zhang et al. 2013). These AS genes 
identified in SMA MN, like differentially expressed gene list, were found to be 
very different from earlier studies in other SMA animal models with only a few 
common genes (Zhang et al. 2008, Baumer et al. 2009, Zhang et al. 2013, 
Huo et al. 2014, Ng et al. 2015, Doktor et al. 2016). 
An interesting uncharacterised gene, si:ch211-225b11.1, was identified to be 
alternatively spliced in SMA MN. This gene is a homolog of Drosophila 
inebriated (ine), which encodes a Na+/Cl--dependent neurotransmitter 
transporter protein Ine. ine mutant flies show increased excitability of motor 
neurons due to defective re-uptake of the neurotransmitter substrate leading 
to overstimulation of motor neurons (Soehnge et al. 1996, Huang et al. 2002). 
Alternative splicing in si:ch211-225b11.1 leads to inclusion of exon 7 in SMA 
MN which creates a pre-mature stop codon leading to the formation of a 
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truncated protein of 338 aa instead of 609 aa. This AS destroys the 
Sodium:neurotransmitter symporter domain and could lead to defects in 
zebrafish motor neuron excitability, similar to Drosophila. This makes 
si:ch211-225b11.1 a potential candidate gene that could be implicated in 
SMA pathology.  
4.4.1 Smn deficiency affects pre-synaptic proteins in motor neurons 
Neurexins are cell adhesion molecules found at the pre-synaptic terminals 
that interact with post-synaptic neuroligins to trigger synapse formation (Dean 
et al. 2003). They exist in over 1000 isoforms due to alternative splicing 
causing different binding properties, thus regulating synapse specificity and 
function (Missler and Sudhof 1998, Rowen et al. 2002, Iijima et al. 2011). 
Alternative splicing at SS1 and SS3 of Nrxn2a in rat neurons has been shown 
to be caused by depolarisation and Ca2+ levels inside neurons (Rozic-Kotliroff 
and Zisapel 2007). Activity-dependent alternative splicing at SS4 of Nrxn1 
mediated by SAM68 has also been reported (Iijima et al. 2011). A recent 
study in the zebrafish SMA model reported alternative splicing of neurexin 
2aa (nrxn2aa) at splice site 3 (SS3) in response to reduced Smn levels (See 
et al. 2014). Alternative splicing of nrxn1a at SS3 was identified in SMA MN 
leading to inclusion of exon at SS3. SS3 alternative splicing in nrxn1a, similar 
to nrxn2aa, could also be dependent on Ca2+ levels and modulated by 
depolarisation of neurons (See et al. 2014). See et al. reported down-
regulation and alternative splicing of nrxn2aa in smn morphants (See et al. 
2014), however, RNAseq data from SMA MN reveal no change in nrxn2aa 
splicing as well as mRNA levels. This could be due to the fact that nrxn2aa 
was shown to be expressed in other neurons apart from motor neurons (See 
et al. 2014). This suggests that nrxn2aa remains unaffected under Smn 
deficiency in zebrafish motor neurons, but not in other neurons. Alternative 
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splicing of another cell adhesion molecule coding gene, cell adhesion 
molecule 1a (cadm1a), was also identified in SMA MN. CADM1 encodes a 
synaptic cell adhesion molecule SynCAM1 in vertebrates which has a role in 
assembly of synapses (Biederer et al. 2002, Fogel et al. 2007). Taken 
together, these provide evidence of a link between the splicing defects and 
motor axon defects observed under reduced Smn levels. A recent study in the 
SMA mouse model also reported that splicing and other mRNA level changes 
affect specific genes that are critical for motor neuron synapses, providing 
evidence for a link between splicing abnormality and motoaxonal dysfunction 
(Zhang et al. 2013).  
4.4.2 Smn deficiency leads to alternative splicing of genes involved in 
axonal transport 
Intracellular transport or axonal transport is very important for the 
maintenance and function of neurons because of their extreme polarity and 
size. Axonal transport supplies proteins and small organelles to the axons 
and nerve terminals and at the same time also clears out misfolded proteins 
from axons to avoid any toxic build up (Perlson et al. 2010). Transport is also 
critical for intracellular neural transmission and allows neurons to respond to 
trophic signals and stress (Perlson et al. 2010). Defects in axonal transport 
have been linked to a variety of neurodegenerative diseases such as 
Alzheimer, Parkinson, Huntington, ALS and others (Perlson et al. 2010, 
Millecamps and Julien 2013). In SMAΔ7 mice, defective axonal transport of 
synaptic vesicle 2 and synaptotagmin proteins leading to synaptic 
transmission defects have been reported (Dale et al. 2011). Motor neurons 
derived from SMN deficient hESCs as well as from SMA1 patient iPSCs 
shows abnormal mitochondrial transport as an early pathological change (Xu 
et al. 2016).  
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Schwann cells, like motor neurons, polarise their surface into multiple 
membrane domains by sorting and targeting specific proteins to these 
domains (Trapp et al. 1981, Trapp and Quarles 1982, Cornbrooks et al. 
1983). These proteins after being synthesised in cytoplasm, are sorted using 
trans-golgi network, transported by carrier vesicles to their target sites using 
microtubules (Trapp et al. 1995). Vesicular transport has been reported to 
play a critical role in “glia-to-axon” communication (Lopez-Verrilli and Court 
2012). Polyribosomes from Schwann cells are secreted in the form of 
microvesicles and transported to the adjoining axons during nerve injury and 
regeneration (Court et al. 2008, Court et al. 2011, Lopez-Verrilli and Court 
2012, Lopez-Verrilli et al. 2013). Interestingly, alternative splicing analysis in 
SMA MN and SC revealed some interesting transport related genes that 
could be implicated in SMA pathology. 
The RAB family of GTPase proteins has been reported to be involved in 
regulation of vesicular transport (Pfeffer 1994, Hutagalung and Novick 2011). 
Mouse Rab7 plays an important role in retrograde axonal transport of the 
neurotrophin Nerve growth factor (NGF) (Hendry et al. 1974, Saxena et al. 
2005, Deinhardt et al. 2006). The neurotrophin family of proteins have major 
roles in CNS and PNS including survival, development, nerve repair and 
synaptic plasticity (Huang and Reichardt 2001, Reichardt 2006). Thus, the 
retrograde transport of these proteins from axon tips to soma is very critical 
for neurons. Components of the retrograde transport routes, such as dynein 
and dynactin, which target neurotrophins and other survival signals to the 
soma have been implicated in motor neuron diseases in humans and mice 
(Hafezparast et al. 2003, Puls et al. 2003). Alternative splicing in the 
uncharacterised gene zgc:91909, encoding a novel protein similar to human 
RAB7, was identified in both SMA MN and SC. In both cell types, this leads to 
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generation of a non-functional truncated protein with incorrect amino acid 
sequence. This suggests reduction in functional protein from zgc:91909 in 
both cell types. Rab15, another member of the RAB family, differentially 
regulates the early steps of endocytic trafficking and directs the membrane 
traffic from early endosomes to recycling endosomes for a transport back to 
the membrane (Zuk and Elferink 2000, Strick and Elferink 2005, Hutagalung 
and Novick 2011). Alternative splicing of rab15 was identified in SMA MN, 
leading to exclusion of exon 5 from rab15 transcripts under Smn deficiency. 
These results suggest that deregulation of axonal retrograde transport (i.e. by 
alternative splicing of zgc:91909 and rab15) could affect processes important 
for SMA pathology. 
Alternative splicing analysis also identified genes encoding members of the 
SNX family of proteins, to be affected by reduced Smn levels in zebrafish. 
SNX proteins are involved in intracellular processes like endocytosis, protein 
sorting and endosomal signalling (Cullen 2008). snx9b and snx27a were 
found to be alternatively spliced in both SMA MN and SC. snx14, however, 
was only found in SMA MN. Smn deficiency leads to an increase in exon 6 
skipping of snx9b in both cell types, which was validated using RT-PCR 
experiments. A human homolog SNX9 is present in the presynaptic 
compartment of cultured hippocampal neurons, where it influences the 
synaptic vesicle endocytosis by interaction with dynamin 1 and N-WASP 
(Shin et al. 2007). SNX9 is also involved in clathrin-mediated endocytosis 
through its interaction with dynamin and clathrin (Lundmark and Carlsson 
2003, Soulet et al. 2005). Interestingly exclusion of exon 6 in snx9b leads to 
creation of a pre-mature stop codon. This generates a truncated Snx9b 
protein of 188 aa with its WASP and SH3 binding domain (for dynamin 
interaction) missing. Taken together, a Smn deficiency could lead to Snx9b 
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protein dysfunction, which is possibly linked to defects in synaptic 
transmission, making it an interesting candidate in SMA pathology.  
Sorting nexin 27 (SNX27) is a brain-enriched PDZ domain protein that has 
been shown to regulate the trafficking of certain G protein-gated potassium 
channels (Kir3), which are important for controlling neuronal excitability in the 
brain (Lunn et al. 2007). It is also important for maintaining glutamate 
receptors and is required for normal synaptic activity (Wang et al. 2013). 
Alternative splicing analysis revealed increased inclusion of exon 12 in SMA 
MN and SC, which was also confirmed by performing RT-PCR. The 
consequence of this splicing, however, is not expected to be severe as only 
the last two exons, with no known domains, were affected.   
Taken together, these results point to a new mechanism, linking Smn 
deficiency-induced splicing defects with deregulated intracellular transport 
inside motor neurons and Schwann cells, which could contribute to SMA 
pathology. 
4.4.3 srsf6b as a novel candidate target of Smn 
Alternative splicing analysis of SMA MN and SC identified an interesting 
candidate, serine/arginine-rich splicing factor 6 (srsf6b), which encodes a 
member of the SR protein family which are important for both constitutive and 
alternative splicing of pre-mRNAs (Zahler et al. 1993, Mayeda et al. 1999). 
Studies have reported alternative splicing in splice factor coding genes under 
SMN deficient conditions that could potentially exacerbate the transcriptomic 
changes in SMA over time by inducing a second wave of splicing 
abnormalities (Zhang et al. 2013, Huo et al. 2014, Doktor et al. 2016). 
Alternative splicing of Srsf5 and Srsf10, two other members of SR protein 
family, has recently been reported in the SMA mouse model and the splicing 
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change was found not only in the spinal cord, but also in brain, muscle and 
liver (Doktor et al. 2016). Skipping of exon 2 in srsf6b transcripts was 
identified by RNAseq in both SMA MN and SC and further validated using 
RT-PCR. This exon skipping leads to a truncated protein with only 37 aa, 
which is likely non-functional, suggesting a reduction in overall Srsf6b protein 
levels under Smn deficient conditions. Consequently, this would affect the 
normal functioning of Srsf6b protein in these two cell types. The expression 
pattern, as determined by in situ hybridisation, revealed that srsf6b is 
expressed in the whole brain and spinal cord, with highest levels in its anterior 
part. In the spinal cord at 31 hpf, srf6b expression was restricted to the ventral 
domain with expression in regions containing motor neurons and V2 
interneurons, suggesting a possible role in neuronal differentiation.  
The function of srsf6b in motor neuron development was assessed by 
injecting CRISPRs targeting two sites in srsf6b gene, one each in exon 1 and 
intron 1. The efficiency of this srsf6b double CRISPR injection in generating 
mutations was very high (26 mutant embryos out of 46 injected; 56.52%), as 
determined by the presence of mutant bands in the injected embryos. This 
high efficiency allowed analysis of a mosaic phenotype directly in the injected 
embryos (in an approach called „transient CRISPR mutagenesis‟; (Willems et 
al. 2015)). Overall, the injected embryos were morphologically normal with 
low lethality when a 100 ng/µl dose of each gRNA was injected. However, 
some embryos developed a curved body curvature and delayed growth and 
several of them showed a srsf6b mutation by PCR. Being a splicing factor, 
Srsf6b is expected to be critical during development, thus explaining the 
morphological defects observed in some mutant embryos. znp1 
immunostaining was performed to assess the effect of a Srsf6b loss on 
motoaxons. Interestingly, 69.2% of the embryos showed more than one 
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motoaxonal defects. Motoaxonal defects observed in injected embryos after 
znp1 immunostaining, provided further evidence of Srsf6b‟s important role in 
motor neuron differentiation. At 31hpf, srsf6b showed expression mostly in 
the anterior part of spinal cord, suggesting a role for Srsf6b in fully developed 
motor neurons with NMJs already formed (Myers et al. 1986).  
SR proteins are involved in pre-mRNA splicing of a wide variety of genes 
including the alternative splicing of SMN1 and SMN2. SRSF1, SRSF2 and 
SRSF9 affect the inclusion of exon 7 in SMN1 (Cartegni and Krainer 2002, 
Young et al. 2002, Kashmina and Manley 2003, Cartegni et al. 2006). Using 
HeLa cells and fibroblasts of SMA patients, Wee et al. reported a role of 
SRSF6 in modulating exon 7 splicing in SMN (Wee et al. 2014). However, it is 
presently unclear whether this is in a positive or negative manner in motor 
neurons. Based on this, there is a possibility that in motor neurons Srsf6b 
enhances exon 7 skipping in smn, suggesting a positive feedback and hence 
an „amplification‟ of splicing defects in motor neurons. However, this needs to 
be addressed in future experiments. 
A reduction of Smn leads to alternative splicing of srsf6b in motor neurons, 
resulting in overall lower levels of Srsf6b proteins. Also, srsf6b was found to 
be expressed in motor neurons and to be important for motor neuron 
differentiation. Taken together, I propose the following model to explain 
increased motor neuronal vulnerability in SMA (Fig. 21). According to this 
model, Smn deficiency leads to a general splicing deficiency, mediated by 
reduced snRNP levels, in all cells. Reduced levels of Srsf6b in SMA MN 
initiates a second wave of splicing deficiencies affecting particularly motor 
neuron-specific genes, leading to defects in motor neurons. On the other 
hand, general splicing deficiencies in non-motor neurons lead to no or low 
level defects in these cells, but possibly contribute non-cell autonomously to 
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cause motor neuron defects. Thus, a possible „amplifier mechanism‟, 
consisting of deficiencies in general and Srsf6b splicing, exists in motor 
neurons making them especially vulnerable to Smn deficiency in SMA. 
 
Figure 21. ‘Amplifier mechanism’ to explain vulnerability of motor 
neurons to splicing defects in SMA. Loss of Smn leads to deficiencies in 
general splicing as well as srsf6b splicing in SMA MN, leading to motor 
neuron-specific defects. In non-motor neurons, low level splicing defects 
caused due to general splicing deficiency contribute non-cell autonomously to 
motor neuron defects. Srsf6b enhances exon 7 skipping in smn. In Smn 
deficient conditions, low level of Srsf6b leads to increased smn exon 7 
inclusion, elevating overall Smn protein levels. This consequently improves 
splicing of srsf6b and could possibly ameliorate the downstream splicing 
defects. 
 
4.5 Future experiments 
Generation and characterisation of srsf6b mutant  
The znp1 immunostaining results presented in this thesis suggest a role of 
Srsf6b in motor neuron differentiation. However, this experiment was 
performed by a transient and mosaic srsf6b knock-out, and thus needs to be 
further corroborated with data from stable mutants. RNAseq data identified 
alternative splicing of srsf6b also in SMA SC, thus it would be interesting to 
test for possible Schwann cell defects in these mutants. By crossing the 
srsf6b mutants with motor neuron and Schwann cell calcium sensor lines, 
HB9:D3cpv/MN and HB9:D3cpv/SC, it would be interesting to analyse the 
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excitability and synaptic transmission of both cell types in a srsf6b mutant 
background. The proposed role of Srsf6b as a negative regulator of smn exon 
7 inclusion can also be validated in the srsf6b mutants by analysing the 
splicing pattern of smn as well as determining changes in Smn protein levels. 
In this respect, I have already generated the gRNAs, targeting two sites in 
srsf6b gene, for injection into wild-type embryos.  
Functional characterisation of novel genes affected in SMA MN and SC 
A major advantage of RNAseq is that it identifies novel genes and transcripts. 
RNAseq of SMA MN and SC identified a large number of previously 
uncharacterised novel genes affected by reduced Smn levels. It would be 
interesting to characterise these novel genes and analyse them in context of 
SMA. One such novel gene identified was si:ch211-225b11.1. The Drosophila 
homolog of this gene encodes for Na-/Cl- dependent neurotransmitter 
transporter protein and controls neuronal excitability. It will be interesting to 
characterise the expression and function of this gene in the context of motor 
neuron differentiation.  
 
4.6 Conclusion 
In this study, I have optimised a protocol for performing RNAseq on FAC 
sorted motor neurons and Schwann cells from whole zebrafish embryos, 
which can easily be adapted for other cell types or tissues. Using this 
protocol, the transcriptomes of motor neurons and Schwann cells under 
disease conditions were analysed. Defects in axonogenesis related genes 
were identified as a common denominator of motoaxonal defects in SMA and 
DSMA1 diseases. The alternative splicing data presented here strongly 
suggests that Smn deficiency leads to splicing and other mRNA expression 
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abnormalities in motor neurons, which primarily affect genes important for 
normal neuronal physiology including synapse formation and axonal 
transport. I report identification of the splicing factor srsf6b in zebrafish as a 
possible novel downstream target of Smn and propose an „amplifier 
mechanism‟ of splicing deficiencies to explain motor neuron vulnerability in 
SMA. To the best of my knowledge, this is the first report analysing 
transcriptome wide splicing changes in the zebrafish SMA model. 
 
4.7 Transcriptome analysis of RNAseq data based on GRCz10 
genome assembly 
During the thesis writing, all the bioinformatics analysis done and reported 
was based on Zv9 zebrafish reference genome assembly. However, after the 
submission of this thesis, an updated reference genome assembly was 
released called GRCz10. This updated reference genome has more than 
1000 new clone sequences and improvements in order and orientation of 
assembly sequences. For this, a different set of bioinformatics tools and 
strategy was employed. Briefly, the raw RNAseq data for both motor neurons 
and Schwann cells was trimmed to remove adaptor sequences using 
Trimmomatic software (version 0.36) instead of CutAdapt tool. The 
commands for running trimmomatic are provided in Appendix 2. The trimmed 
RNAseq data was then mapped to GRCz10 zebrafish reference genome 
using Spliced Transcripts Alignment to Reference (STAR) software (version 
2.4.1). Previously, TopHat was used for mapping of trimmed data with Zv9 
genome assembly. The STAR aligner commands are provided in Appendix 2. 
The mapping % for all the libraries (Table 19) considerably improved with 
STAR-GRCz10 as compared to TopHat-Zv9 mapping (Table 11 and 17). The 
STAR aligned data (bam files) were than analysed using Partek Genomics 
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suite for quantification, differential gene expression and GO enrichment 
analysis as mentioned earlier. 
Table 19. Comparison of mapping percentages between Zv9 and 
GRCz10 mapped data 
 
Mapping % with Zv9 
genome assembly 




Sample 1 74.6% 89.01% 
Sample 2 58.5% 82.22% 
Sample 3 59.1% 82.09% 
SMA MN 
Sample 1 74.1% 87.1% 
Sample 2 57.3% 80.52% 
Sample 3 59.6% 81.38% 
Control SC 
Sample 1 29.3% 85.72% 
Sample 2 36.7% 53.56% 
SMA SC 
Sample 1 61.3% 86.42% 
Sample 2 58.3% 81.66% 
 
(A) SMA MN  
In case of SMA MN (n=3), Partek identified 27,258 genes to be expressed in 
motor neurons at the 28 hpf stage. These genes were then filtered and low 
expressing genes (genes with RPKM values less than 1 in at least 4 out of 6 
samples) were excluded. After filtering out low expression genes, the samples 
were analysed for clustering and Sample 1 of both Control MN and SMA MN 
were found to be clustering together and not with other Control and SMA MN 
samples. Ideally, all the controls should appear as one cluster and the test 
samples as another cluster. Clustering of Sample 1 in both control and SMA 
MN might be due to low level of significant difference among the two samples. 
Sample 1 from both Control MN and SMA MN was then rejected from the 
downstream analysis to better statistically significant genes among controls 
and SMA MN. The filtering reduced the overall genes to about 13,484 genes, 
out of which 223 genes were found to be significantly differentially expressed 
in SMA MN at a False Discovery rate (FDR) of 20% (0.2) and a fold change 
greater than 1.5. Out of the 223 genes, 117 were found to be down-regulated 
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while 106 were up-regulated in SMA MN. GO enrichment analysis identified 
311 significantly enriched terms (p-value <0.05, Enrichment score >3). Most 
of the top GO terms were related to ribosome and translation indicating 
deregulation of genes related to them (Figure 22). A closer look at the 
differentially expressed gene list revealed more than 30 ribosomal protein 
coding genes, both for the small and large subunits, and all of them were 
down-regulated under Smn knockdown conditions. This indicates a possible 
defect in ribosomal assembly and translation in SMA MN. This was also 
supported by Pathway analysis using online resource David. Ribosome 
pathway was found to be significantly affected in down-regulated genes while 
Oxidative phosphorylation was the only enriched pathway among the up-
regulated genes.  
Figure 22. Gene Ontology (GO) analysis of differentially expressed 
genes between SMN deficient and control motor neurons. GO analysis 
was performed on differentially expressed genes with at least a 1.5-fold 
change and FDR less than 0.2 (20%). Top 10 GO terms enriched are 
represented in a bar graph with the Y-axis showing the enriched GO terms 
and the X-axis showing the respective enrichment score values. 
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(B) SMA SC 
Partek software identified a total of 26,285 genes to be expressed in 
Schwann cells. Low expression genes (RPKM less than 1 in at least 3 out of 
4 samples) were filtered out. 12,666 genes passed the criterion and were 
used for differential gene expression analysis. Out of 12,666 genes, 338 gene 
were found to differentially expressed with fold change greater than 1.5 and 
p-value less than 0.05 (FDR 0.22). Among these differentially expressed 
genes, 159 genes were found to be down-regulated while 179 were up-
regulated. On comparing the differentially expressed gene list from both cell 
types, only five genes were found to be commonly affected. ascl1a, med14 
and her3 were down-regulated in both cell types while itm2ba was up-
regulated and prdm14 was down-regulated in Schwann cells but up-regulated 
in motor neurons. This again highlights an interesting observation that the 
SMN knockdown leads to tissue-specific gene expression changes.  
GO analysis of differentially expressed genes in SMA SC identified a total of 
271 terms to be significantly enriched (p-value < 0.05, enrichment score >3). 
Genes involved in developmental process, myosin filament assembly related 
processes, syntaxin-1 binding etc. were identified to be deregulated under 
Smn knockdown conditions. Alternative splicing analysis using the newly 








Appendix 1. Amplified double stranded cDNA profiles for Positive 




















Appendix 2. RNAseq data processing and alignment software 
commands. 
(A) CutAdapt tool 
cutadapt -b GATCGGAAGAGCACACGTCTGAACTCCAGTC -g 
ACACTCTTTCCCTACACGACGCTCTTCCGATCT input.fastq > output.fastq 
2> report.txt 
Here in the above code “-b” attribute looks for the adaptor sequence at 5‟ or 3‟ 
end while “-g” looks for 5‟ adaptor  
input.fastq - Raw RNAseq reads with the adaptor sequence 
output.fastq – Trimmed reads without adaptor sequence 
 
(B) TopHat mapping tool 
#!/bin/bash 
#PBS -j oe  
#PBS -l walltime=720:00:00 
#PBS -l nodes=1:ppn=4 




num-threads 8 --min-anchor 8 --splice-mismatches 1 --min-intron-length 50 --
max-intron-length 500000 --min-isoform-fraction 0.15 --max-multihits 1 --
segment-length 25 --segment-mismatches 2 --min-coverage-intron 50 --max-
coverage-intron 20000 --min-segment-intron 50 --max-segment-intron 500000 
--keep-fasta-order --read-mismatches 3 --read-gap-length 3 --read-edit-dist 3 
--read-realign-edit-dist 3 --max-insertion-length 3 --max-deletion-length 3 --
mate-inner-dist 200 --mate-std-dev 20 --no-coverage-search --library-type fr-











Default parameters were used for running TopHat with only few changes. 
 mate-inner-dist : Distance between the mates (concordant paired-end 
reads) aligning to the genome. It is calculated as Fragment length 
minus two times the read length. 
 mate-std-dev : The standard deviation for the distribution on inner 
distances between mate pairs 
 
(C) Trimmomatic tool 
#!/bin/bash 
#PBS -j oe  
#PBS -l walltime=720:00:00 
#PBS -l nodes=1:ppn=4 














A custom made adaptor file, Adaptor-file.fa, was generated that contained 
information on sequences that needs to be removed from all the samples. 






















(D) STAR aligner tool 
#!/bin/bash 
#PBS -j oe  
#PBS -l walltime=720:00:00 
#PBS -l nodes=1:ppn=4 
/cluster/apps/x86_64/packages/STAR_2.4.1d/src/bin/Linux_x86_64_static/ST
AR --runThreadN 4 --genomeDir /home/vyash/STAR-Danio10-new/Danio-
rerio-genome-dir-new --readFilesIn /home/vyash/RZN001-HV/ 
RZN001_CTTGTA_L003_forward_paired_long.fastq /home/vyash/RZN001-
HV/ RZN001_CTTGTA_L003_reverse_paired_long.fastq --outFilterType 
BySJout --outFilterMultimapNmax 20 --alignSJoverhangMin 8 --
alignSJDBoverhangMin 1 --alignIntronMin 20 --alignIntronMax 1000000 --








Appendix 3. List of differentially expressed genes in SMA MN 
S. No. Gene symbol p-value Fold Change Regulation 
1 zgc:153759 0.01821 30757.60 down 
2 tnni2a.1 0.00852 21.09 down 
3 glis3 0.01793 16.43 down 
4 lft1 0.00284 16.03 down 
5 zp2l2 0.00137 14.27 down 
6 si:dkey-11p23.7 0.00698 11.99 down 
7 foxg1d 0.02047 11.03 down 
8 lta 0.00412 10.58 down 
9 zgc:195356 0.02966 9.99 down 
10 slc38a8 0.00548 8.75 down 
11 tssk6 0.01694 8.57 down 
12 gsto1 0.00896 7.92 down 
13 loxl5a 0.00075 7.61 down 
14 hspb2 0.04110 6.73 down 
15 crygm2d17 0.01003 6.63 down 
16 nitr3c 0.04813 6.22 down 
17 mettl11b 0.02312 6.10 down 
18 pvalb3 0.03452 5.58 down 
19 ifitm5 0.02242 5.29 down 
20 rtn4rl2a 0.01377 5.24 down 
21 tas2r3 0.01896 5.23 down 
22 neurog1 0.00731 4.91 down 
23 camk2a 0.00259 4.88 down 
24 cpa5 0.01614 4.83 down 
25 si:dkey-228a15.1 0.03432 4.72 down 
26 s100z 0.02611 4.59 down 
27 cdnf 0.00107 4.57 down 
28 gnb3a 0.00939 4.55 down 
29 lrrc20 0.00450 4.54 down 
30 ugt2a1 0.01250 4.48 down 
31 pvalb2 0.04406 4.22 down 
32 gadd45gb.1 0.02548 4.20 down 
33 si:ch211-152f23.5 0.02775 4.16 down 
34 hoga1 0.03192 4.16 down 
35 zgc:158296 0.03575 4.09 down 
36 nme2b.2 0.04330 3.95 down 
37 pde6h 0.01088 3.86 down 
38 tgm2a 0.03862 3.86 down 
39 dhrs7cb 0.02528 3.79 down 
40 hsc70 0.03104 3.78 down 
41 adh8a 0.00622 3.73 down 
42 casq1b 0.02529 3.71 down 
43 tnnt3b 0.03209 3.69 down 
44 ascl1a 0.00616 3.68 down 
45 zic5 0.02122 3.61 down 
46 zgc:66455 0.01260 3.60 down 
47 rx2 0.04132 3.59 down 
48 myl1 0.03618 3.55 down 
49 zgc:174931 0.01112 3.54 down 
50 olig2 0.00032 3.54 down 
51 ckmb 0.02980 3.52 down 
52 smyd1a 0.02125 3.49 down 
53 mylz3 0.04338 3.47 down 
54 cyp1b1 0.01890 3.47 down 
55 prom1b 0.04727 3.41 down 
56 pygma 0.04600 3.37 down 
57 casq1a 0.00373 3.33 down 
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S. No. Gene symbol p-value Fold Change Regulation 
58 fezf2 0.00227 3.30 down 
59 actc1b 0.04051 3.29 down 
60 ckma 0.04469 3.23 down 
61 arl3l2 0.03485 3.22 down 
62 tnni2a.4 0.02600 3.22 down 
63 myoz2a 0.03393 3.22 down 
64 gsx1 0.00386 3.15 down 
65 sox21b 0.03705 3.10 down 
66 zgc:110045 0.00155 3.08 down 
67 tnnc2 0.04595 3.03 down 
68 zgc:173585 0.02855 3.01 down 
69 mybpc2b 0.01510 3.00 down 
70 rtn2b 0.00580 2.98 down 
71 tpma 0.02934 2.97 down 
72 vcla 0.01696 2.94 down 
73 tspan12 0.02997 2.92 down 
74 hhatla 0.01275 2.89 down 
75 rx1 0.04731 2.88 down 
76 six3b 0.00084 2.88 down 
77 murca 0.02183 2.85 down 
78 cldn8 0.04820 2.85 down 
79 ctssa 0.04103 2.85 down 
80 actn3a 0.02073 2.76 down 
81 gapdh 0.04016 2.75 down 
82 ak1 0.02303 2.69 down 
83 olfm2b 0.01121 2.67 down 
84 zgc:162356 0.00785 2.67 down 
85 dld 0.00401 2.62 down 
86 npas4a 0.00492 2.59 down 
87 zgc:162595 0.01228 2.58 down 
88 stac3 0.03101 2.57 down 
89 apobec2a 0.02191 2.55 down 
90 nr5a5 0.02680 2.55 down 
91 bhlhe22 0.04264 2.54 down 
92 aqp4 0.03332 2.50 down 
93 si:dkey-23c22.6 0.01270 2.47 down 
94 si:ch211-170d8.2 0.00053 2.42 down 
95 si:dkey-238o13.4 0.03789 2.42 down 
96 hspb6 0.00249 2.42 down 
97 ahr1b 0.04587 2.41 down 
98 foxd1l 0.00877 2.41 down 
99 pou3f3a 0.04802 2.40 down 
100 pax6b 0.00110 2.40 down 
101 fzd5 0.01483 2.39 down 
102 sst1.1 0.04195 2.37 down 
103 tbx2b 0.02647 2.36 down 
104 mmp13a 0.04201 2.36 down 
105 pde6a 0.00030 2.35 down 
106 si:ch211-243a20.3 0.01151 2.34 down 
107 si:ch211-251b21.1 0.03428 2.34 down 
108 cx43 0.00467 2.31 down 
109 grem2b 0.02388 2.28 down 
110 casq2 0.03795 2.26 down 
111 zgc:172079 0.03948 2.26 down 
112 znf362a 0.01593 2.26 down 
113 rtn4ip1 0.01120 2.25 down 
114 vax1 0.00948 2.21 down 
115 lbx1b 0.01099 2.21 down 
116 dmrt3a 0.00069 2.20 down 
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117 jag1a 0.02254 2.20 down 
118 zgc:158463 0.00086 2.17 down 
119 sc:d217 0.03683 2.16 down 
120 p2rx5 0.04061 2.16 down 
121 hoxa13a 0.03985 2.15 down 
122 wfdc1 0.02289 2.14 down 
123 eng1b 0.01893 2.12 down 
124 med14 0.00745 2.12 down 
125 eno3 0.02714 2.10 down 
126 dct 0.02848 2.09 down 
127 hdhd1 0.00739 2.08 down 
128 apela 0.01265 2.07 down 
129 sfrp1a 0.00740 2.06 down 
130 zc3h10 0.02535 2.04 down 
131 mycn 0.02849 2.03 down 
132 cmyb 0.00851 2.03 down 
133 mibp2 0.00842 2.00 down 
134 nipsnap1 0.02462 55.72 up 
135 kcnj8 0.00468 52.65 up 
136 mespbb 0.02217 39.23 up 
137 itga2b 0.00832 19.60 up 
138 mespba 0.00336 19.49 up 
139 zgc:194733 0.00699 16.58 up 
140 rhbg 0.02410 14.45 up 
141 rad21l1 0.00167 12.33 up 
142 paqr8 0.02610 10.83 up 
143 cfd 0.04887 9.86 up 
144 si:ch211-12h2.6 0.01577 9.29 up 
145 isg15 0.00941 9.03 up 
146 utrnp 0.01844 7.14 up 
147 tectb 0.01871 7.02 up 
148 calhm2 0.02584 6.74 up 
149 eif2ak2 0.00142 6.70 up 
150 cyp2k16 0.04218 6.57 up 
151 slc27a1b 0.03850 6.43 up 
152 apoc1l 0.00118 6.29 up 
153 slc9a2 0.00185 6.25 up 
154 ela2l 0.01147 5.71 up 
155 ap1m3 0.01836 5.68 up 
156 zgc:101699 0.00167 5.58 up 
157 wnt10b 0.01059 5.46 up 
158 wnt1 0.01209 5.42 up 
159 si:ch211-14a17.6 0.03936 5.31 up 
160 eva1bb 0.02054 4.78 up 
161 mat2al 0.00688 4.78 up 
162 trhr2 0.01348 4.75 up 
163 erbb3a 0.04388 4.67 up 
164 dkk1b 0.01314 4.67 up 
165 zgc:162324 0.01894 4.66 up 
166 ppil6 0.01128 4.55 up 
167 ptgdsa 0.01497 4.50 up 
168 zgc:65811 0.02279 4.47 up 
169 cdh15 0.02448 4.42 up 
170 apoeb 0.00152 4.38 up 
171 rpz5 0.00385 4.35 up 
172 ccdc106b 0.00646 4.27 up 
173 si:ch211-14a17.7 0.02613 4.10 up 
174 lrrc48 0.00198 3.97 up 
175 plxnb2b 0.01036 3.95 up 
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176 upb1 0.02984 3.88 up 
177 fam129aa 0.04582 3.79 up 
178 slc5a2 0.04235 3.76 up 
179 hepacama 0.02629 3.74 up 
180 fn1b 0.00018 3.74 up 
181 ddx43 0.01340 3.67 up 
182 si:ch211-81a5.5 0.02457 3.55 up 
183 htra3a 0.03111 3.51 up 
184 glrba 0.00230 3.51 up 
185 pcdh8 0.00462 3.38 up 
186 loc100536659 0.02368 3.35 up 
187 zgc:153740 0.01157 3.28 up 
188 acsl5 0.00984 3.25 up 
189 zgc:113363 0.01237 3.21 up 
190 nrm 0.02060 3.20 up 
191 fbxo32 0.01697 3.11 up 
192 si:dkey-261j4.5 0.01274 3.10 up 
193 s100v2 0.03128 3.07 up 
194 hapln4 0.02525 3.07 up 
195 smkr1 0.00547 3.07 up 
196 zgc:113337 0.02348 3.05 up 
197 kcnk1a 0.01861 3.04 up 
198 baiap2l1b 0.01304 3.03 up 
199 si:dkey-222p3.1 0.01833 3.02 up 
200 hmox1a 0.00295 3.01 up 
201 mink1 0.02653 2.98 up 
202 casp8 0.03940 2.97 up 
203 zgc:195173 0.02624 2.94 up 
204 rpe65b 0.03594 2.94 up 
205 si:dkey-188i13.10 0.04310 2.91 up 
206 gcga 0.03785 2.88 up 
207 ccdc125 0.03596 2.86 up 
208 efemp2b 0.01026 2.84 up 
209 mgc172218 0.02885 2.83 up 
210 nfe2 0.02006 2.83 up 
211 lingo3a 0.02723 2.82 up 
212 tspan15 0.00502 2.80 up 
213 mdm1 0.03314 2.76 up 
214 si:dkey-121a9.3 0.04280 2.76 up 
215 si:ch211-222k6.3 0.01442 2.76 up 
216 oc90 0.01133 2.76 up 
217 urp2 0.03162 2.75 up 
218 chrng 0.02193 2.75 up 
219 jam2a 0.03123 2.74 up 
220 epor 0.04414 2.74 up 
221 sepw2b 0.04551 2.74 up 
222 sesn3 0.02784 2.70 up 
223 klf17 0.01081 2.66 up 
224 hcst 0.01637 2.66 up 
225 acot8 0.01070 2.64 up 
226 ggh 0.00480 2.61 up 
227 dmrt2a 0.00344 2.60 up 
228 zgc:92326 0.02318 2.60 up 
229 si:dkeyp-59c12.1 0.04683 2.59 up 
230 pls3 0.02885 2.58 up 
231 si:dkey-169i5.4 0.00081 2.56 up 
232 snrkb 0.01632 2.56 up 
233 zgc:101663 0.00888 2.56 up 
234 lgi2b 0.03168 2.55 up 
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235 scgn 0.03943 2.50 up 
236 cx35.4 0.01711 2.47 up 
237 tdrd6 0.01782 2.46 up 
238 kcnc4 0.02887 2.45 up 
239 eps8l1 0.02633 2.45 up 
240 kcnk1b 0.00410 2.45 up 
241 tagln2 0.01354 2.45 up 
242 tmed1a 0.01159 2.44 up 
243 ppp1r1c 0.00198 2.44 up 
244 foxi1 0.00821 2.44 up 
245 unc45a 0.01104 2.43 up 
246 zp3a.2 0.04623 2.42 up 
247 mmp9 0.04253 2.42 up 
248 rbm24a 0.02840 2.42 up 
249 zgc:153219 0.03311 2.40 up 
250 pik3cg 0.02360 2.38 up 
251 itm2bb 0.01041 2.38 up 
252 arrb1 0.01255 2.37 up 
253 cyp3c1 0.00206 2.36 up 
254 gnmt 0.00323 2.36 up 
255 abhd6b 0.02214 2.36 up 
256 myl4 0.00946 2.34 up 
257 kremen1 0.01810 2.34 up 
258 itcha 0.04642 2.33 up 
259 trim2a 0.03284 2.32 up 
260 fsta 0.01466 2.31 up 
261 capn2a 0.01954 2.30 up 
262 socs1a 0.01474 2.29 up 
263 arhgdig 0.01995 2.28 up 
264 zgc:92912 0.03169 2.27 up 
265 fbxl22 0.04956 2.26 up 
266 abcg4b 0.02109 2.26 up 
267 phlda2 0.02738 2.24 up 
268 sox7 0.04464 2.24 up 
269 smad9 0.01979 2.24 up 
270 ldlrap1b 0.02442 2.22 up 
271 loc556326 0.03008 2.22 up 
272 ttpa 0.00304 2.22 up 
273 ptpreb 0.00117 2.21 up 
274 csf2rb 0.02916 2.21 up 
275 hsd3b1 0.00257 2.21 up 
276 slc9a8 0.00092 2.20 up 
277 rab36 0.00990 2.20 up 
278 myl9a 0.01923 2.19 up 
279 zgc:154077 0.00882 2.18 up 
280 pxmp2 0.03518 2.16 up 
281 rtn3 0.00639 2.16 up 
282 timp2b 0.02234 2.14 up 
283 si:ch211-237l4.6 0.02600 2.14 up 
284 optn 0.03697 2.13 up 
285 ttc25 0.02459 2.13 up 
286 parp3 0.02832 2.13 up 
287 acot11b 0.01756 2.12 up 
288 serpinb1 0.00250 2.10 up 
289 uck1 0.02434 2.10 up 
290 lmcd1 0.00417 2.09 up 
291 srsf7b 0.00815 2.09 up 
292 prkg1a 0.04795 2.09 up 
293 gata1a 0.04864 2.09 up 
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294 slc27a6 0.02240 2.08 up 
295 kcnj2a 0.04862 2.07 up 
296 lrrc15 0.02223 2.06 up 
297 acvrl1 0.03358 2.06 up 
298 ppp1r14aa 0.03277 2.05 up 
299 cntn1b 0.00443 2.05 up 
300 arf3a 0.00616 2.05 up 
301 csad 0.02771 2.04 up 
302 tnfaip2a 0.01266 2.04 up 
303 gadd45ga 0.03181 2.04 up 
304 anxa13 0.00197 2.03 up 
305 skap2 0.02760 2.03 up 
306 hsd3b7 0.03565 2.03 up 
307 fuom 0.01242 2.03 up 
308 kitlgb 0.01167 2.02 up 
309 kdrl 0.01777 2.02 up 
310 zgc:193681 0.03643 2.02 up 
311 scrn2 0.02459 2.01 up 
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Appendix 4. List of differentially expressed genes in SMA SC 
S. 
No. 
Gene symbol p-value Fold Change Regulation 
1 mir137-2 0.00029 679516000 down 
2 mir137-3 0.00029 679516000 down 
3 mogat2 0.04119 70.99 down 
4 mpz 0.01056 60.35 down 
5 pfkmb 0.01360 26.03 down 
6 nsmfb 0.00378 24.01 down 
7 slc30a1b 0.04665 21.47 down 
8 sox12 0.03287 20.20 down 
9 fgf22 0.00709 14.94 down 
10 olfm3a 0.02106 12.29 down 
11 scpp8 0.03430 11.48 down 
12 ifitm5 0.01914 11.45 down 
13 zgc:91944 0.02645 10.57 down 
14 cabp5b 0.01111 10.56 down 
15 si:ch211-71m22.3 0.01957 9.66 down 
16 tfap2d 0.01957 9.66 down 
17 fbp2 0.04358 9.26 down 
18 cldn10a 0.03314 9.21 down 
19 zgc:171579 0.03830 8.56 down 
20 her3 0.01431 8.41 down 
21 glrba 0.04471 7.60 down 
22 si:dkey-32m20.1 0.00375 6.50 down 
23 fabp7b 0.00826 6.45 down 
24 gnat1 0.03507 6.11 down 
25 zgc:136336 0.03117 5.73 down 
26 mpp5b 0.04991 5.43 down 
27 bcl11aa 0.04772 5.40 down 
28 glra1 0.03602 5.04 down 
29 and3 0.01010 5.03 down 
30 vil1 0.04306 5.03 down 
31 serp2 0.03473 5.01 down 
32 ptf1a 0.00156 4.99 down 
33 chgb 0.03735 4.51 down 
34 usp43a 0.04205 4.27 down 
35 zgc:114175 0.00474 4.18 down 
36 prss35 0.03827 4.15 down 
37 dgat1a 0.04250 4.13 down 
38 pdyn 0.02786 4.11 down 
39 zgc:103438 0.03259 4.11 down 
40 si:dkey-228a15.1 0.02110 4.10 down 
41 bmp8a 0.01624 4.03 Down 
42 itga11a 0.03257 3.99 Down 
43 scn12aa 0.04025 3.84 Down 
44 saga 0.01180 3.82 down 
45 zgc:56231 0.00796 3.69 down 
46 ppox 0.02045 3.61 down 
47 foxq1b 0.00510 3.57 down 
48 figf 0.01039 3.55 down 
49 pvalb1 0.02603 3.52 down 
50 ccbe1 0.00439 3.47 down 
51 cx39.9 0.04389 3.43 down 
52 phkg1b 0.00297 3.40 down 
53 insb 0.02628 3.37 down 
54 tnfsf13b 0.01659 3.33 down 
55 cbln1 0.03988 3.28 down 
56 grin2bb 0.00223 3.02 down 
57 ascl1a 0.00288 3.00 down 
58 zgc:158423 0.02038 2.97 down 





Gene symbol p-value Fold Change Regulation 
60 lrrc20 0.03633 2.91 down 
61 ascl1b 0.03650 2.84 down 
62 neurod4 0.02242 2.84 down 
63 foxf2a 0.01707 2.80 down 
64 pvalb2 0.00905 2.79 down 
65 onecut1 0.01203 2.77 down 
66 zgc:193807 0.02103 2.75 down 
67 lgi1b 0.01362 2.75 down 
68 nrsn1 0.03929 2.74 down 
69 zgc:158296 0.01088 2.72 down 
70 jph2 0.02593 2.69 down 
71 rbfox1l 0.00401 2.67 down 
72 si:ch211-245j22.3 0.03795 2.62 down 
73 krt96 0.03989 2.61 down 
74 actc1b 0.00361 2.61 down 
75 vcam1 0.03253 2.60 down 
76 si:ch211-155m12.1 0.01904 2.58 down 
77 smyd1a 0.01059 2.55 down 
78 tnni2a.4 0.02791 2.54 down 
79 rell2 0.02682 2.54 down 
80 tlx2 0.00793 2.53 down 
81 slc1a3b 0.00436 2.51 down 
82 pou4f1 0.01116 2.50 down 
83 emx2 0.03232 2.49 down 
84 scrt1a 0.02704 2.49 down 
85 gbx2 0.00917 2.47 down 
86 caprin2 0.01767 2.46 down 
87 ckma 0.02277 2.45 down 
88 alox5a 0.04358 2.45 down 
89 crygm2d5 0.01278 2.44 down 
90 foxd1 0.03965 2.44 down 
91 rem2 0.00820 2.41 down 
92 myl1 0.00951 2.39 down 
93 foxc1a 0.04491 2.37 down 
94 ak1 0.01652 2.35 down 
95 fbxl7 0.00423 2.34 down 
96 ckmb 0.03136 2.34 down 
97 gpr27 0.03390 2.33 down 
98 cd151 0.00476 2.32 down 
99 pdlim5a 0.02377 2.32 down 
100 nhlh2 0.03855 2.31 down 
101 wnt9a 0.00447 2.28 down 
102 nme4 0.02162 2.26 down 
103 mylz3 0.01389 2.25 down 
104 hey2 0.03236 2.25 down 
105 wu:fc66h01 0.03338 2.24 down 
106 gadd45gb.1 0.02522 2.24 down 
107 gstr 0.01277 2.22 down 
108 rbfox1 0.02586 2.22 down 
109 snap25a 0.02974 2.22 down 
110 kif3cb 0.00905 2.22 down 
111 rtn1b 0.00215 2.22 down 
112 si:busm1-160c18.6 0.02432 2.21 down 
113 syn1 0.03649 2.21 down 
114 phyhiplb 0.04577 2.19 down 
115 hoxb5b 0.01904 2.13 down 
116 tpma 0.04070 2.12 down 
117 nfil3-2 0.03679 2.11 down 
118 dpf1 0.03994 2.11 down 
119 palm1a 0.00563 2.10 down 
120 mid1ip1b 0.02322 2.09 down 
121 tmod4 0.01139 2.07 down 





Gene symbol p-value Fold Change Regulation 
122 si:dkey-23c22.6 0.03584 2.06 down 
123 mylpfb 0.03377 2.05 down 
124 crispld1b 0.02771 2.04 down 
125 acta1b 0.02828 2.04 down 
126 olig4 0.04823 2.04 down 
127 bcat1 0.00914 2.02 down 
128 sept5b 0.00242 2.02 down 
129 tagln3b 0.00952 2.00 down 
130 dpp4 0.01460 75.86 up 
131 cfhl2 0.02403 54.25 up 
132 trpa1b 0.01648 53.73 up 
133 lrp2bp 0.00258 49.65 up 
134 c8g 0.04862 18.48 up 
135 zgc:66449 0.01275 18.41 up 
136 otos 0.00548 16.17 up 
137 nipsnap1 0.01910 14.57 up 
138 zp2.6 0.00837 13.48 up 
139 sim1a 0.00828 12.97 up 
140 zgc:92162 0.00828 12.97 up 
141 ifnphi1 0.00854 12.22 up 
142 si:zfos-1425h8.1 0.02596 11.92 up 
143 loxl5b 0.02596 11.92 up 
144 c8b 0.01176 11.37 up 
145 ntf7 0.01078 11.15 up 
146 zgc:173837 0.02584 10.04 up 
147 lat 0.03698 9.76 up 
148 kcnj8 0.01999 9.69 up 
149 cyp2aa8 0.03276 9.56 up 
150 neu3.5 0.01743 8.70 up 
151 loc567472 0.01813 8.64 up 
152 apobec2b 0.04255 8.13 up 
153 trim35-31 0.02062 8.09 up 
154 nr4a2a 0.02062 8.09 up 
155 glra2 0.03708 7.53 up 
156 ppil6 0.01264 7.18 up 
157 fam113 0.03726 7.07 up 
158 slc24a2 0.04144 7.04 up 
159 nos2b 0.00100 6.83 up 
160 enpep 0.03410 6.40 up 
161 tyrobp 0.04840 5.95 up 
162 ifit8 0.04616 5.51 up 
163 cdkn2c 0.01276 5.25 up 
164 si:dkeyp-110e4.3 0.03335 4.82 up 
165 smkr1 0.00796 4.77 up 
166 rspo1 0.00158 4.76 up 
167 fhl2a 0.02239 4.63 up 
168 pawr 0.01645 4.56 up 
169 si:ch211-154a22.8 0.00382 4.56 up 
170 sptssb 0.01695 4.46 up 
171 ta 0.04735 4.29 up 
172 dock5 0.03205 4.07 up 
173 adh8a 0.03968 3.99 up 
174 prom1b 0.03890 3.98 up 
175 loc100500728 0.03004 3.90 up 
176 il17c 0.02490 3.84 up 
177 grip2a 0.02048 3.64 up 
178 nr5a2 0.03364 3.61 up 
179 loc567180 0.01882 3.61 up 
180 zp2.1 0.00909 3.58 up 
181 chadlb 0.03359 3.52 up 
182 zgc:153738 0.03557 3.25 up 
183 si:ch211-57h10.1 0.04141 3.18 up 





Gene symbol p-value Fold Change Regulation 
184 morn3 0.02287 3.16 up 
185 camk2n1b 0.04183 3.09 up 
186 ehd2b 0.00582 2.94 up 
187 trpv4 0.00460 2.89 up 
188 ptgdsb 0.01716 2.81 up 
189 col9a1b 0.04219 2.74 up 
190 apoc1l 0.03741 2.74 up 
191 sesn3 0.04346 2.67 up 
192 mdm2 0.01221 2.66 up 
193 lrp2a 0.03452 2.65 up 
194 runx2b 0.01334 2.55 up 
195 zgc:66484 0.04074 2.48 up 
196 ankar 0.01753 2.44 up 
197 her11 0.01284 2.44 up 
198 plod2 0.01620 2.43 up 
199 cyp2aa3v1 0.02830 2.41 up 
200 klhl21 0.01631 2.39 up 
201 he2 0.03155 2.38 up 
202 olfml3b 0.02651 2.35 up 
203 sid4 0.01681 2.34 up 
204 npffr1l2 0.00580 2.34 up 
205 zgc:110712 0.02124 2.33 up 
206 gtpbp1l 0.01621 2.29 up 
207 pkhd1l1 0.03879 2.25 up 
208 dpyda.1 0.02222 2.23 up 
209 si:dkey-91m11.5 0.00200 2.21 up 
210 asb13a.2 0.02059 2.17 up 
211 pnocb 0.00809 2.16 up 
212 e2f5 0.03417 2.16 up 
213 loc794484 0.03453 2.14 up 
214 si:ch211-244b2.4 0.03453 2.14 up 
215 zgc:136493 0.02698 2.11 up 
216 gabra6a 0.02770 2.10 up 
217 tlr3 0.02476 2.10 up 
218 cacnb2a 0.00774 2.09 up 
219 slc4a2a 0.03008 2.06 up 
220 tubd1 0.04921 2.05 up 
221 stat7 0.04971 2.05 up 
222 zgc:113426 0.03633 2.05 up 
223 zgc:193681 0.00831 2.04 up 
224 camkvb 0.02045 2.02 up 
225 zgc:165514 0.04473 2.02 up 
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Appendix 5. List of differentially expressed genes common to 
SMA MN and SC 





SMA MN SMA SC 
1 adh8a -3.73 3.99 
2 glrba 3.51 -7.60 
3 prom1b -3.41 3.98 
(B) Genes down-regulated in both lists 
1 ifitm5 -5.29 -11.45 
2 si:dkey-228a15.1 -4.72 -4.10 
3 lrrc20 -4.54 -2.91 
4 pvalb2 -4.22 -2.79 
5 gadd45gb.1 -4.20 -2.24 
6 zgc:158296 -4.09 -2.72 
7 ascl1a -3.68 -3.00 
8 myl1 -3.55 -2.39 
9 ckmb -3.52 -2.34 
10 smyd1a -3.49 -2.55 
11 mylz3 -3.47 -2.25 
12 actc1b -3.29 -2.61 
13 ckma -3.23 -2.45 
14 tnni2a.4 -3.22 -2.54 
15 tpma -2.97 -2.12 
16 ak1 -2.69 -2.35 
17 si:dkey-23c22.6 -2.47 -2.06 
(C) Genes up-regulated in both lists 
1 nipsnap1 55.72 14.57 
2 kcnj8 52.65 9.69 
3 apoc1l 6.29 2.74 
4 ppil6 4.55 7.18 
5 smkr1 3.07 4.77 
6 sesn3 2.70 2.67 












Appendix 6. List of AS events identified in SMA MN 
(A) Skipped exon AS events 
geneSymbol chr strand 
exonStart_
0base 
exonEnd upstreamES upstreamEE downstreamES downstreamEE FDR 
IncLevel 
Difference 
ptenb 12 - 18482144 18482188 18481820 18482059 18482466 18482511 0 0.412 
zgc:136639 2 - 22431832 22431907 22431667 22431739 22431977 22432077 3.69E-17 0.406 
ptpreb 17 + 29391604 29391701 29390738 29390810 29393243 29393317 2.16E-132 0.36 
zgc:165580 17 + 19332145 19332289 19329309 19329524 19332461 19332594 3.97E-164 0.353 
copz2 3 + 24399366 24399399 24399117 24399156 24401054 24401645 0.0010874 0.333 
melk 1 - 20709535 20709622 20708388 20708517 20710511 20710610 4.07E-06 0.318 
dll4 20 + 28282568 28282677 28281373 28282091 28282930 28283618 1.81E-42 0.314 
vcla 13 - 25440846 25441038 25438586 25438790 25445064 25445250 0.0076964 0.313 
zgc:77838 21 - 5270280 5270352 5264911 5264996 5295568 5296327 3.11E-19 0.304 
si:dkey-57a22.11 9 + 23011522 23011600 23011155 23011331 23011793 23011833 2.15E-48 0.299 
mettl20 25 - 29777244 29777375 29774501 29774933 29792980 29793322 3.49E-07 0.292 
calcrla 9 - 43436606 43436648 43433737 43433998 43439509 43439728 1.61E-104 0.276 
naa30 17 + 44515679 44515735 44515295 44515419 44520359 44523265 5.73E-37 0.263 
snx27a 19 + 9267840 9267889 9266968 9267097 9269978 9270104 9.29E-08 0.251 
ppp5c 15 - 2738101 2738167 2737889 2737988 2739221 2739343 4.03E-06 0.249 
zgc:162576 17 + 42113203 42113284 42110438 42110601 42119446 42120017 9.86E-29 0.244 
tbl1xr1a 11 + 8751012 8751110 8750860 8750924 8755159 8755220 2.03E-203 0.235 
myom1a 2 + 30631792 30631981 30631019 30631133 30636188 30636317 5.28E-05 0.226 
ccnt2a 9 - 24272951 24273014 24272683 24272729 24274684 24274813 5.38E-16 0.22 
prkcbp1l 23 - 9947491 9947569 9947022 9947138 9947734 9947790 1.18E-262 0.215 
map7d2a 5 - 25649734 25649815 25645497 25645610 25653003 25653103 3.11E-141 0.195 
nav3 4 + 19829258 19829327 19817838 19818022 19834542 19834685 0.0058625 0.191 
ptpn2a 16 - 11652840 11652968 11650025 11650181 11659517 11659679 9.84E-05 0.189 
gnmt 17 - 49084872 49085000 49084673 49084787 49091454 49091737 9.55E-18 0.188 
ccdc93 9 - 39417471 39417570 39417340 39417397 39418862 39418974 7.85E-91 0.187 
chd2 18 - 24762723 24762840 24760407 24760560 24764807 24764869 0.0153645 0.186 
ash2l 10 - 2802789 2802807 2800288 2800391 2802902 2802978 1.51E-09 0.183 
rasl11a 7 - 52775097 52775154 52770813 52771284 52775794 52775945 1.47E-11 0.176 
pho 5 + 65383451 65383509 65383269 65383367 65386804 65394595 6.61E-104 0.166 
ccnl1a 18 + 39853090 39853165 39852454 39852747 39854442 39854552 9.76E-27 0.163 
mtfmt 7 + 54213413 54213490 54212737 54212816 54216274 54216652 5.81E-08 0.16 
mthfd1b 17 - 49558065 49558119 49557843 49557980 49559738 49559798 2.45E-81 0.159 
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geneSymbol chr strand 
exonStart_
0base 
exonEnd upstreamES upstreamEE downstreamES downstreamEE FDR 
IncLevel 
Difference 
ncalda 16 - 11482548 11482610 11440893 11441293 11491536 11491628 0.0012406 0.157 
dzip1 6 + 7182987 7183036 7182596 7182725 7187096 7187245 1.45E-12 0.156 
tnikb 24 - 27312868 27313015 27310149 27310243 27313315 27313424 0.0370144 0.154 
slc25a46 5 - 57336927 57336985 57330075 57331276 57337290 57337347 3.10E-109 0.153 
zgc:63907 16 - 46220791 46220996 46218555 46218700 46226625 46226686 2.95E-10 0.153 
lrrc40 6 + 29831369 29831542 29831151 29831294 29833063 29833154 6.14E-18 0.151 
tmem141 5 + 63139243 63139310 63138374 63138431 63139545 63139629 0.0028726 0.151 
zgc:171429 9 + 8955787 8956225 8954520 8954600 8959667 8959806 0.0560507 0.146 
kat7 12 - 6681634 6681685 6679510 6679658 6682216 6682360 2.35E-126 0.145 
mknk2a 2 + 22470087 22470161 22469471 22469551 22471300 22471405 9.72E-06 0.138 
atp2b3b 23 - 20178807 20178849 20175290 20175455 20181879 20182005 0.0082438 0.138 
fktn 5 - 72951785 72951842 72951227 72951428 72952933 72953088 2.99E-51 0.135 
etf1b 10 + 21518356 21518496 21517960 21518136 21521366 21521505 8.97E-20 0.135 
palm2 10 + 4806732 4806834 4804528 4804550 4811303 4812013 0.0083147 0.135 
snx14 20 - 881444 881485 879451 879571 885115 885227 5.88E-26 0.133 
ptp4a2b 19 - 37020794 37020903 37020617 37020710 37021182 37021457 2.22E-08 0.132 
rasl11a 7 - 52774809 52774892 52770813 52771284 52775794 52775945 1.52E-09 0.13 
zgc:172295 1 - 27739970 27740044 27719129 27719267 27762582 27762679 0.002891 0.13 
aamp 6 + 59646330 59646421 59644657 59644746 59646520 59646675 0.0627878 0.13 
srek1 5 - 55757839 55757914 55757644 55757759 55760608 55760740 5.53E-07 0.127 
trim33 8 + 11749390 11749441 11744779 11744932 11749637 11750361 5.87E-15 0.125 
zgc:101840 20 - 9624961 9625056 9614622 9614680 9640293 9640457 5.74E-25 0.124 
clasp2 19 + 44369688 44369796 44368961 44369003 44372784 44372891 2.66E-37 0.123 
rab4b 15 - 8975296 8975377 8969887 8970002 8991519 8991664 4.89E-08 0.123 
sec31a 10 - 5113837 5113933 5108976 5109070 5114036 5114237 2.11E-05 0.122 
gabrg2 21 + 40871128 40871152 40863601 40863807 40879879 40880456 0.000193 0.122 
mpzl1l 10 + 285404 285510 282421 282551 288869 292623 0.0742519 0.122 
ergic3 6 + 50358017 50358082 50353079 50353176 50360176 50360313 8.60E-174 0.121 
dgcr6 8 - 1825064 1825165 1822365 1822506 1828265 1828426 1.60E-75 0.121 
tspan18a 7 + 27929967 27930042 27888875 27889049 27950852 27950948 0.0150772 0.121 
ndrg4 25 + 12611061 12611100 12610745 12610797 12613573 12618682 1.15E-27 0.119 
zgc:91976 17 + 23590629 23590796 23587289 23587407 23592342 23594895 2.21E-09 0.118 
cep57l1 20 - 32185291 32185408 32185095 32185173 32185545 32185667 9.02E-71 0.117 
tsr2 8 - 8890775 8890906 8890385 8890476 8894400 8894486 1.31E-36 0.117 
nip7 18 - 4483409 4483496 4482156 4482295 4486203 4486341 3.56E-05 0.117 
zgc:162431 23 - 30273126 30273189 30270995 30271125 30282950 30283032 0.0007815 0.117 
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geneSymbol chr strand 
exonStart_
0base 
exonEnd upstreamES upstreamEE downstreamES downstreamEE FDR 
IncLevel 
Difference 
immt 14 + 20032423 20032528 20026771 20026922 20038602 20038719 1.18E-30 0.116 
osbpl9 8 - 17162192 17162231 17158737 17158837 17162832 17162883 1.20E-11 0.116 
si:ch211-225b11.1 5 - 22584455 22584580 22576972 22577085 22584800 22584904 1.18E-30 0.114 
smc2 1 + 18282294 18282333 18281430 18281553 18282437 18282548 1.47E-92 0.11 
fmr1 14 + 21163217 21163334 21163034 21163128 21169097 21169268 0.0043671 0.109 
zgc:91976 17 + 23587652 23587806 23587289 23587407 23592342 23594895 1.18E-07 0.107 
aldh9a1b 2 + 5713906 5714052 5710136 5710335 5715973 5716103 0.0013932 0.107 
rcor2 7 - 26157753 26157876 26157398 26157455 26161314 26161593 2.77E-21 0.105 
amph 2 - 31615426 31615480 31611929 31612100 31616123 31616177 0.0010333 0.101 
nrxn1a 12 + 26022927 26022954 26014891 26015095 26036723 26036846 5.25E-05 0.099 
grin1b 5 - 31242076 31242187 31236439 31238473 31249510 31249656 0.0261435 0.098 
scn8ab 6 - 39334919 39335042 39328804 39329089 39338675 39338849 0.0002555 0.096 
zgc:112175 23 + 4415628 4415744 4414986 4415088 4415849 4416010 0.0244282 0.096 
stk24b 6 + 12454440 12454503 12454240 12454358 12462228 12462377 0.0995308 0.09 
kansl3 8 - 53594464 53594542 53592155 53592335 53597188 53597345 8.75E-05 0.089 
alcama 10 - 29419431 29419458 29419036 29419151 29422447 29422577 8.50E-25 0.088 
tmem161b 5 - 49843488 49843592 49833279 49833366 49853374 49853570 1.54E-12 0.085 
nprl3 3 - 55930223 55930293 55922561 55922694 55930801 55931414 1.82E-05 0.085 
rhd 13 - 46124367 46124447 46121189 46121263 46133117 46133255 0.0572333 0.085 
garnl3 5 - 34999812 34999887 34999616 34999731 34999977 35000082 1.85E-51 0.084 
zgc:153606 25 - 22447290 22447432 22447072 22447204 22452846 22453056 0.0001699 0.084 
cast 21 - 10003350 10003407 10001841 10001898 10003624 10003675 0.0005927 0.083 
rnf111 7 - 31904734 31904815 31902661 31902757 31905198 31905316 0.0867303 0.083 
fmr1 14 + 21163217 21163334 21161243 21161392 21169097 21169268 1.94E-09 0.082 
si:ch211-140m22.7 9 + 20540761 20540825 20527705 20527808 20540910 20541035 0.0254538 0.082 
dpp7 5 + 30802414 30802550 30801194 30801358 30802641 30802723 3.61E-23 0.078 
psma6b 15 + 46848401 46848496 46847760 46847957 46849877 46850428 1.18E-10 0.077 
fmr1 14 + 21163034 21163128 21161243 21161392 21169097 21169268 0.056565 0.076 
mthfd1b 17 - 49543018 49543116 49536826 49537000 49545767 49545895 5.06E-08 0.075 
si:dkey-119o24.1 7 + 71175471 71175570 71166214 71166358 71183864 71184038 1.84E-05 0.075 
wwp2 25 + 35819422 35819560 35816007 35816129 35824317 35824393 1.41E-12 0.073 
capza1a 6 - 48273855 48274062 48266432 48266583 48276501 48276565 0.0440833 0.07 
zgc:77650 18 + 7019133 7019214 7017445 7017591 7023235 7023345 0.0005616 0.069 
ptbp2b 2 - 18283651 18283711 18282869 18282985 18284397 18284596 0.0931317 0.069 
brd8 14 + 7679744 7679870 7679371 7679474 7683711 7683896 3.71E-20 0.068 
trove2 2 + 11730499 11730616 11727586 11727703 11731015 11731159 1.35E-08 0.068 
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geneSymbol chr strand 
exonStart_
0base 
exonEnd upstreamES upstreamEE downstreamES downstreamEE FDR 
IncLevel 
Difference 
pyroxd2 13 - 40644621 40644694 40641526 40641683 40647591 40647726 5.99E-10 0.067 
dbnlb 8 + 54621015 54621087 54615539 54615657 54621232 54621336 0.0024939 0.067 
lamb1a 25 - 32548488 32548665 32545558 32545638 32578124 32578313 2.26E-45 0.066 
ero1lb 11 - 46600418 46600492 46597626 46597747 46600946 46601029 1.63E-06 0.064 
emc10 3 - 30393234 30393337 30392356 30392660 30396121 30396215 8.64E-12 0.063 
impad1 2 - 11433991 11434087 11431284 11431446 11434285 11434445 0.0778992 0.061 
si:ch211-216l23.2 18 + 17421766 17421966 17418528 17418670 17427555 17427831 1.11E-27 0.06 
ttyh3b 1 - 10971467 10971647 10969706 10969782 10975774 10975911 0.0002286 0.06 
dpf3 20 + 28505736 28505778 28502369 28502442 28513091 28513229 9.10E-10 0.058 
pnkp 15 + 14013301 14013394 14012999 14013070 14013704 14013801 0.0001462 0.057 
cstf3 18 - 44173340 44173436 44168060 44168093 44173587 44173689 0.0816906 0.057 
atp6v1h 2 + 30522124 30522178 30514647 30514752 30523194 30523292 0.0986457 -0.052 
avl9 12 - 15297581 15297648 15293142 15293615 15303538 15303659 1.80E-07 -0.053 
ncor1 5 - 43512439 43512589 43510125 43510269 43514882 43515083 0.0004309 -0.053 
cdkl5 11 + 31101742 31101865 31101038 31101144 31104045 31104261 5.34E-11 -0.057 
rspry1 18 + 17395235 17395362 17394294 17394407 17396510 17396569 1.22E-11 -0.064 
rraga 14 + 17944562 17944685 17944381 17944477 17944845 17944937 0.067898 -0.065 
mibp2 18 - 4948122 4948171 4947821 4947999 4949034 4949125 0.0499535 -0.066 
dmd 1 - 10018272 10018387 10012089 10012182 10024681 10024925 0.0588136 -0.071 
nif3l1 12 + 4565794 4565878 4561085 4561209 4570385 4570705 1.69E-05 -0.073 
serpinb1l3 24 + 43923696 43923864 43922269 43922412 43926062 43926518 0.0352831 -0.073 
cwc22 9 - 44667761 44667822 44635124 44635202 44681527 44681612 7.96E-05 -0.076 
casp2 16 - 19630976 19631126 19629652 19629728 19639128 19639281 0.0004072 -0.082 
cxxc1l 8 - 8272562 8272663 8271058 8271186 8272749 8272862 0.0558729 -0.083 
si:ch211-160d20.3 18 + 35136401 35136478 35133564 35133708 35138821 35139866 2.05E-25 -0.088 
eya1 24 + 13839464 13839530 13838222 13838350 13846246 13846324 0.0061107 -0.088 
otub1a 21 + 27898780 27898879 27897197 27897259 27901978 27902063 1.33E-05 -0.089 
coq4 5 + 63027390 63027520 63027219 63027322 63027742 63027836 0.0100031 -0.089 
tlk1a 9 + 3545614 3545757 3544897 3545177 3565807 3565929 0.0333669 -0.093 
nexn 8 - 19052138 19052330 19051650 19051735 19055062 19055434 5.42E-09 -0.098 
olfm3a 24 - 29614320 29614476 29613875 29614095 29622573 29622717 0.01364 -0.098 
pank4 11 + 16241055 16241237 16240556 16240710 16241544 16241626 1.02E-14 -0.1 
slx4ip 13 - 35616366 35616480 35616055 35616169 35616741 35616855 1.21E-06 -0.105 
ap3d1 22 - 22538989 22539078 22538818 22538904 22540156 22540346 3.38E-05 -0.106 
ppp3ca 21 + 28463499 28463547 28462856 28462954 28468301 28470211 9.40E-25 -0.107 
nif3l1 12 + 4563477 4563616 4561085 4561209 4570385 4570705 0.0156311 -0.107 
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geneSymbol chr strand 
exonStart_
0base 
exonEnd upstreamES upstreamEE downstreamES downstreamEE FDR 
IncLevel 
Difference 
cbsa 1 + 28008207 28008314 28001272 28001531 28008574 28008709 0.0159099 -0.107 
mbip 17 + 38470308 38470374 38467344 38467441 38470837 38470990 5.36E-07 -0.108 
gabpb2b 16 + 41011708 41011827 41008182 41008347 41011913 41012327 1.83E-08 -0.111 
cpt1a 7 + 50270839 50270927 50268413 50268521 50272474 50272670 8.24E-05 -0.111 
zgc:101016 5 - 27374389 27374503 27371703 27373094 27377839 27378294 1.08E-08 -0.112 
si:dkey-286j15.1 22 + 32718693 32718875 32718382 32718548 32720721 32720849 0.0261914 -0.112 
nif3l1 12 + 4563477 4563616 4561085 4561209 4565794 4565878 2.68E-11 -0.115 
mus81 7 + 21015253 21015339 21013096 21013177 21015443 21015596 0.0012166 -0.116 
LOC794757 22 + 25190435 25190511 25189467 25189603 25191105 25191239 6.24E-09 -0.118 
zgc:110366 2 + 6847743 6847868 6845984 6846044 6852620 6853273 1.80E-05 -0.118 
pum1 19 + 44690129 44690322 44686844 44686966 44692450 44693856 0.0004337 -0.121 
slc25a39 3 - 30036880 30036931 30035816 30035926 30038279 30038339 2.18E-18 -0.122 
lrrc40 6 + 29835022 29835100 29834534 29834645 29835516 29835702 1.61E-22 -0.124 
cratb 19 + 18402766 18402886 18402354 18402455 18405598 18405721 3.25E-05 -0.125 
zgc:55558 3 + 16291739 16291899 16290822 16291001 16298544 16299951 5.59E-157 -0.128 
kcnma1a 13 + 16931154 16931183 16927699 16927924 16934670 16934822 0.0051851 -0.133 
tfb1m 17 - 49427581 49427733 49416803 49416923 49431522 49431627 1.06E-19 -0.138 
ppp2r5d 13 - 3901745 3901799 3901425 3901596 3903467 3903576 7.72E-08 -0.14 
eif2d 8 - 38560005 38560180 38559756 38559921 38563886 38564007 5.64E-56 -0.141 
psip1 1 + 27252154 27252353 27251720 27251779 27254997 27255094 7.13E-21 -0.144 
taf6l 7 + 19212183 19212680 19210414 19210543 19215695 19217567 1.36E-06 -0.146 
golga1 8 - 43544500 43544575 43541474 43541605 43548228 43548319 4.06E-07 -0.148 
odz4 15 + 10723451 10723670 10656006 10656279 10747466 10747713 0.0137908 -0.148 
odc1 17 + 52273121 52273255 52271121 52271256 52275325 52275499 2.19E-20 -0.149 
bbs7 14 - 49317790 49317856 49317554 49317694 49317953 49318028 2.57E-35 -0.156 
zgc:112023 6 - 8632169 8632306 8631377 8631506 8632393 8632725 7.67E-05 -0.157 
wdr41 21 + 7552173 7552222 7545667 7546131 7554156 7554285 3.06E-33 -0.159 
slc29a4 3 + 40333432 40333556 40328336 40328593 40340362 40340550 1.91E-20 -0.161 
nr5a2 22 - 23082643 23082785 23074668 23075074 23084491 23084610 7.27E-42 -0.162 
cdkl5 11 + 31078765 31078825 31077159 31077280 31087892 31088082 1.66E-07 -0.162 
fbxo22 7 + 31303318 31303484 31301375 31301528 31304465 31305382 0.0005745 -0.166 
pard3 2 + 43415556 43415601 43409047 43409190 43417598 43417829 2.21E-09 -0.168 
rad18 6 + 41784237 41784367 41780790 41780910 41799494 41799541 1.06E-15 -0.17 
ascc2 5 - 19688086 19688154 19687874 19687988 19689564 19689738 0.0007366 -0.174 
csnk1g2a 2 + 22519310 22519459 22513924 22513994 22519548 22519783 1.30E-10 -0.176 
elmo1 19 - 35388935 35388971 35382991 35383091 35401913 35402083 7.35E-138 -0.177 
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geneSymbol chr strand 
exonStart_
0base 
exonEnd upstreamES upstreamEE downstreamES downstreamEE FDR 
IncLevel 
Difference 
mkl1b 12 + 19810948 19811035 19810682 19810817 19811141 19811202 2.37E-13 -0.18 
scn2b 15 + 12936697 12936765 12936410 12936606 12939298 12940842 3.88E-08 -0.184 
fam3a 23 + 25433300 25433324 25426861 25426969 25433413 25433537 1.26E-09 -0.185 
msrb3 4 - 11971377 11971531 11967052 11967161 11978585 11978673 1.44E-05 -0.186 
zmat5 5 + 33714216 33714297 33714048 33714111 33716042 33716151 3.48E-10 -0.189 
mlh1 13 + 43257035 43257126 43255510 43255631 43257222 43257321 1.80E-42 -0.191 
si:dkey-46l15.1 6 - 50565813 50565888 50549825 50549983 50568161 50568253 8.82E-92 -0.198 
cdkl5 11 + 31078765 31078825 31077159 31077280 31081117 31081208 2.92E-07 -0.204 
tbpl1 23 + 31839698 31839762 31838881 31838964 31839844 31839948 1.45E-08 -0.205 
cyp2p10 20 + 25617677 25617838 25617444 25617594 25620762 25620939 5.90E-06 -0.207 
pbx3b 8 - 34764046 34764124 34761214 34761261 34764689 34764855 0.0009128 -0.208 
si:ch211-22i13.2 20 - 13926804 13926874 13926522 13926684 13927427 13927613 2.46E-287 -0.217 
kdsr 2 - 13034313 13034397 13034114 13034198 13034484 13034676 1.42E-20 -0.228 
fgfr2 13 - 46998391 46998658 46995484 46995559 47032754 47033011 4.48E-11 -0.228 
rab24 21 + 37698031 37698091 37697890 37697941 37699066 37700268 7.37E-74 -0.23 
rab15 20 - 28811960 28812050 28810532 28810598 28812306 28812384 7.15E-09 -0.24 
polr3gla 19 - 25036239 25036296 25036034 25036111 25039030 25039099 0.026561 -0.241 
zgc:162431 23 - 30253820 30253903 30251819 30252766 30255392 30255509 0.0015118 -0.247 
upp1 16 - 18262563 18262675 18262315 18262474 18263094 18263143 0.0024989 -0.248 
afap1l1b 21 - 29178293 29178372 29171593 29171749 29178882 29178975 0.0005114 -0.257 
eif4e3 23 - 10833717 10833873 10830270 10832309 10835228 10835295 2.25E-37 -0.258 
zgc:112466 21 - 229427 229477 229066 229193 230124 230223 5.87E-21 -0.26 
cadm1a 21 + 23658825 23658858 23619570 23619743 23689082 23689211 2.24E-06 -0.27 
tbp 13 - 24609972 24610140 24608891 24608986 24610243 24610335 1.54E-173 -0.273 
ptpn13 21 + 8854505 8854634 8849905 8850333 8857330 8857424 6.46E-06 -0.283 
pmvk 16 - 8152297 8152427 8150792 8152212 8153823 8153976 8.30E-36 -0.289 
mthfd1b 17 - 49514486 49514594 49511436 49511589 49515216 49515394 5.33E-28 -0.292 
snx9b 20 - 43078665 43078804 43076099 43076181 43084230 43084396 1.27E-124 -0.294 
zgc:91909 8 - 53244356 53244483 53240686 53240905 53247444 53247516 9.86E-14 -0.294 
zgc:153901 9 + 25243578 25243674 25243254 25243447 25244400 25244589 0.0043491 -0.294 
srsf6b 11 + 1489084 1489248 1487469 1487604 1490569 1490691 2.31E-22 -0.298 
eya3 19 + 25385908 25386040 25385561 25385671 25386240 25386320 4.72E-38 -0.322 
pot1 25 + 28290895 28290974 28277055 28277175 28291396 28291494 4.27E-58 -0.325 
wdr41 21 + 7549093 7549209 7545667 7546131 7552173 7552222 4.47E-28 -0.329 
si:ch211-284b7.3 2 - 5687295 5687373 5684736 5684802 5690364 5690446 1.93E-122 -0.334 
pet112 1 - 23409017 23409131 23397583 23397782 23411570 23411721 4.45E-05 -0.335 
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geneSymbol chr strand 
exonStart_
0base 
exonEnd upstreamES upstreamEE downstreamES downstreamEE FDR 
IncLevel 
Difference 
wdr41 21 + 7549093 7549209 7545667 7546131 7554156 7554285 0.0007194 -0.342 
lpar2b 1 - 59943763 59943796 59938281 59938611 59947173 59947427 0.001061 -0.342 
foxp2 4 - 5885772 5885950 5854178 5854268 5940846 5940911 0.0440833 -0.362 
sepn1 17 + 24521976 24522078 24521347 24521460 24522170 24523355 0 -0.408 
zgc:63674 2 + 20670032 20670164 20669812 20669872 20670479 20670567 1.52E-33 -0.452 
mogat3b 25 + 16967040 16967109 16965085 16965175 16967208 16967303 2.77E-91 -0.481 
osbpl6 9 - 1410398 1410491 1402248 1402417 1413039 1413143 9.44E-21 -0.535 
rmnd5b 14 + 51492793 51492931 51491250 51491393 51493033 51493134 0 -0.587 
ptges3a 23 + 27297788 27297845 27297616 27297706 27299207 27299235 1.98E-178 -0.74 
mdm2 4 + 22063129 22063204 22062973 22063045 22064660 22064794 7.70E-308 -0.807 
 
 
(B) Mutually exclusive exon AS events 





















mdm2 4 + 22064660 22064794 22065101 22065151 22062973 22063045 22065262 22065321 2.44E-117 0.408 
rgs12b 1 - 41597618 41597715 41598335 41598403 41596812 41597373 41598765 41598862 0.033852846 0.302 
cadm1a 21 + 23639862 23639946 23658825 23658858 23619570 23619743 23689082 23689211 7.36E-20 0.244 
mthfd1b 17 - 49514486 49514594 49515216 49515394 49511436 49511589 49518894 49518995 5.64E-19 0.235 
zgc:63674 2 + 20670479 20670567 20670999 20671185 20669812 20669872 20671811 20671928 9.50E-88 0.221 
msi2b 15 - 29831831 29832011 29848475 29848598 29816580 29816735 29876177 29876252 0.000105091 0.197 
upb1 8 + 31571366 31571448 31573263 31573306 31569615 31569785 31577052 31577207 0.058373803 0.181 
rab15 20 - 28811960 28812050 28812306 28812384 28810532 28810598 28815556 28815617 5.81E-10 0.144 
zmp:0000000686 3 + 60198681 60198963 60202056 60202317 60197856 60198150 60205249 60205516 0.033852846 0.144 
sulf2b 23 - 15317606 15317660 15319653 15319687 15314865 15317132 15322241 15322365 1.78E-08 0.133 
dgcr6 8 - 1822365 1822506 1825064 1825165 1819021 1819406 1828265 1828426 0.002266556 0.121 
ncs1a 5 - 34048574 34048663 34050992 34051071 34046162 34046240 34051970 34052109 0.069756709 0.121 
rcor2 7 - 26157398 26157455 26157753 26157876 26152572 26152625 26161314 26161593 7.00E-30 0.119 
glmna 2 + 10637701 10637837 10639963 10640040 10632969 10633033 10648472 10649203 0.000105091 0.118 
tex261 7 - 9510124 9510278 9514629 9514709 9506871 9506974 9518538 9518712 3.41E-32 0.116 
reep3a 17 - 19443548 19443685 19444367 19444488 19439856 19440428 19446887 19447001 0.00686345 0.113 
map7d2a 5 - 25653003 25653103 25656415 25656579 25645497 25645610 25659434 25659512 1.70E-28 0.11 
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hipk3b 18 + 27898725 27898849 27909809 27909929 27875746 27877008 27912776 27912863 0.011188039 0.107 
melk 1 - 20707035 20707188 20709535 20709622 20704399 20704664 20710511 20710610 7.27E-05 0.106 
qkia 17 + 27604540 27604683 27629112 27629229 27579731 27580116 27639990 27640134 2.01E-240 0.096 
nom1 7 - 42041432 42041565 42041938 42042060 42040108 42040240 42042250 42042421 0.034834675 0.094 
mnat1 13 + 31881360 31881513 31883216 31883320 31871902 31872092 31883775 31883916 0.01769779 0.093 
odc1 17 + 52271121 52271256 52273121 52273255 52270230 52270353 52275325 52275499 5.01E-10 0.089 
pemt 12 + 1531594 1531706 1562879 1562954 1526401 1526547 1564315 1566132 2.76E-11 0.085 
lemd3 4 - 11984405 11984487 11985063 11985242 11984139 11984245 11986366 11986469 0.000413679 0.077 
cdon 18 - 42487765 42487879 42489815 42489990 42481794 42482001 42492487 42492771 1.99E-07 0.072 
tcf7l1a 10 - 43569792 43569936 43576703 43576787 43567404 43567564 43576951 43577054 0.058496646 0.071 
adarb1a 22 - 12807237 12807264 12819972 12820030 12793681 12794619 12832950 12833138 0.006016418 0.067 
abi2a 9 + 14063058 14063217 14066970 14067057 14054379 14054501 14073827 14074001 8.67E-06 0.058 
agfg1a 15 - 34463353 34463557 34468451 34468571 34459857 34460017 34470687 34470847 5.31E-11 0.051 
hoxc3a 23 + 36178766 36178818 36196567 36196737 36138840 36138951 36196927 36197195 0.002266556 -0.053 
nr6a1b 21 + 7743288 7743344 7745771 7745923 7739453 7739681 7748647 7748833 0.002829475 -0.058 
adck3 20 + 38528235 38528329 38533074 38533216 38525080 38525162 38536556 38536664 0.005699956 -0.061 
dgcr6 8 - 1825064 1825165 1828265 1828426 1822365 1822506 1830518 1830653 0.032432488 -0.065 
tlk1a 9 + 3545614 3545757 3565807 3565929 3544897 3545177 3566451 3566523 0.004379908 -0.07 
rtn1b 20 + 20763179 20763318 20765748 20765807 20762886 20763094 20767016 20768113 0.005699956 -0.07 
aplp2 18 - 42804960 42805134 42813908 42814008 42794004 42794087 42818533 42818662 0.007302814 -0.07 
adarb1a 22 - 12807237 12807264 12819972 12820030 12800273 12800345 12832950 12833138 6.53E-18 -0.074 
msrb1a 3 - 18624713 18624828 18625439 18625582 18620802 18623176 18627008 18627178 0.058373803 -0.078 
xrn1 2 + 16463538 16463652 16464279 16464379 16460365 16460553 16464485 16464643 2.72E-05 -0.08 
hagh 3 - 18606922 18607040 18608198 18608263 18604712 18604821 18609706 18609870 8.16E-06 -0.081 
adck3 20 + 38528235 38528329 38537960 38538026 38525080 38525162 38538109 38538196 0.000159081 -0.081 
rad18 6 + 41784237 41784367 41799494 41799541 41780790 41780910 41817999 41818262 1.30E-08 -0.105 
si:ch211-57i17.1 20 + 46995223 46995365 46997610 46997876 46993794 46993911 47005668 47005744 3.36E-10 -0.108 
hdac4 9 - 47058912 47059123 47064792 47064905 47053400 47053594 47065264 47065393 1.02E-10 -0.111 
nif3l1 12 + 4563477 4563616 4565794 4565878 4561085 4561209 4570385 4570705 1.28E-08 -0.116 
upb1 8 + 31557702 31557797 31563756 31563918 31556544 31556632 31569615 31569785 0.022005778 -0.127 
bcar3 8 - 15625695 15625824 15666975 15667015 15617316 15617756 15678952 15679281 0.083699072 -0.145 
slc52a2 19 - 22820224 22820348 22821972 22822825 22817617 22818186 22822909 22823046 6.53E-05 -0.151 
wdr41 21 + 7549093 7549209 7552173 7552222 7545667 7546131 7554156 7554285 0.000345264 -0.156 
atp7a 14 + 23430961 23431096 23431856 23432051 23429736 23429891 23433295 23433478 0.044817223 -0.195 
nbas 20 - 33111158 33111221 33116126 33116260 33099753 33099876 33123707 33123881 6.53E-05 -0.216 
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calcrla 9 - 43436606 43436648 43439509 43439728 43433737 43433998 43439995 43440062 1.62E-213 -0.22 
slc50a1 16 + 25544865 25544943 25545374 25545498 25543186 25543397 25550234 25550396 1.60E-05 -0.225 
vps39 17 + 50620145 50620287 50622664 50622751 50616275 50616416 50627058 50627132 2.39E-08 -0.226 
zgc:162576 17 + 42110438 42110601 42113203 42113284 42108713 42108776 42119446 42120017 0.002266556 -0.276 
slc7a7 7 + 20737619 20737723 20739853 20739950 20736689 20736813 20740994 20741144 0.01825428 -0.358 
si:ch211-284b7.3 2 - 5690364 5690446 5691753 5691810 5684736 5684802 5694006 5694090 5.20E-257 -0.359 
 
 








longExonEnd shortES shortEE flankingES flankingEE FDR IncLevel Difference 




(D) Alternative 5’ splice site AS events 
geneSymbol chr strand longExonStart_0base longExonEnd shortES shortEE flankingES flankingEE FDR 
IncLevel 
Difference 
ptp4a2b 19 - 37020794 37021457 37021182 37021457 37020617 37020710 2.09E-12 0.164 
 
(E) Retained intron AS events 
 
geneSymbol chr strand 
riExonStart_
0base 
riExonEnd upstreamES upstreamEE downstreamES downstreamEE FDR IncLevel Difference 
ccnt2a 9 - 24267577 24270178 24267577 24269032 24269127 24270178 3.84E-25 0.166 
tmem234 13 - 33540557 33540930 33540557 33540709 33540896 33540930 1.69E-05 -0.333 
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Appendix 7. List of AS events identified in SMA SC 
(A) Skipped exon AS events 
geneSymbol chr strand exonStart_0base exonEnd upstreamES upstreamEE downstreamES downstreamEE FDR 
IncLevel 
Difference 
mdm2 4 + 22063129 22063204 22062973 22063045 22064660 22064794 0 -0.775 
ptges3a 23 + 27297788 27297845 27297616 27297706 27299207 27299235 0 -0.7 
wdr41 21 + 7549093 7549209 7545667 7546131 7552173 7552222 0.003753895 -0.477 
mthfd1b 17 - 49514486 49514594 49511436 49511589 49515216 49515394 0 -0.402 
mogat3b 25 + 16967040 16967109 16965085 16965175 16967208 16967303 8.63E-07 -0.384 
rmnd5b 14 + 51492793 51492931 51491250 51491393 51493033 51493134 0 -0.371 
pet112 1 - 23409017 23409131 23397583 23397782 23411570 23411721 0.000212796 -0.314 
sepn1 17 + 24521976 24522078 24521347 24521460 24522170 24523355 0 -0.313 
znf609 7 - 55793542 55793908 55792628 55792707 55794414 55794739 0.015730428 -0.291 
zgc:91909 8 - 53244356 53244483 53240686 53240905 53247444 53247516 6.50E-13 -0.285 
odc1 17 + 52273121 52273255 52271121 52271256 52275325 52275499 0 -0.237 
si:ch211-22i13.2 20 - 13926804 13926874 13926522 13926684 13927427 13927613 4.13E-10 -0.209 
zgc:63674 2 + 20670032 20670164 20669812 20669872 20670479 20670567 0.041763267 -0.207 
srsf6b 11 + 1489084 1489248 1487469 1487604 1490569 1490691 9.14E-14 -0.187 
si:ch211-160d20.3 18 + 35136401 35136478 35133564 35133708 35138821 35139866 0.001554926 -0.168 
snx9b 20 - 43078665 43078804 43076099 43076181 43084230 43084396 0.000644025 -0.159 
pum1 19 + 44690129 44690322 44686844 44686966 44692450 44693856 2.58E-07 -0.155 
stx6 22 - 16712415 16712478 16712209 16712338 16713637 16713732 5.47E-05 -0.141 
nenf 17 + 45563920 45563981 45563361 45563805 45569379 45569483 0.066148894 -0.136 
csnk1g2a 2 + 22519310 22519459 22513924 22513994 22519548 22519783 0.004977037 -0.119 
prdx5 21 + 26056193 26056325 26053497 26053632 26056437 26056476 0.058653284 -0.113 
cds2 5 + 22937693 22937790 22936711 22936836 22941625 22941723 0.015413046 -0.102 
fam3a 23 + 25433300 25433324 25426861 25426969 25433413 25433537 0.00090344 -0.099 
fmr1 14 + 21163217 21163334 21163034 21163128 21169097 21169268 0.007290535 0.139 
ergic3 6 + 50358017 50358082 50353079 50353176 50360176 50360313 1.68E-07 0.148 
phf2 11 - 28545121 28545237 28542410 28542589 28546538 28546658 0.01289792 0.167 
ccnl1a 18 + 39853090 39853165 39852454 39852747 39854442 39854552 0 0.196 
ccdc93 9 - 39417471 39417570 39417340 39417397 39418862 39418974 2.06E-05 0.198 
aamp 6 + 59646330 59646421 59644657 59644746 59646520 59646675 0.000212796 0.218 
snx15 7 - 21123289 21123325 21123093 21123214 21123781 21123965 0.011685496 0.221 
mthfd1b 17 - 49558065 49558119 49557843 49557980 49559738 49559798 0.01289792 0.264 
melk 1 - 20709535 20709622 20708388 20708517 20710511 20710610 0.001297067 0.268 
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geneSymbol chr strand exonStart_0base exonEnd upstreamES upstreamEE downstreamES downstreamEE FDR 
IncLevel 
Difference 
ptp4a2b 19 - 37021182 37021457 37020617 37020710 37040965 37041074 0.008983682 0.287 
calcrla 9 - 43436606 43436648 43433737 43433998 43439509 43439728 0.062196472 0.302 
prkcbp1l 23 - 9947491 9947569 9947022 9947138 9947734 9947790 2.52E-09 0.318 
ptenb 12 - 18482144 18482188 18481820 18482059 18482466 18482511 1.67E-07 0.359 
zgc:165580 17 + 19332145 19332289 19329309 19329524 19332461 19332594 0.083978973 0.376 
snx27a 19 + 9267840 9267889 9266968 9267097 9269978 9270104 9.16E-05 0.633 
 
(B) Mutually exclusive exon AS events 
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Appendix 8. List of significantly enriched GO terms identified from AS analysis of 
SMA MN 
GO.ID Term Annotated Significant Expected elim 
GO:0008150 biological_process 4220 189 347.16 1.2E-28 
GO:0005575 cellular_component 3564 153 280.94 5.8E-27 
GO:0003674 molecular_function 4154 184 347.36 1.3E-25 
GO:0016021 integral to membrane 747 36 58.88 2E-07 
GO:0005737 cytoplasm 1227 55 96.72 1.8E-06 
GO:0003824 catalytic activity 1737 78 145.25 0.000016 
GO:0003723 RNA binding 228 15 19.07 0.000023 
GO:0005634 nucleus 954 42 75.2 0.000029 
GO:0044464 cell part 2792 122 220.08 0.000035 
GO:0008152 metabolic process 2641 117 217.26 0.000095 
GO:0008589 regulation of smoothened signaling pathway 6 3 0.49 0.00012 
GO:0061351 neural precursor cell proliferation 7 3 0.58 0.00021 
GO:0035335 peptidyl-tyrosine dephosphorylation 47 6 3.87 0.00022 
GO:0004725 protein tyrosine phosphatase activity 47 6 3.93 0.00022 
GO:0006468 protein phosphorylation 249 14 20.48 0.00023 
GO:0006886 intracellular protein transport 138 10 11.35 0.00025 
GO:0007165 signal transduction 660 31 54.3 0.00026 
GO:0005524 ATP binding 486 21 40.64 0.00028 
GO:0033743 peptide-methionine (R)-S-oxide reductase activity 2 2 0.17 0.00035 
GO:0006352 transcription initiation, DNA-dependent 19 4 1.56 0.00036 
GO:0016023 cytoplasmic membrane-bounded vesicle 74 7 5.83 0.00036 
GO:0043234 protein complex 622 27 49.03 0.00039 
GO:0016192 vesicle-mediated transport 190 15 15.63 0.00041 
GO:0006355 regulation of transcription, DNA-dependent 402 18 33.07 0.0005 
GO:0004674 protein serine/threonine kinase activity 153 10 12.79 0.00057 
GO:0003677 DNA binding 372 17 31.11 0.00058 
GO:0044428 nuclear part 298 16 23.49 0.00067 
GO:0010951 negative regulation of endopeptidase activity 10 3 0.82 0.00069 
GO:0031090 organelle membrane 285 17 22.47 0.00082 
GO:0022891 substrate-specific transmembrane transporter activity 184 13 15.39 0.00101 
GO:0031167 rRNA methylation 3 2 0.25 0.00102 
GO:0030091 protein repair 3 2 0.25 0.00102 
GO:0016433 rRNA (adenine) methyltransferase activity 3 2 0.25 0.00103 
GO:0019003 GDP binding 25 4 2.09 0.00109 
GO:0002009 morphogenesis of an epithelium 88 7 7.24 0.00124 
GO:0006897 endocytosis 66 6 5.43 0.00138 
GO:0008170 N-methyltransferase activity 27 4 2.26 0.00147 
GO:0016788 hydrolase activity, acting on ester bonds 200 16 16.72 0.00155 
GO:0009790 embryo development 209 15 17.19 0.00177 
GO:0006464 protein modification process 591 33 48.62 0.00188 
GO:0007423 sensory organ development 122 8 10.04 0.00197 
GO:0008270 zinc ion binding 347 15 29.02 0.0021 
GO:0006139 nucleobase-containing compound metabolic process 972 48 79.96 0.00219 
GO:0051276 chromosome organization 125 8 10.28 0.00229 
GO:0044427 chromosomal part 75 6 5.91 0.0023 
GO:0005743 mitochondrial inner membrane 52 5 4.1 0.00239 
GO:0006397 mRNA processing 74 6 6.09 0.0025 
GO:0048562 embryonic organ morphogenesis 52 5 4.28 0.00272 
GO:0003779 actin binding 75 8 6.27 0.00279 
GO:0030334 regulation of cell migration 16 3 1.32 0.00298 
GO:0045132 meiotic chromosome segregation 5 2 0.41 0.00332 
GO:0034453 microtubule anchoring 5 2 0.41 0.00332 
GO:0048738 cardiac muscle tissue development 17 3 1.4 0.00356 
GO:0019829 cation-transporting ATPase activity 17 3 1.42 0.00358 
GO:0005488 binding 2500 101 209.05 0.0037 
GO:0035239 tube morphogenesis 56 5 4.61 0.00376 
GO:0061371 determination of heart left/right asymmetry 35 4 2.88 0.00388 
GO:0051188 cofactor biosynthetic process 43 6 3.54 0.00416 
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GO.ID Term Annotated Significant Expected elim 
GO:0022603 regulation of anatomical structure morphogenesis 58 5 4.77 0.00438 
GO:0005768 endosome 60 5 4.73 0.00447 
GO:0001518 voltage-gated sodium channel complex 6 2 0.47 0.00466 
GO:0007420 brain development 84 6 6.91 0.0047 
GO:0005525 GTP binding 141 8 11.79 0.00484 
GO:0044237 cellular metabolic process 2015 93 165.77 0.00485 
GO:0044238 primary metabolic process 1967 89 161.82 0.00489 
GO:0045214 sarcomere organization 6 2 0.49 0.00492 
GO:0006807 nitrogen compound metabolic process 1054 55 86.71 0.00519 
GO:0044425 membrane part 923 44 72.76 0.00521 
GO:0044281 small molecule metabolic process 1155 58 95.02 0.00524 
GO:0005794 Golgi apparatus 117 7 9.22 0.00524 
GO:0050790 regulation of catalytic activity 220 13 18.1 0.0053 
GO:0070013 intracellular organelle lumen 260 13 20.49 0.00545 
GO:0006396 RNA processing 167 14 13.74 0.00554 
GO:0051252 regulation of RNA metabolic process 423 21 34.8 0.00559 
GO:0044446 intracellular organelle part 789 39 62.19 0.0058 
GO:0048856 anatomical structure development 677 39 55.69 0.00584 
GO:0007049 cell cycle 184 11 15.14 0.00586 
GO:0000793 condensed chromosome 21 3 1.66 0.0061 
GO:0048869 cellular developmental process 389 18 32 0.00642 
GO:0071842 cellular component organization at cellular level 588 28 48.37 0.00667 
GO:0001946 lymphangiogenesis 7 2 0.58 0.00681 
GO:0006744 ubiquinone biosynthetic process 7 2 0.58 0.00681 
GO:0016814 
hydrolase activity, acting on carbon-nitrogen (but not 
peptide) bonds, in cyclic amidines 
7 2 0.59 0.00683 
GO:0004437 inositol or phosphatidylinositol phosphatase activity 7 2 0.59 0.00683 
GO:0032482 Rab protein signal transduction 41 4 3.37 0.00689 
GO:0034220 ion transmembrane transport 120 7 9.87 0.00706 
GO:0006812 cation transport 121 7 9.95 0.00737 
GO:0051015 actin filament binding 22 3 1.84 0.00757 
GO:0004888 transmembrane signaling receptor activity 94 6 7.86 0.00814 
GO:0000118 histone deacetylase complex 8 2 0.63 0.00849 
GO:0048747 muscle fiber development 23 3 1.89 0.00855 
GO:0006366 transcription from RNA polymerase II promoter 125 7 10.28 0.00876 
GO:0060840 artery development 8 2 0.66 0.00897 
GO:0042559 pteridine-containing compound biosynthetic process 8 2 0.66 0.00897 
GO:0021903 rostrocaudal neural tube patterning 8 2 0.66 0.00897 
GO:0004867 serine-type endopeptidase inhibitor activity 8 2 0.67 0.009 
GO:0008289 lipid binding 69 5 5.77 0.00917 
GO:0005886 plasma membrane 277 13 21.83 0.00922 
GO:0005773 vacuole 46 4 3.63 0.00935 
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TAATACGACTCACTATA - T7 promoter sequence 
ggcttgccgatgtacacccg - srsf6b exon 1 gRNA target site 
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